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Introduction 
1. Bioactive sulfoximines: methionine sulfoximine, buthionine sulfoximine 
 
Historically, the sulfoximine moiety has been identified and incorporated in many bioactive 
molecules. The first sulfoximine was reported in the 1940s following investigations into a 
toxic substance that was formed by bleaching wheat with NCl3 and was observed to cause 
dogs to develop a disease called canine hysteria.1 In 1949, Bentley and co-workers confirmed 
the structural features of methionine sulfoximine (1, MSO) after isolation of the toxic factor 
and structural determination of the bioactive components.  In fact, sulfoximine 1, a glutamine 
synthetase inhibitor, was derived from the amino acid methionine, and it was observed that 
the modification of the sulfur unit could have a profound effect on biological activity.2  
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Figure 1. Methionine sulfoximine (1, MSO) and buthionine sulfoximine (2, BSO) 
 
Today, buthionine sulfoximine (2, BSO), a synthetic amino acid, has attracted remarkable 
attention in the medicinal community due to its specific inhibitory effects on γ-
glutamylcysteine synthetase. This is the most potent analog of a series of methionine 
sulfoximines. The substitution of an n-butyl moiety for the methyl group of methionine 
sulfoximine results in a notable inhibitor of γ-glutamylcysteine synthetase (γ-GCS) (Scheme 1). 
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Scheme 1. Proposed reaction mechanism for γ-glutamylcysteine synthetase (γ-GCS)3b 
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By reducing levels of gluthionine (5), BSO may improve the in vitro and in vivo cytotoxicities 
of various chemotherapeutic agents in drug-resistant tumors. Furthermore, it is reported that 
the suppression of glutathione by BSO could lead to estrogen-induced apoptosis, which can 
sensitize breast cancer cells.3  
 
 
2. Sulfoximines in medicinal chemistry 
 
In regards to drug discovery, sulfoximines have several attractive features, including a small 
hydrophilic core, a stereogenic center at the sulfur atom, possible diversity at the imine 
nitrogen, a hydrogen-bond acceptor at the sulfur-bound heteroatoms, and, if R3 is hydrogen 
(NH-sulfoximine), a hydrogen-bond donor.  
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Figure 2. Sulfone and sulfoximine core structures 
 
Consequently, sulfoximines have already found a number of bio-applicable uses, and recent 
interest has manifested itself through the significant number of reports in the literature. For 
example, intriguing biological activities of sulfoximines have been reported by Posner and co-
workers who showed that a sulfoximine-containing Vitamin D3 analog 9 has a remarkable 
inhibitory effect against hydroxylase and a high selectivity for cytochrome CYP24.4 For HIV 
protease, Vince and coworkers designed and synthesized a potent sulfoximine-containing 
inhibitor 10.5 Walker and co-workers also reported that sulfonimidoyl-substituted 
trifluoromethylpyrimidines 11 showed prominently reduced hERG activity when compared to 
their sulfonyl-based analog, but were equally potent as inhibitors of proline-rich tyrosine 
kinase 2 (PYK2).6 Interest in the use of sulfoximines for medicinal chemistry has resulted in a 
significant number of patents in this area. For example, researchers at Bayer Pharma 
Aktiengesellschaft prepared sulfoximine 12 and reported that it is a selective cyclin-dependent 
kinase (CDK) inhibitor and a novel oral cytotoxic agent that is currently in phase I clinical 
trials.7 
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Figure 3. Recent examples of sulfoximines applied in medicinal chemistry 
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3. Sulfoximines in crop protection 
 
In addition to medicinal chemistry applications, novel compounds containing the sulfoximine 
moiety have shown outstanding insecticidal activities. Recently, Dow Agroscience and 
Syngenta employed sulfoximine-containing substances in crop protection.8  
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Figure 4. Representative examples of sulfoximines in crop protection 
 
Among these sulfoximines, sulfoxaflor 15, developed by Dow AgroSciences, is the first 
molecule to be commercialized from the new sulfoximine-containing class of insecticides. It 
exhibited broad-spectrum efficacy against many sap-feeding insect pests, including aphids, 
whiteflies, hoppers, and Lygus, with levels of activity that are comparable to those of other 
classes of insecticides targeting sap-feeding insects, including the neonicotinoids. After the 
discovery of sulfoxaflor, N-cyano sulfoximine moiety has attracted significant attention for its 
role in compounds designed for crop protection.9 Finally, sulfoxaflor has received its first 
country registration from South Korea (November 2011).10 
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Figure 5. The structure of sulfoxaflor 
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4. Conversion of sulfones to sulfoximines 
 
The proposed concept for this research project is the investigation of the effect on biological 
activity by a structural conversion of a sulfone to a sulfoximine. 
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Figure 6. The investigation of the effect on biological activity 
 
 
 
4.1. Biological aspects 
 
In the initial phase, one particular study at Pfizer caught our attention. Walker and co-workers 
have shown in their studies that the structural change from sulfone 16 to the corresponding N-
alkylsulfoximines 11 led to a compound with potent biological activities for proline-rich 
tyrosine kinase inhibitors. Furthermore, they unexpectedly found a compound with reduced 
hERG blocking potency, an early indicator of cardiovascular safety.6 In this context, the 
replacement of other sulfonyl-based compounds might also lead to compounds with beneficial 
biological effects, similar to the achievement of Walker. 
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Figure 7. Walker’s research at Pfizer 
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4.2. Synthetic aspects 
 
Synthetic methods and strategies have been investigated that enable access to sulfoximine-
containing molecules through the structural conversion of a sulfone to a sulfoximine. From 
literature screening, it came to our attention that arene diazoium salts (tetrafluoroborates and 
hexafluorophosphates) have been successfully employed as reagents for the synthesis of 
sulfoximines when starting from sulfones. However, surprisingly, there were only four 
articles that covered that transformation.  
 
4.2.1. Synthesis of aryloxysulfoxonium salts 
 
In 1970, Whiting and co-workers reported the synthesis of aryloxysulfoxonium salts by the 
decomposition of arene diazonium salts (tetrafluoroborates and hexafluorophosphates) in the 
presence of an excess of sulfones (Scheme 2).11a 
 
N2 X
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S
O
O
R2R1
X
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R1, R2 = alkyl, aryl, aryloxy, sulfonyl, dialkylamino; R3 = H, Me, NO2, F.
R3
+
F
R3
+ N2
Aryloxysulfoxonium salts Schiemann productsArenediazonium salts
(3 - 44% yield) (20 - 47% yield)X = BF4 or PF6
 
Scheme 2. Formation of the aryloxysulfoxonium salts using arene diazonium salts 
 
4.2.2. Nucleophilic substitution of aryloxysulfoxonium salts 
 
Further investigations by Whiting and co-workers displayed that aryloxysulfoxonium salts 
could be effective electrophiles. Thus, aryloxysulfoxonium cations can react with 
nucleophiles at the cationic sulfur atom. The reactions of aryloxysulfoxonium salts with 
primary aliphatic amines afforded sulfoximines (Scheme 3).11b 
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In 1978, Oishi and co-workers reported the direct nucleophilic reactions of oxosulfonium 
ylide with alkyllithiums, dialkyl copper lithiums, amines, thiols and alcohol.11c Their efforts, 
focusing on the preparation of the methylphenyl sulfoximine and the sulfoxide when starting 
from the methylphenyl sulfone, are most closely related to the project proposed herein. They 
described that the nucleophilic substitution of the oxosulfonium ylide with primary amines 
such as n-hexyl, benzyl and cyclohexyl amine gave the N-alkyl sulfoximines in high yields 
(Scheme 3).11c 
 
Whiting (3.7 - 95% yield): R1, R2 = aryl, aryloxy, dialkylamino; R3 = methyl, t-butyl, benzyl, cyclohexyl
Electrophile
S
OAr
O
R2R1
S
O
R2R1
N
S
N
O
R2R1
2 R3NH2
R3R
3H
R3NH2 N-alkyl sulfoximine
Oishi (92 - 97% yield): R1 = phenyl; R2 = methyl; R3 = n-hexyl , benzyl, cyclohexyl  
Scheme 3. Synthesis of the N-alkyl methylphenyl sulfoximine 
 
4.2.3. The reduction of a sulfone to a sulfoxide 
 
In additional examinations by Oishi and coworkers, they unexpectedly found that the reaction 
of oxosulfonium ylide with benzylmercaptane in the presence of pyridine provided the 
methylphenyl sulfoxide in good yield (Scheme 4).11c 
Furthermore, in 1979, Still reported that the p-chlorobenzene diazonium tetrafluoroborate was 
able to react with sulfones to give the aryloxysulfoxonium salts in moderate yield (37 – 61% 
yield). They found that through reduction, a p-chlorophenoxysulfoxonium salt was readily 
converted to the sulfoxide through nucleophilic hydride attack (Scheme 4).11d 
 
 Introduction 
8 
 
S
OAr
O
R2R1
S
O
R2R1
S
S
O
R2R1
RSH
BF4
pyridine R
RS
R1 = phenyl, R2 = methyl, R = H, benzyl
Sulfoxide
NaBH4-Al2O3 S
H
O
R2R1 -H
+
R1, R2 = alkyl, aryl
Oishi's approach (79 - 84%)
Still's approach (13 - 95%)
Sulfoxonium salt
 
Scheme 4. The reduction of the sulfoxonium salt 
 
4.2.4. The investigation of reaction parameters 
 
Shortly after, Still and co-workers investigated several of the reaction parameters, including 
the amount of diazonium salt used, its counter ion, the reaction temperature, and the solvent 
concentration. For synthetic studies using a 3:1 ratio of sulfone to diazonium salt, they found 
that using more sulfone led to increasing amounts of black decomposition products. In 
addition, they showed that the excess amount of sulfone can be readily recovered and recycled. 
With the effects of various structures of the arene diazonium salts, the counter ion used, and 
solvent/temperature conditions in hand, they reported that p-chlorobenzene diazonium 
tetrafluoroborate salt showed the highest level of electrophilicity and there were no ortho-
substituted effects due to steric factors. Furthermore, the hexafluorophosphate salt was not 
able to minimise the competing Schiemann reaction (Scheme 2) compared with the 
tetrafluoroborate salt. In order to avoid the Schiemann product, several attempts to use 
metallic copper and add 18-crown-6 were carried out. Unfortunately, all trials failed. For one 
specific case of dimethylsulfone, however, the reaction in heating under vacuum to 130 oC led 
to the corresponding ary1oxysulfoxonium salt in significantly higher yield (72%).11e  
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5. General procedure for the synthesis of sulfoximines 
 
In Scheme 5, the oldest and most popular method for the synthesis of free NH-sulfoximines is 
shown. Accordingly, a sulfoxide is synthesized by oxidation of the sulfide with a combination 
of H2O2 and AcOH. Subsequently, the NH-sulfoximine is obtained by imination of the 
sulfoxide with hydrazoic acid, which is generated in situ by reaction of sodium azide and 
sulfuric acid. However, due to the limited scope and toxicity of the reagents, this strategy is 
considered synthetically problematic.12 
 
Ph
S
CH3
1. H2O2, AcOH
2. NaN3, H2SO4
17 18
Ph
S
CH3
O NH
 
Scheme 5. Synthesis of NH-sulfoxmine starting from sulfide 
 
A more practical method for the synthesis of NH-sulfoximines, a procedure reported by Bolm 
and co-workers13 is considered an alternative and safe method (Scheme 6). Furthermore, the 
N-cyano sulfoxmine functionality has attracted remarkable attention in agrochemicals after 
the discovery of Sulfoxaflor by Dow AgroScience. This method can be considered the most 
preferable way for the preparation of the N-cyano sulfoximine moiety.9a  
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R2
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R2
N
CN
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S
R2
O N
CN
R1
S
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O NH
Sulfide N-Cyano sulfilimine NH sulfoximineN-Cyano sulfoximine
a b c
 
Scheme 6. Reaction conditions: (a) NH2CN, PhI(OAc)2, CH3CN, 0 oC to RT or NH2CN, NBS, t-
BuOK, MeOH, RT; (b) m-CPBA, K2CO3, EtOH, RT; (c) TFAA, CH2Cl2, RT, then K2CO3, MeOH, RT 
or aqueous H2SO4 (50%), 110 oC, 1 h. 
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6. The lead compounds having a methylphenyl sulfonyl moiety 
 
Vioxx® (Rofecoxib)
O
O
S
CH3
O O
19
 
Figure 8. Vioxx® for initial studies 
 
In order to investigate the effect on biological activity of changing the sulfone functional 
group to a sulfoximine, several lead compounds containing the sulfone moiety were identified. 
To this end, the widely known drug Vioxx® (Rofecoxib), a nonsteroidal anti-inflammatory 
drug (NSAID),14 was selected for the initial studies. Because of safety concerns (increased 
risk of heart attack and stroke associated with long-term, high-dosage use), it was withdrawn 
from the market on September 30, 2004.15 It had obtained widespread acceptance among 
physicians dealing patients with arthritis and other conditions causing chronic or acute pain. 
Since Vioxx® was one of the most widely used drugs and had sold US$ 2.5 billion in the 
market,16 it was believed that the finding of beneficial effects would attract significant 
attention in the medicinal community.  
In constructing additional examples of the sulfoximine-based analogs, other known 
methylphenyl sulfone-based COX-2 inhibitors17 were selected for the subsequent studies. 
These reported COX-2 inhibitors will be described in more detail in Section 6.3 (particularly, 
DuP 697 and Arcoxia®). Here in Figure 9, their structural features are highlighted.  
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Figure 9. The additional examples of the known methylphenyl sulfone-based COX-2 inhibitors 
 
6.1.  Cyclooxygenase (COX) enzymes 
 
Vane and colleagues,18 in their study on aspirin and other nonsteroidal anti-inflammatory 
drugs (NSAIDs), discovered that they inhibited the enzyme activity that converts 
polyunsatuarted fatty acid to prostaglandins during the inflammatory process. 
Cyclooxygenase (COX) catalyzes the double dioxygenation of arachidonic acid to 
prostaglandin endoperoxides (PGG2 and PGH2), which serve as the precursor for the 
biosynthesis of various PGs, thromboxanes, and prostacyclin.21h After isolation of a purified 
and enzymatically active COX in 1976,19 two isoforms of COX with approximately 60% 
identical amino acid sequences but very differential patterns of regulation and tissue 
localization were reported in 1991.20 In contrast to the somewhat widespread constitutive 
expression and oxidation of COX-1 with only free fatty acids, COX-2 is highly inducible and 
oxidizes fatty acids and certain fatty acid ester and amides.21g COX-2 expression is stimulated 
by an extremely broad range of agonists, including cytokines, growth factors, tumor 
promoters, viruses, bacterial lipopolysaccharide, and laminar flow stress inter alia. The 
inducibility of COX-2, particularly in macrophages treated with cytokines, and its inhibition 
by anti-inflammatory steroids suggested that COX-2 is the true molecular target for the anti-
inflammatory effects of NSAIDs. Furthermore, the presence of COX-1 in the gastrointestinal 
tract led to the hypothesis that COX-2 selective inhibitors could be potent anti-inflammatory 
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agents without the undesired side effects, especially gastrointestinal toxicity, which has been 
associated with the inhibition of COX-1.21h 
 
6.2. COX enzymes catalyzed prostaglandin synthesis 
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Scheme 7. Highlighted cyclooxygenase pathway of arachidonic acid metabolism.27a 
The release of arachidonic acid from phospholipid stores following cell stimulation is the 
major control point in PG biosynthesis. Arachidonic acid is oxygenated by one of three 
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different oxygenases.22 Certain cytochromes, namely P-450, insert a single oxygen atom in 
the double bonds of arachidonic acid to generate epoxy-arachidonic acids.23 Lipoxygenases 
place one molecule of O2 in the carbon framework of arachidonic acid to generate a series of 
isomeric hydroperoxy acids.24 These hydroperoxy fatty acids are transformed to hydroxy fatty 
acids, to leukotrienes, and to lipoxins.22b 
COX-1 and COX-2 perform the double dioxygenation of arachidonic acid to prostaglandin G2 
(PGG2) and the reduction of PGG2 to PGH2. Arachidonic acid oxygenation takes place in the 
cyclooxygenase active site, and PGG2 reduction happens in the peroxidase active site. PGH2 
spreads from the COX proteins and is converted by different tissue-specific isomerases to 
prostaglandins (PGE2, PGD2, PGF2α, PGI2) and thromboxane A2 (TxA2).21h 
 
6.3. The diaryl heterocycle class of COX-2 selective inhibitors 
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Figure 10. Derivation of COX-2 selective inhibitors from an early lead compound21g 
Phenylbutazone and oxaprozin were developed as both anti-inflammatory and analgesic 
agents. With variations on the central heterocyclic ring, other diaryl heterocycles were 
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synthesized and screened as COX inhibitors and anti-inflammatory agents. DuP 697, 
developed by DuPont-Merck, was able to inhibit the COX activity of activated macrophages 
but not the COX activity present in platelets. Although this was an enigmatic discovery at the 
time, it was later explained through differences in the expression profiles of COX-2 and 
COX-1. DuP 697 showed selective inhibitory activity against the COX-2 protein induced in 
lipopolysaccharide-activated macrophages. Thus, this compound became an attractive lead for 
the development of selective COX-2 inhibitors. In further extensive structure-activity 
relationship studies, it was proved that the important structural features of various COX-2 
selective inhibitors include (1) two aromatic rings attached to a heterocycle or carbocycle and 
(2) the presence of a sulfonamide or methyl sulfone group on one of the para positions of one 
of the phenyl rings.21g,25  
A general interest in fundamental factors of COX-2 selective inhibitors has prompted these 
studies, which explore new sulfilimine- and sulfoximine-based COX-2 inhibitors. 
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6.4. The relationship between COX-2 and cancer 
Since the first report of the link between tumors and a high-level of prostaglandin E2 (PGE2), 
the involvement of COX in the development and progression of cancer has been recognized.26 
Strong preclinical data supports that COX plays a key role in tumorigenesis.28a In 1991, the 
report, which studied the application of aspirin for reduced risk of fatal colon cancer, 
suggested a strategy for cancer prevention via COX inhibiton.27 The discovery, that there is 
high expression of COX-2 in human colon cancers led to the strategy of utilizing COX-2 
inhibition. In addition, similar observations have been reported for most solid tumors except 
ovarian cancer, where COX-1 appears to be induced. In retrospective studies, a significant 
relationship between over-expression of COX-2 and survival of patients with various cancers 
has been reported.28c It is supported by an even larger amount of evidence that COX-2 affects 
cancer by increasing in the production of PGs, carcinogenesis, inhibition of apoptosis, 
angiogenesis, and invasion of cancer.28d Despite their profound activities, however, the 
cardiovascular side effects of COX-2 inhibitors have limited their use in cancer prevention 
and therapy. This is considered to only be an issue in the case of long-term usage. Thus, 
COX-2 is a very promising target for cancer prevention and treatment.21g 
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Results and discussion 
    Part I. Chemistry 
A. Direct structural conversion using arene diazonium tetrafluoroborate salts 
This section first introduces the arene diazonium tetrafluoroborate salts used for the direct 
conversion of a sulfone to a sulfoximine and a sulfonamide to a sulfonimidamide. It then 
covers the optimization procedures, which attempt to increase the yield by using various arene 
diazonium salts, substrates, and heating methods. The section ends with a brief discussion of 
achievements and limitations. 
 
1. Initial studies 
 
It was envisaged that the arene diazonium salts could be applied to the direct structural 
conversion of a sulfone to a sulfoximine in a more convenient and facile way than the 
approaches previously reported in the literature. Following Oishi’s work,11c the studies began 
with the preparation of N-benzylmethylphenyl sulfoximine (23a). An initial difficulty for 
performing the reaction was that it was not clear which reaction condition to take from the 
literature, since each report did not clearly mention the procedure details. Finally, the optimal 
reaction conditions involved the use of sulfone (3 eq), a solvent (CH3CN, 6 eq), a 
decomposition temperature of p-chlorobenzene diazonium tetrafluoroborate salt (21b, 145 οC: 
10 οC above its melting point), a reaction time (0.5 h), and the amount of benzyl amine (3 eq). 
Initial studies, unfortunately, only afforded the desired N-benzylmethylphenyl sulfoximine 
(23a) in low yield (over two steps, 31%) (Scheme 8). Furthermore, all additional attempts to 
obtain the pure sulfoxonium salt 22b were unsuccessful. 
 
 Results and discussion 
17 
 
Scheme 8. The synthesis of N-benzylmethylphenyl sulfoximine (23a) 
145 oC, 0.5 h
21b Iminationb
20
S
CH3
O O
BF4
22b
S
CH3
O O
Cl
23a
S
CH3
O N
Bn
31% yieldc  
           a20 (3 eq), 21b (1 eq); bbenzyl amine (3 eq), CH3CN (6 eq), RT, overnight; 
           cAfter column chromatography, over two steps. 
 
 
2. From the methylphenyl sulfone to the N-cyanomethylphenyl sulfoximine 
2.1. Oil-bath heating 
 
In order to synthesize an N-cyano sulfoximine, the protocol discussed above was applied and 
optimized. The first attempt, using cyanamide as a nucleophile, was unsuccessful. It was 
subsequently determined that potassium or sodium cyanamide successfully afforded the 
desired N-cyano sulfoximine. No difference in yield was observed when sodium or potassium 
salts were used.  
Moreover, various arene diazonium tetrafluoroborate salts were tested, all bearing one or 
more substituents, such as OMe and CH3, at the meta or para position. In Still’s research, 
when electron-withdrawing groups, such as NO2, CN, F, CF3, and Cl, were used, it was found 
that the p-chlorobenzene diazonium tetrafluoroborate salt (21b) was the most effective 
electrophile.11e Because of this result, m- and p-chloro substituents 21b and 21c were also 
examined. Of note, with a compound bearing a p-methoxy substituent 21d, the desired 
sulfoxonium salt was not formed. As shown in Table 1, although all of the obtained yields 
were moderate, the compounds with m-OMe and m,m-OMe  substituent 21e, 21h showed 
comparative yields with the p-chloro compound 21b. 
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Table 1. The investigation of various arene diazonium tetrafluoroborate salts 
N2 BF4
100-155 oC,a 0.5 h
BF4
KHNCN (3 eq)
RT, overnight
CH3CN (15 eq)
(3 eq)
(1 eq)
20
21a-g
22a-h 23b
R
S
CH3
O O
S
CH3
O O
S
CH3
O N
CN
R
 
Entry R
N-Cyano Sulfoximine (23b)
Yield (%)b
1 24
2 p-Cl 35
3 m-Cl 19
4 m-OMe 30
5 p-CH3 10
6 m-CH3 17
7 m,m-OMe 27
Arene diazonium 
tetrafluoroborate salt
21a
21b
21c
21e
21f
21g
21h
H
 
                     a10 oC above the melting point of the corresponding arene diazonium tetrafluoroborate salt; 
                     bAfter column chromatography, over two steps. 
 
 
2.2. Microwave heating 
 
In previous studies focused on sulfone preparation, oil-bath heating has been used as the 
standard method of heating. To extend the scope of the procedure with high heating efficiency, 
and to increase the yield (over two steps), the use of microwave-assisted heating during the 
oxosulfonium salt formation was investigated. It has been demonstrated that microwave 
radiation can lead to a rapid temperature increase throughout the reaction mixture, resulting in 
minimization of byproducts and decomposition products.30  
 
 Results and discussion 
19 
 
Scheme 9. The conversion of sulfone 20 to sulfoximine 23b using microwave heatinga  
 
MW, 40-145 oC, 15-20 min
21b Iminationb
20
S
CH3
O O
BF4
22a-h
S
CH3
O O
Cl
23b
S
CH3
O N
CN
38% yieldc (69%)d  
           a20 (5 eq), 21b (1 eq); bKHNCN (3 eq), CH3CN (15 eq), RT, overnight; 
           cAfter column chromatography, over two steps; dRecovered excess substrate. 
 
As shown in Scheme 9, the highest yield (38%) was achieved using microwave heating at 60 
oC for 20 min. When heated over 100 oC, the substrate decomposed to the sulfide. Moreover, 
the microwave heating and oil-bath heating in the imination step afforded a lower yield (for 
more details, see experimental section, Table 31). 
 
3. From a sulfonamide to the corresponding N-cyano sulfonimidamide 
3.1. Oil-bath heating 
 
With the optimized conditions established, the procedure for directly converting the structure 
of a sulfonamide to a sulfonimidamide was explored.   
 
Scheme 10. The conversion of sulfonamide 24 to sulfonimidamide 26a 
Iminationb
S
N
O N
CN
CH3
CH3
I
26a (27% yieldc)
S
N
O N
CN
CH3
CH3
26b (28% yieldc)
S
N
O N
CN
26c (12% yieldc)
S
N
O N
CN
CH3
CH3
26d (25% yieldc)
BF4
24a-d 25a-d 26a-d
145 oC, 0.5 h
21b
R1
S
N(R2)2
O O
R1
S
N(R2)2
O O Cl
R1
S
N(R2)2
O N CN
 
 
                 a24a-d (3 eq), 21b (1 eq); bKHNCN (3 eq), CH3CN (15 eq), RT, overnight;  
                 cAfter column chromatography, over two steps. 
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Similar to the previous work with the sulfone, the reaction of sulfonamide 24 with p-
chlorobenzene diazonium tetrafluoroborate salt (21b) was carried out at 145 oC for 0.5 h. 
Imination was then performed at room temperature overnight to give the desired N-cyano 
sulfonimidamide 26 in low to moderate yield (12%–29%) (Scheme 10). 
 
To optimize this process, the amount of sulfonamide employed as substrate was then 
examined (Table 2). Increasing it from 3 equivalent to 10 equivalent led to a higher yield 
(over two steps, 3 eq: 27%, 10 eq: 39%). Furthermore, it is important to note that almost all of 
the excess substrate was easily recovered after the reaction. 
 
Table 2. Investigation in the amount of sulfonamide 24a 
Entry Sulfonamide (24a) eq
N-Cyano sulfonimidamide (26a)
Yield (%)a
1
5 36 (90)b2
3 27 (83)b
3 10 39 (83)b
 
                                      aAfter column chromatography, over two steps; bRecovered excess substrate. 
 
 
3.2. Microwave heating 
 
In the same context, microwave heating was also considered for the preparation of 
sulfonimidamides (Scheme 11). A test reaction was performed under a similar set of reaction 
conditions. The optimal condition was obtained using microwave heating at 100 oC for 20 
minutes (over two steps, 37% yield). Of note, heating to 120 oC led to decomposition. An 
investigation of the heating time showed that a shorter reaction time allowed better recovery 
of the excess substrate (20 min vs. 40 min). For the solution-phase synthesis, CH3CN was 
added as a solvent during microwave heating in failed attempt to enhance yield (for more 
details, see experimental section, Table 32). 
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Scheme 11. Conversion of sulfonamide 24a to sulfonimidamide 26a using microwave heatinga 
 
S
N
O O
CH3
CH3
I
S
N
O O
CH3
CH3
I
Cl S
N
O N
CN
CH3
CH3
IMW, 60-120 
oC, 20-40 min
BF4
24a 25a 26a
21b Iminationb
37% yieldc (91%)d  
  a24a (5 eq), 21b (1 eq); bNaHNCN (3 eq), CH3CN (15 eq), RT, overnight;  
cAfter column chromatography, over two steps; dRecovered excess substrate. 
 
 
4. Summary 
 
New approaches have been established that incorporate the N-cyano group on sulfoximine 
and sulfonimidamide via direct structural conversion using p-chlorobenzene diazonium 
tetrafluoroborate salt. At this stage, the highest yield provided by these procedures was near 
40% (over two steps) for both sulfone and sulfonamide. Unfortunately, all attempts to 
increase the yield have so far been unsuccessful. In Whiting’s studies on the various arene 
diazonium salts, aryloxysulfoxonium salts were obtained only in a low yield (3%-44%).11a 
Moreover, Still reported that the reaction of sulfone with p-chlorobenzene diazonium 
tetrafluoroborate afforded the aryloxysulfoxonium salts in moderate yield (37%–61%).11d 
Based on the literature and reactions reported herein, it appears that the limitation of this 
approach could be the activation of the oxygen atom of sulfone using arene diazonium salts. 
In addition, it should be highlighted that difficulties exist for the purification of the 
sulfoxonium salts. Further studies should be carried out to identify a better electrophile for the 
activation of sulfone.  
Due to these difficulties, a more facile and practical synthetic method, involving key 
intermediates of N-cyano sulfilimines and sulfoximines,13 has been employed in the 
preparation of sulfilimine- and sulfoximine-based COX-2 inhibitors.           
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B. Synthesis of sulfilimine- and sulfoximine-based COX-2 inhibitors 
 
This section describes synthetic approaches toward target molecules. It begins by looking at 
the best stages of the sulfoximination. It then discusses the arising difficulties during the 
preparation of sulfilimine- and sulfoximine-based COX-2 inhibitors. The section ends with 
the highlighted table, focusing on how the synthetic method, including the key intermediates 
of N-cyano sulfilimine and sulfoximine, is facile and practical. 
   
1. Vioxx® analogs 
1.1. Retrosynthetic analysis 
 
S
CH3
O N
R
O
O
S
CH3
O N
CN
O
Br
S
CH3
H3C
O
S
O
O
CH3 OH
O
O
Synthetic route A
Synthetic route B
2831
38 35
32a-c
 
Figure 12. Retrosynthesis of sulfilimine- and sulfoximine-based Vioxx® analogs 
 
A retrosynthesis of sulfilimine- and sulfoximine-based Vioxx® analogs is shown in Figure 12. 
For the synthesis, the reported synthetic approach of Vioxx® was planned to be modified.31 
The sulfoximine moiety could readily be introduced through the key intermediates of N-cyano 
sulfilimines and sulfoximines.13 In the case of synthetic route A,32 the N-cyano sulfoximine 
moiety would be introduced at an early stage. In order to prepare the lactone 32, the coupling 
and cyclization of bromoketone could be completed in a one-pot procedure. The 
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sulfoximination and subsequent bromination of acetophenone 28 should provide the desired 
2-bromo-1-[4-(N-cyanomethyl-sulfonimidoyl)phenyl]ethanone (31).  
An alternative synthetic route was also planned, illustrated in Figure 12, Synthetic route B.33 
In this case, lactone 35 would initially be prepared, and Suzuki cross-coupling should provide 
4-[4-(methylthio)phenyl]-3-phenylfuran-2(5H)-one (38). Finally, sulfoximination of the 
sulfide would give the desired compounds 32.  
    
1.2. Synthetic route A (Sulfoximination at the early stage) 
 
S CH3
H3C
O
S CH3
H3C
O
S
CH3H3C
O
N CN
O N
CNS
CH3
O
O N
CN
Br
O
O
S
CH3
O N
CN
28 29
303132a
S CH3
27
a b
c
de
87% 81%
86%
49%54%
 
Scheme 12. Reagents and conditions (a) Acetylchloride, AlCl3, CH2Cl2, RT, 30 min; (b) NH2CN, 
PhI(OAc)2, CH3CN, RT, 1 h; (c) K2CO3, m-CPBA, MeOH, RT, 30 min; (d) AlCl3, Br2, CH2Cl2, 45 °C, 
24 h; (e) Et3N, Phenylacetic acid, DBU, CH3CN, 90 °C, 24 h.  
 
As illustrated in Scheme 12,32 a Friedel-Crafts acylation of commercially available 
thioanisole 27 produced acetophenone 28. Imination of 28 with a reaction mixture of 
cyanogen amine and PhI(OAc)2 led to N-cyano sulfilimine 29, and the subsequent oxidation 
with a combination of m-CPBA and K2CO3 in methanol provided the desired N-cyano 
sulfoximine 30.13 Of note, the sulfoximination proceeded with yields above 80%. The N-
cyano sulfoximine 30 was then reacted with bromine in CH2Cl2 in the presence of a catalytic 
amount of AlCl3 to give bromoketone 31. For the ensuing steps (coupling and cyclization), a 
one-pot procedure was applied. First, a mixture of 31 and phenyl acetic acid in acetonitrile 
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was reacted with triethylamine at room temperature, affording an ester intermediate (not 
shown), followed by cyclization by addition of DBU at 0 oC to yield lactone 32a.31 
 
 
1.2.1.  Studies of Friedel-Crafts acylation 
 
The investigation of the Friedel-Crafts acylation is shown in Table 3. The acylated compound 
28 could be readily synthesized by Friedel-Crafts acylation of thioanisole 27, whereas it was 
not possible in the case of the substrate 27a having the N-cyano sulfoximine moiety. In 
contrast to the electron-rich sulfide, the electron-deficient sulfonimidoyl group caused these 
difficulties (Scheme 13).34  
 
Table 3. Friedel-Crafts acylation (structure dependence)a 
Entry Substrate Product Yield (%)b
1
2
S
CH3
H3C
O
87
S
CH3H3C
O
O N
CN
no recation
S
CH3
S
CH3
O N
CN
27 28
27a 28a
 
                                    aReaction conditions: Acetyl chloride, AlCl3, CH2Cl2, RT, 30 min; 
                                bAfter column chromatography. 
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O AlCl3
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O
AlCl3
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S
CH3
H3C
O
H
Cl
S
CH3
H3C
O
Case 1: Thioanisole
Case 2: N-cyano sulfoximine
27
28
27a 28a  
Scheme 13. Mechanism of Friedel-Crafts acylation34  
 
 
1.2.2. Synthesis of N-cyano sulfilimine 29 
 
Metal-free oxidative imination methods13 were employed to introduce the N-cyano sulfilimine 
group. While the reaction with NBS as the halogenating agent in the presence of t-BuOK as a 
base (Table 4, entry 1) did not afford N-cyano sulfoximine 29, the procedure using 
hypervalent iodinanes such as PhI(OAc)2 provided the target molecule 29 in good yield. 
Kemp and co-workers,35e in their studies on penicillin N-cyanosulfilimines, showed that 
imination of sulfide with a combination of cyanamide and PhI(OAc)2 afforded the N-cyano 
sulfilimine via a sulfide diacetate intermediate (mechanistic studies using lead tetra acetate,35d 
see Scheme 15) . It is proposed that an acidic proton of the acetyl group caused difficulties in 
the oxidative addition of the halo compound to the sulfide, as well as the nucleophilic attack 
of the amide anion on the sulfonium salt (Scheme 14).35a,b  
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Table 4. Metal-free oxidative iminations 
 
S
CH3
H3C
O
S
CH3
H3C
O
N
CN
Conditions
28 29
Entry Condition Yield (%)a
1 H2NCN, t-BuOK, NBS, MeOH, rt, 0.5 h to overnight No reaction
2 PhI(OAc)2, H2NCN, MeCN, rt, 0.5 h 81
 
                          aAfter column chromatography 
 
R1
S
R2
+
R1
S
R2
X
N
O
O
R1 S
R2
N
O
O
X R3NH2
base
R1
S
R2
NR3N
O
O
X
X = Cl, Br  
Scheme 14. The reaction of sulfides with halogenating agents  
N-chlorosuccinimide (NCS) and N-bromosuccinimide (NBS)35a,b 
 
 
Pb(OAc)4 ArSO2NH2
Sulfide diacetate
intermediate
Me
S
Me
Me
S
Me
OAc
OAc
Me
S
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NSO2Ar
 
Scheme 15. Synthesis of sulfilimines via a sulfide diacetate intermediate 
 in the studies of Cadogan and Gosney35d 
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1.3. Synthetic route B (Sulfoximination at the final stage)33 
 
O
O
O
EtO
HO
O O
OH
O
O
OTf
O
O
Br
O
O
O
S
CH3
O
O
S
CH3
N
CN
O
O
S
CH3
N
CN
O
a b
c
de
f
g
92%
43%
33 34 35
363738
39 32a
87% 43%
66%
88%52%
 
Scheme 16. Reagents and conditions: (a) Ethyl bromoacetate, Et3N, THF, 60 °C, 1 h; (b) Potassium 
tert-butoxide, tert-butanol, 70 °C, 1 h; (c) N,N-diisopropylethylamine, trifluoromethansulfonyl 
anhydride, CH2Cl2, 0 °C, 10 min; (d) Lithium bromide, acetone, 50 °C, 30 min; (e) Pd(PPh3)4, aqueous 
2M Na2CO3, 4-methylthiophenyl boronic acid, toluene/EtOH (1:1), 110 °C, overnight; (f) NH2CN, 
PhI(OAc)2, CH3CN, RT, 1 h; (g) K2CO3, m-CPBA, MeOH, RT, 30 min. 
 
Starting from phenylacetic acid 33, esterification of 33 with a combination of ethyl 
bromoacetate and triethylamine afforded ester 34, followed by cyclization employing t-
BuOK/t-BuOH to give tetronic acid 35. Triflation of tetronic acid 35 with N,N-
diiospropylethyl amine and trifluoromethansulfonyl anhydride led to the desired tetronic acid 
triflate 36. The Pd(0)-catalyzed cross-coupling (Suzuki) reaction of 4-bromo tetronic acid 37, 
which was obtained by bromination of triflated tetronic acid 36, with 4-methylthiophenyl 
boronic acid afforded the sulfide 38. Imination of 38 with a mixture of cyanogen amine and 
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PhI(OAc)2 readily led to the N-cyano sulfilimine 39, which was subsequently oxidized with 
m-CPBA and K2CO3 in methanol, providing a facile route to N-cyano sulfoximine 40. 
 
 
1.4. Synthesis of NH-sulfoxmine 32b 
 
Initially, cleavage of the N-cyano group was attempted with the N-trifluoroacetylsulfoximine 
substrate through methanolysis of the trifluoroacetyl moiety (Table 5, entry 1).13b 
Unexpectedly, using this condition, the desired product was not obtained. This was 
presumably due to the fact that the lactone core structure is not stable under basic conditions 
because of acidic protons. Alternatively, the approach using strong acid (Table 5, entry 2) 
readily afforded NH-sulfoximine 32b.36 Based on this observation, this procedure was 
employed for the removal of cyano group in all other reactions.      
 
Table 5. Cleavage of the N-cyano group 
S
CH3
O NH
O
O
S
CH3
O N
O
O
CN
32a 32b
Entry Condition Yield (%)a
1 i) TFAA , CH2Cl2, RTii) K2CO3, MeOH, RT
aqueous H2SO4 (50%), 4 h2
No reaction
62
 
                                                   aAfter column chromatography 
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1.5. Synthesis of N-methyl sulfoximine 32c 
 
In order to prepare the N-methyl sulfoximine moiety, various methods were trialed. In the 
case of basic conditions such as using NaH and the t-BuOK/t-BuOH system, the desired 
product was not obtained. Reductive methylation under Eschweiler-Clarke conditions37 led to 
the mono-methylated product 32c. However, the reaction required a high temperature and a 
long time to reach completion (Table 6, entry 5). It seems reasonable to consider that high 
temperatures and longer reaction times are required due to the difficulty in forming the N-
imine structure. With the optimized conditions established, this protocol was employed in the 
preparation of N-methyl sulfoximine. 
 
Table 6. Investigations of N-methylation 
S
CH3
O N
O
O
CH3S
CH3
O NH
O
O
Conditions S
CH3
O N
CH2
N-imine sulfoximine
32b 32c  
Entry Condition Yield (%)a
1 NaH, MeI, DMF
t-BuOK, MeI, t-BuOH, 40 oC, overnight2
No reaction
aqueous CH2O (37%), formic acid, 100 oC, 24 h
para-formaldehyde (10 eq), formic acid, 100 oC, 5 days
para-formaldehyde (10 eq), formic acid, 150 oC, 3 days
No reaction
No reaction
No reaction
75
3
4
5
 
           aAfter column chromatography 
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1.6. Summary 
 
Using a different approach, sulfilimine- and sulfoximine-based Vioxx® analogs have 
successfully been prepared. Due to the difficulties arising from bromination and cyclization of 
bromoketone 31 containing the N-cyano sulfoximine moiety, synthetic route A cannot be 
considered an efficient route. Synthetic route B, involving sulfoximination at the last stage, is 
more convenient than route A.  
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2. Arcoxia® analogs 
2.1. Retrosynthetic analysis 
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N
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O N
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48a-e
 
Figure 13. Retrosynthesis of sulfilimine- and sulfoximine-based Arcoxia® analogs 
 
A retrosynthetic analysis of sulfilimine- and sulfoximine-based Arcoxia® analogs 48 is 
illustrated in Figure 13. An original strategy for the synthesis of Arcoxia® was planned to be 
followed.17a,b The sulfoximine moiety could be introduced by methods that include the key 
intermediates of N-cyano sulfilimine and sulfoximine.13  
For synthetic route A, sulfoximination at the final stage would lead to the desired sulfoximine 
48a-e. In order to prepare the derivative containing sulfide and bispyridine 46, a Pd(0) 
catalyzed cross-coupling reaction (Suzuki) was predicted. A 2-hydroxy pyridine 41 compound 
could be used for the starting material.  
In synthetic route B, a cross-coupling reaction of the 2-trifluoromethanesulfonate pyridyl 
compound 58c would afford the target molecule 48a. In this case, the sulfoximination could 
be carried out at an early stage. The sulfoximination of 2-hydroxy and 2-amino pyridine 
compounds 41, 50 would lead to the desired N-cyano sulfoximines 53, 55. A Suzuki cross-
coupling reaction of 2-hydroxy and amino pyridine compounds 41, 50 should provide 3-[4-
(methylthio)phenyl]pyridine 44, 51, respectively.  
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2.2. Synthetic route A (Sulfoximination at the final stage) 
 
Starting from 5-chloropyridin-2-ol (40), 2-(benzyloxy)-5-chloro-3-[4-(methylthio)-
phenyl]pyridine (43) was prepared in good overall yield.   
 
N
40
N
Br
41
OH N
Br
42
OBn
N OBn
43
a b cCl
OH
Cl Cl
S
CH3
Cl
66% 86% 99%
 
Scheme 17. Reagents and conditions: (a) Acetic acid, Br2, RT, 1 h; (b) Ag2CO3, BnBr, toluene, 90 °C, 
4 h; (c) Pd(PPh3)4, 4-(methylthio)phenylboronic acid, K2CO3, CH3CN/H2O(3:1), 90 °C, 1.5 h. 
 
As described in Scheme 17, 3-bromo pyridine 41 was prepared by bromination of 5-
chloropyridin-2-ol (40) with acetic acid and Br2. O-Benzyl protection of 41 with silver 
carbonate and benzyl bromide easily gave O-Benzyl protected pyridine 42, which was 
subsequently reacted through Pd(0)-catalyzed cross-coupling (Suzuki) with 4-
(methylthio)phenylboronic acid, affording the desired compound 43 in quantitative yield.17a,b 
Next, for the subsequent cross-coupling reaction, the introduction of a chloride group in the 2-
position of pyridine was investigated (Scheme 18). 
 
N OBn
43 44 45
a b
S
CH3
Cl
N OH
S
CH3
Cl
N Cl
S
CH3
Cl
63% 90%
 
Scheme 18. Reagents and conditions: (a) Trifluoroacetic acid, 40 °C, 30 min; (b) POCl3, 150 °C, 24 h. 
 
Debenzylation of 43 in acidic conditions yielded a 2-hydroxy pyridine compound 44. 
Subsequently, chlorination with POCl3 afforded a 2-chloro pyridine derivative 45.17a,b  
Finally, as shown in Schemes 19 and 20, sulfoximine-based Arcoxia® analogs 48a,b were 
readily obtained via the N-cyano sulfilimine intermediate 47. 
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Scheme 19. Reagents and conditions: (a) Pd(PPh3)4, 2-Picoline-5-boronic acid pinacol ester, 2M 
Na2CO3, EtOH/toluene(1:1), 120 °C, 24 h. (b) NH2CN, PhI(OAc)2, CH3CN, RT, 2 h. 
 
A Pd(0)-catalyzed cross-coupling reaction provided a bispyridine derivative 46.17a,b 
Subsequent imination of the sulfide 46 successfully gave N-cyano sulfilimine 47.13  
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Scheme 20. Reagents and conditions: (a) m-CPBA, K2CO3, RT, 2 h. (b) Aqueous H2SO4 (50%), 
110 °C, 1 h. 
 
The oxidation of 47 with a combination of m-CPBA and K2CO3 in MeOH provided the 
desired N-cyano sulfoximine 48a.13 NH-sulfoximine 48b was obtained following the cleavage 
of the cyano group of 48a using highly acidic conditions.32, 36 
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2.3. Synthetic route B (Sulfoximination at the early stage) 
 
Encouraged by the straightforward method of using 2-hydroxy pyridine as a starting material 
(synthetic route A), the 2-amino pyridine compound 51 was also examined. 
N
Cl
NH2 89% N
Cl
NH2
Br
N
Cl
NH2
S
CH3
91%
a b
49 50 51  
Scheme 21. Reagents and conditions: (a) NaOAc, Br2, CH3CO2H, 45 °C, 30 min; (b) Pd(PPh3)4, 
K2CO3, 4-(methylthio)phenylboronic acid, CH3CN/H2O (3:1), 80 °C, 19 h. 
 
A facile procedure for preparing the sulfide 51 is described in Scheme 21. Pd(0) catalyzed 
cross-coupling reaction (Suzuki) of 3-bromo pyridine derivative 50, which was obtained by 
bromination of 5-chloropyridin-2-amine (49), resulted in the desired compound 51 in 
excellent yield.17a,b 
 
As shown in Scheme 22, imination of the sulfide 51 was attempted using metal-free oxidative 
imination.13 However, both trials only afforded the product in an unknown mixture (analyzed 
by 1H, 13C NMR). Unfortunately, all attempts to purify the mixture by normal column 
chromatography failed.  
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Scheme 22. Reagents and conditions: (a) H2NCN, t-BuOK, NBS, MeOH or PhI(OAc)2, H2NCN, 
CH3CN (b) m-CPBA, K2CO3, MeOH, RT, 30 min. 
 
The subsequent oxidation13 of crude sulfilimine 52 with a combination of m-CPBA and 
K2CO3 afforded the sulfone analog (13 %) instead of the desired N-cyano sulfoximine 53. It 
seems reasonable to believe that N-cyano sulfoximine 53 was not readily available under 
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standard conditions13 in the compound containing the free amino group. In particular, the 
amidyl moiety may have caused these difficulties in the imination by using a halogenating 
agent in the presence of a base or hypervalent iodinanes. Further attempts to protect the 
substrate containing the 2-amino group 51, unfortunately, were unsuccessful.  
 
It became clear that the free amino group did not allow the targeted sulfoximination to 
proceed. O-Benzyl protected pyridine 43 was alternatively selected for the preparation of N-
cyano sulfoximine 55. 
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Scheme 23. Reagents and conditions: (a) PhI(OAc)2, H2NCN, CH3CN (b) m-CPBA, K2CO3, MeOH, 
RT, 30 min. 
 
In this case, it was possible to obtain the N-cyano sulfoximine 55 by imination and 
oxidation.13  
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2.3.1. Studies of deprotection of the O-benzyl group 
 
Table 7. Attempts at debenzylation 
N OBn
S
CH3
Cl
N OH
S
CH3
Cl
O N
CN
O N
CN
55 56
Conditions
 
Entry Condition Yield (%)a
1 TFA, RT-40°C, 15-30 min No reaction
2 10% Pd/C, H2, EtOAc, overnight 18
3 10% Pd/C, H2, MeOH, overnight 71  
                                             aAfter column chromatography. 
 
Although initial studies were based on the same conditions of the sulfide 43 case,17a,b it was 
not successful in the case of the compound 55 with N-cyano sulfoximine moiety. It may be 
because the N-cyano sulfoximine 55 could not be tolerated in this strong acidic condition (see 
Section 3.4). Alternatively, hydrogenation with Pd/C38 led to the desired 5-chloro-3-[4-(N-
cyanomethylsulfonimidoyl)phenyl]pyridine-2-ol (56). It is interesting to note that the solvent 
was important for increasing yield (Table 7, entry 2: EtOAc, entry 3: MeOH).  
 
 Results and discussion 
37 
 
2.3.2. Attempt to convert a hydroxyl group to a chlorine group and a OTf group in 
2-position of pyridine 
 
Table 8. Investigation of the introduction of arylhalide and pseudohalide groups 
N OH
S
CH3
Cl
N X
S
CH3
Cl
O N
CN
O N
CN
56 58a-c
Conditions
N
H
O
S
CH3
Cl
O N
CN
57
 
Entry Condition Yield (%)a
1 POCl3, 80-115 °C, 2 - 19 h No reaction
2 P2O5, Bu4NBr, 1,2-dichlorobenzene (185 °C) No reaction
X
Cl
Br
3 Br NBS, PPh3, dioxane, 115 °C, 3h No reaction
5 OTf Pyridine, Tf2O, toluene, reflux, overnight 7
6 OTf Pyridine, Tf2O, MeCN, rt, overnight 53
OTf aqueous K3PO4 (30%), Tf2O, toluene, reflux, 18 h 164
Compound
58a
58b
58b
58c
58c
58c
 
           aAfter column chromatography. 
 
Following the original procedure,17a,b a cross-coupling reaction was considered for 
introducing a 2-methyl pyridine group. For arylhalide and pseudohalide, there were the 
attempts to convert the 2-hydroxy group to a halogen or triflate group. At first, chlorination 
(Table 8, entry 1) was attempted, but did not afford the desired product 58a.17a,b The 
subsequent trials to brominate39 the 2-position were also unsuccessful (Table 8, entry 2). It 
may be explained by the poor stability of the N-cyano sulfoximine group in these harsh 
conditions. The introduction of a triflate group on the hydroxyl moiety,40 fortunately, afforded 
the target molecule 58c. In optimization reactions, a combination of pyridine and 
trifluoromethanesulfonic anhydride gave the pseudohalide 58c in 53 % yield (Table 8, entry 
6). 
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2.3.3. Studies of cross-coupling reactions 
 
Table 9. Introduction of the 2-methyl pyridyl group 
N OTf
S
CH3
Cl
N
S
CH3
Cl
O N
CN
O N
CN
N
CH3
N
Y
CH3
N
H
O
S
CH3
Cl
O N
CN
+
N
Cl+
57 59 48a
Coupling
58c
S
CH3
O N
CN
 
Entry Coupling condition Product (Yield)a
1 Pd(PPh3)4, K2CO3, MeCN/H2O (3:1)
Y
B(OH)2
2 Br Pd(PPh3)4, (Me3Sn)2, LiCl, Dioxane, 120°C, 3 days
57 (90%)
59 + 48a (56%)b
 
    aAfter column chromatography; bRatio: 59:48a = 2.6:1 (Determined by 1H NMR spectroscopy). 
 
In order to introduce the 2-methyl pyridyl group, cross-coupling reactions were examined 
using various conditions. For the Suzuki cross-coupling,41 it was possible to obtain the 
compound 57, instead of the desired product 48a, in an excellent yield. In the case of a Stille 
coupling,42 a mixture of a byproduct 59 and the desired product 48a were formed (59:48a = 
2.6:1, analyzed by 1H NMR). Unfortunately, it was difficult to separate the mixture by 
column chromatography because of the two products’ similar polarities. Since it was assumed 
that the byproduct 59 was formed by a hydrogen source, a number of trials to maintain in 
anhydrous condition were undergone. For example, all chemicals were added in a glove box. 
However, this approach only provided the desired product 48a as a mixture with the 
compound 59, which could not be isolated by normal column chromatography. It is notable 
that the N-cyano sulfoximine moiety could tolerate various coupling conditions.41    
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2.4. Studies of N-cyano sulfoximines in acidic conditions 
 
Table 10. Synthesis of N-urea 48c and NH sulfoximines 57c’ and 48b 
S
CH3
O N
CN
N
Cl
R
Conditions
S
CH3
O NH
N
Cl
R
+
S
CH3
O N
N
Cl
R
O
NH2
58c: R = OTf
48a: R = 2-methylpyridyl
58c': R = OTf
48b: R = 2-methylpyridyl 48c: R = 2-methylpyridyl
Entry R Condition Product (Yield)a
1 OTf TfOH, MeCN, 40 oC, 3 days 58c' (67%)
2-methylpyridyl2 TfOH, MeCN, 40 oC, 18 h 48c (38%)
3 2-methylpyridyl Aqueous H2SO4 (50%), 110 oC, 1h 48b (71%)  
                aAfter column chromatography. 
 
In general, an NH-sulfoximine is readily available by cleavage of the N-cyano group using a 
strong acid, such as aqueous H2SO4 (Table 10, entry 3).32,36 In the case of 
trifluoromethanesulfonic acid, however, different trends were observed. While it required 
long reaction times to obtain the NH-sulfoximine (Table 10, entry 1), shorter reaction times 
led to N-urea sulfoximine, a synthetic intermediate to NH-sulfoximine (Table 10, entry 2). 
Interestingly, it appears that the different product might be a result of reaction conditions such 
as acidity and reaction time. In regards to the mechanism (Scheme 24), a urea compound is 
formed by the nitrile hydrolysis in an acidic condition, and urea undergoing subsequent acid-
catalyzed hydrolysis leads to a free amine.13d,34  
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O
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Scheme 24. Mechanisms of acid-catalyzed hydrolysis34 
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2.5. Synthesis of  N-methyl sulfoximine 48e 
 
Table 11. Examination of N-methylation of sulfoximine 
S
CH3
N
Cl
N
CH3
O NH
S
CH3
N
Cl
N
CH3
O N
CH3
Route A
S
CH3
N
Cl
N
CH3
O N
Boc
48b
48d
48e
Route B
 
Entry Condition Product (Yield)a
1 para-formaldehyde, formic acid, 150 °C, 4 days 48e (no reaction)
3 NaH, (Boc)2O, THF, reflux, overnight 48d (43%)
LiAlH4, THF, RT-80 °C, 30 min-3days 48e (no reaction)
Route
A
B
B4
2 A NaH, MeI, THF, RT 48e (70%)
 
                     aAfter column chromatography. 
 
The initial attempt of N-methylation, which followed a procedure based on previous studies of 
sulfoximine-based Vioxx® analogs (Table 11, entry 1)32,37 was unsuccessful. Alternatively, 
the reduction of the carboxylic ester group of N-Boc moiety to a methyl group by using 
excess amounts of LiAlH4 was investigated.43 The attempts, which had various reaction times 
(Table 11, entry 4), started from N-Boc protected sulfoximine 48d, which is prepared by the 
protection of NH-sulfoximine 48b with a combination of NaH and (Boc)2O,38 did not afford 
the desired product 48e. It may be that an excess amount of LiAlH4 reduced the sulfoximine 
to give the sulfide. Finally, it was possible to obtain N-methyl sulfoximine 48e using very 
simple conditions with a combination of NaH and methyliodide44 in good yield (Table 11, 
entry 2). In contrast to the previous studies on the preparation for the N-alkylated 
sulfoximines starting from NH-sulfoximines,45 this result unexpectedly showed that N-
methylation could be conducted under mild conditions. 
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2.6. Summary 
 
Synthetic route A has successfully generated the target molecule, whereas no success was 
seen using synthetic route B. In detail, examination of the reaction scope with respect to the 
analog of N-cyano sulfoximine generally revealed poor functional group tolerance. According 
to these observations, it appeared that it was better to perform the sulfoximination at the final-
stage (synthetic route A). 
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3. L-784506 analogs 
 
a
S
CH3
98%
BrO
S
CH3
O NO
OEt
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N
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O
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Scheme 25. Reagents and conditions: (a) Br2, Et3N, CH2Cl2, RT, overnight; (b) 4-
(methylthio)phenylmagnesium bromide (0.5M in THF), THF, RT, overnight; (c) Pd(PPh3)4, aqueous 
2M Na2CO3, pyridin-3-yl-3-boronic acid, toluene/EtOH (1:1), 100 °C, overnight; (d) NH2CN, 
PhI(OAc)2, CH3CN, RT, 5 h; (e) K2CO3, m-CPBA, MeOH, RT, 30 min. 
 
For further testings, N-cyano sulfilimine and sulfoximine-based L-784506 analogs 64 and 65 
were prepared (Scheme 25). The original procedure of L-78450617c was followed for their 
preparation. Starting from the commercially available 3-ethoxycyclopent-2-enone (60), 
bromination at the 2-position, using a combination of Br2 and Et3N, generated the 2-bromo 
compound 61 in quantitative yield.  By using the reaction conditions for introducing a 4-
(methylthio)phenyl group, the synthetic approach of the original method of L-78450617c was 
changed. Since it was impossible to achieve the nucleophilic substitution by using a 
combination of 4-bromoanisole and n-BuLi, an alternative strategy involving a Grignard 
reagent was applied for the preparation of 62. 4-(Methylthio)phenylmagnesium bromide 
(0.5M in THF) was readily prepared and directly used for the substitution reaction. The Pd(0) 
catalyzed cross-coupling (Suzuki) of 62 led to the desired sulfide 63 in 84% yield. Using 
generally employed conditions for introducing the sulfoximine moiety,13 the targeted N-cyano 
sulfilimine 64 and N-cyano sulfoximine 65 were produced in good yields over two steps.   
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4. Fujisawa Pharm analogs 
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N N
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N N
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N
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O
F
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d
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CH3
N N
F3C
NHO
F
71%
e
S
CH3
N N
F3C
NO
F
f 11%
NO2
28 66 67
6869a69b
69c  
Scheme 26. Reagents and conditions: (a) NaOMe (in methanol, 30%), ethyl trifluoroacetate, MTBE, 
70 °C, 4 h; (b) 1-(3-fluorobenzyl)hydrazine hydrochloride, EtOH, 70 °C, overnight; (c) NH2CN, 
PhI(OAc)2, CH3CN, RT, 2 h; (e) K2CO3, m-CPBA, MeOH, RT, 30 min; (e) aqueous H2SO4 (50%), 
70 °C, 30 min; (f) HNO3, H2SO4, acetic anhydride, RT to 50 °C, 30 min. 
 
In the similar way to previous work with the sulfilimine- and sulfoximine-based Vioxx® and 
Arcoxia® analogs, sulfoximination was performed at the last stage. The proposed synthesis 
followed the known procedure.46 Para-substituted acetophenone derivative 28 was obtained 
by Friedel-Craft acylation of thioanisole. Claisen condensation of 1-[4-
(methylthio)phenyl]ethanone (28) with ethyl trifluoroacetate in the presence of NaOMe (in 
methanol, 30%) provided 1,3-diketo adduct 66 in good yield. It has been reported that the 
reaction of 1,3-diketone with phenylhydrazine leads to a mixture of 1,5-diarylpyrazolyl and 
1,3-diarylpyrazolyl product. However, it was demonstrated by Penning et al. that refluxing 
the hydrochloride salt of phenyl hydrazine with 1,3-diketone in ethanol exclusively formed 
the 1,5-diarylpyrazolyl analog. The 1,5-diarylpyrazole would be the major product if a bulky 
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alkyl group was present on the diketone.47a Probably, the free NH2 group of the hydrazine 
preferentially attacks the less sterically hindered carbonyl group.47b In this study, it was 
confirmed that the reaction of 1,3-diketone with phenyl hydrazine hydrochloride 
regioselectively formed a 1,5-diarylpyrazolyl derivative 67. Imination of sulfide 67 produced 
N-cyano sulfilimine 68 in excellent yield. The subsequent oxidation of 68 with m-CPBA 
provided the target N-cyano sulfoximine 69a.  The use of an aqueous H2SO4 solution (50%) 
allowed the cleavage of the nitrile group to obtain the desired NH-sulfoximine 69b in a good 
yield. The nitro group, which is an electron-withdrawing substituent similar to the nitrile, was 
also introduced by a known method9a,48 to give N-nitro sulfoximine 69c (in 11% yield). 
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5. SC-58125 analogs 
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Scheme 27. Reagents and conditions: (a) NaOMe (in methanol, 30%), ethyl trifluoroacetate, MTBE, 
70 °C, 4 h; (b) 1-[4-(methylthio)phenyl]hydrazine hydrochloride, EtOH, 70 °C, overnight; (c) for 73a: 
NH2CN, PhI(OAc)2, CH3CN, RT, 2 h; for 73b: NH2CN, t-BuOK, NBS, MeOH, RT, 30 min; (d) 
K2CO3, m-CPBA, MeOH, RT, 30 min; (e) aqueous H2SO4 (50%), 70 °C, 30 min. 
 
Next, SC-58125 analogs, which also contained a pyrazole core, were prepared for the study 
on sulfilimine- and sulfoximine-based COX-2 inhibitors (Scheme 27). This study aimed to 
develop an efficient synthetic route to a para-fluorophenyl derivative containing N-cyano 
sulfilimine 73a and sulfoximine 74a moieties. Those analogs (73a and 74a) would enable 
further PET investigation of this potent COX-2 inhibitor (see Part II, Section 5.3).49 The 
synthetic approach was based on the original procedure for SC-58125.46 Claisen condensation 
of para-fluoro and para-N,N-dimethylamine acetophenone 70a,b with ethyl trifluoroacetate 
provided the 1,3-dicarbonly adducts 71a,b in an excellent yield. Each 1,5-diarylpyrazole 
72a,b was exclusively generated by performing the condensation with a combination of 
phenyl hydrazine hydrochloride salt and 1,3-diketone in refluxing methanol and MTBE. 
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Fortunately, it was possible to obtain compounds 72a,b in good to excellent yield. While the 
imination of para-fluoro sulfide 72a using PhI(OAc)2 led to the desired N-cyano sulfilimine 
73a in a good yield, it was not successful in the case of the para-N,N-dimethylamino analog 
72b. Alternatively, the combination of cyanamide, NBS, and t-BuOK gave the targeted N-
cyano sulfilimine 73b in moderate yield (for mechanistic aspects, see Section 1.2.2). The 
subsequent oxidation of the sulfilimine 73a with a combination of m-CPBA and K2CO3 
resulted in N-cyano sulfoximine 74a. By using aqueous H2SO4 (50%), the NH-sulfoximine 
74a’ was synthesized in good yield. 
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6. DuP 697 analogs 
 
S
b
38%
Br a
99%
c
82%
d 45%
e
64%
S
CH3
S
S
CH3
S Br
S
CH3
S
F
S
CH3
S
F
Br
S
CH3
S
F
Br
N
CN
f
53%
S
CH3
S
F
Br
N
CN
O
75 76 77 78
798081
Scheme 28. Reagents and conditions: (a) Pd(PPh3)4, aqueous 2M Na2CO3, pyridin-3-yl-3-boronic acid, 
toluene/EtOH (1:1), 90 °C, overnight; (b) NBS, CH2Cl2, 50 °C, 1 h; (c) Pd(PPh3)4, aqueous 2M 
Na2CO3, 4-fluorophenylboronic acid, toluene/EtOH (1:1), 90 °C, overnight; (d) NBS, CH2Cl2, 50 °C, 1 
h; (e) NH2CN, PhI(OAc)2, CH3CN, RT, 10 min; (f) K2CO3, m-CPBA, MeOH, RT, 30 min. 
 
On the basis of the previous synthesis of DuP 697,17g the preparation of the N-cyano 
sulfilimine and sulfoximine-based derivatives 80, 81 was planned, as shown in Scheme 28. 3-
bromothiophene (75) was transformed in quantitative yield into compound 76 by Suzuki 
cross-coupling. Again, Pd(0) catalyzed cross-coupling of 77, which was obtained by regio-
selective bromination of 76, led to the desired derivative 78. Reaction of 78 with NBS 
provided the sulfide analog of DuP 697 (79). Metal-free oxidative imination of 79, followed 
by oxidation, yielded the N-cyano sulfoximine 81. 
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7. The enantiopure N-cyano sulfilimines and sulfoximines 
 
NN
S
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X
F
S
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F
S
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Fujisawa Pharm analogs (68, 69a) DuP 697 analogs (80, 81)
CN
CN
X = O,
 
Figure 14. Selected compounds for studies of enantiomers 
 
The new stereogenic centers at the sulfur atom formed by imination and subsequent oxidation 
afforded enantiomers, which may exhibit different biological activities due to stereoselective 
interaction with an enzyme. Because of their proven significant effects on the COX-2 isozyme, 
the Fujisawa Pharm and DuP 697 analogs were selected for exploring the properties of the 
corresponding racemic and enantiomerically pure N-cyano sulfilimines and sulfoximines (for 
biological activities, see Part II, Section 4 and 6). 
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Scheme 29. Preparation of enantiopure N-cyano sulfilimines and sulfoximines 
 
The enantiomer separation of the N-cyano sulfilimine derivatives 68, 80 was readily achieved 
by preparative HPLC. Currently, there is no effective enantiospecific approach for the 
introduction of the N-cyano moiety. The subsequent oxidation generated N-cyano 
sulfoximines with a retained enantiomeric excess (ee). For the enantiopure Fujisawa Pharm 
analogs, 69a-I, 69a-II were obtained in 68% and 53% yield from each enantiopure sulfilimine 
68-I, 68-II, respectively. In the case of DuP 697 derivatives, the oxidation afforded 81-I, 81-
II in 26% and 25% yield, respectively. Since all enantiomers were noncrystalline, the absolute 
 Results and discussion 
50 
 
configuration was assigned by comparing calculated and measured electronic circular 
dichroism (ECD) spectra (Figure 15 and 16). According to the data of the N-cyano 
sulfilimine-based Fujisawa Pharm analog 68,50 enantiopure N-cyano sulfilimine 68-I, 68-II 
are believed to have the S and R configuration, respectively. In the case of enantiopure N-
cyano sulfoximine, compounds 81-I, 81-II are considered to have the R and S configuration, 
respectively.51 
 
 
 
 
Figure 15. Boltzmann-weighted ECD spectrum of the (R)-sulfilimine 68-II calculated on B3LYP/6-
311++G(d,p) level. Reused with permission by Dr. Stefanie Mersmann.50 
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Figure 16. Experimental ECD spectra of both enantiomers of the N-cyano sulfilimine-based Fujisawa 
Pharm analog in acetonitrile. Black: 68-I (eluted first), grey: 68-II (eluted last).  Reused with 
permission by Dr. Stefanie Mersmann.50 
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8. Summary 
 
Table 12. Improved synthesis of N-cyano sulfilimines and sulfoximinesa 
N
S
Me
N
O
X
CN
NN
S
Me
N
F3C
X
F
CN
S
Br
F
S
Me
NX CN
S
NNF3C
F
Me
NX
CN
Entry
3
4
6
5
Structure
N-Cyano sulfilimine (X =     )b N-Cyano sulfoximine (X = O)c
Reaction
time Yield (%)
d
0.5 h 80 0.5 h 65
2 h 98 0.5 h 86
10 min 64 0.5 h 53
2 h 79 0.5 h 56
Reaction
time Yield (%)
d
S
Me
X N
CN
O
O
S
Me
X N
CN
N
Cl
N
Me
1
2
1 h 92 0.5 h 43
2 h 66 0.5 h 64
Compound
39
47
64
68
73a
80
Compound
32a
48a
65
69a
74a
81
 
   aAll reactions were  performed at room temperature; bH2NCN, PhI(OAc)2, CH3CN; cK2CO3, m-CPBA, MeOH;   
  dAfter column chromatography. 
 
In summary, the synthesis of sulfilimine- and sulfoximine-based COX-2 inhibitors have 
successfully been established by using the approach, containing the key intermediates of N-
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cyano sulfilimine and sulfoximine.  In particular, this procedure has been applied to prepare 
real drug-like molecules and has provided a significant improvement over the method in the 
literature.13a By using mild conditions, N-cyano sulfilimine- and sulfoximine-based COX-2 
inhibitors, as well as NH-sulfoximines, could be readily prepared in good to excellent yield 
(Table 12).       
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Part II. Biological activities of sulfilimine- and sulfoximine-based COX-2 
inhibitors 
 
In order to examine the effect on biological activity resulting from the formal conversion of a 
sulfone to a sulfoximine, newly prepared sulfilimine- and sulfoximine-based COX-2 
inhibitors have been evaluated for their COX-1/2 inhibition.53 Furthermore, based on their 
suggested stimulating effect COX-2 selective inhibitors for cancer prevention, newly prepared 
compounds have launched a probe into how COX-2 inhibitory activity is associated with anti-
cancer activitiy.55  
 
 
1. Vioxx® analogs 
1.1. COX inhibitory activity 
 
Results for COX inhibitory activities are shown in Table 13. Indometacin and Vioxx® were 
also tested as reference compounds (for IC50 values, see biological activities in experimental 
section). At 10 µM concentrations, NH- and N-methyl sulfoximine-based Vioxx® 32b, 32c 
had moderate COX-2 inhibitory activity, whereas N-cyano sulfoximine 32a showed good 
potency against COX-2 isozyme. Furthermore, N-cyano sulfilimine 39, the key synthetic 
intermediate for N-cyano sulfoximine, also showed good COX-2 inhibitory activity and 
selectivity (Table 13, entry 1). It is worthy to note that the N-cyano group substituted 
compounds 39, 32a retain more activity than other substituents (Table 13, entry 1 and 2). 
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Table 13. COX-1/2 inhibitory activities of sulfoximine-based Vioxx® analogs 
S
Me
O
O
X Y
 
% inhibition (at 10 µM)
Entry X Y
3 O NH 26
4 O NMe 11
2 O NCN 48
1 NCN 47
COX-1 COX-2
-4
1
-13
10
Compound
39
32a
32b
32c
 
 
 
 
1.2. hERG blocking potency54 
 
Walker and co-workers, in their study on the sulfoximine-based PYK2 inhibitor, reported that 
the formal structural conversion of sulfone to the corresponding sulfoximine could lead to a 
compound with reduced hERG inhibitory activity.6 Therefore, the hERG blocking potencies 
of NH-sulfoximine 32b and (sulfone) Vioxx® were determined in whole-cell patch clamp 
recordings using HEK293 cell stably expressing the hERG ion channel. Screening data at 1.0, 
3.16, 10, 31.6 and 100 µM concentrations, each with two individual cells, were obtained for 
all compounds. Results of the studies are shown in Fig. 17. NH-sulfoximine 32b and sulfone 
generally retain a weak inhibitory effect on the hERG ion channel. In addition, it was 
estimated that, in both cases, the IC50 values could be higher than those of the 100 µM 
concentration. However, the sulfoximine 32b clearly revealed a channel inhibition at 
concentrations of 31.6 µM and higher, whereas for (sulfone) Vioxx®, the respective 
concentration was 10 µM. Although the effect is only moderate, the NH-sulfoximine analog 
32b appeared to show a beneficial effect of reduced hERG activity, which is cross-linked with 
cardiovascular safety. 
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Figure 17. Blocking potencies of Vioxx® (sulfone) and NH-sulfoximine 32b on the hERG ion channel. 
Reused with permission from Ref. 32. Elsevier Ltd. 
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1.3. Anticancer activity 
1.3.1.  A one-dose primary screening at 10 µM 
 
 
Table 14. Anticancer screening at a single dose (10 µM) 
S
Me
O
O
X Y
 
Entry
Growth percent at 10 µM
X Y
3 O NH 20.79
4 O NMe 19.03
2 O NCN 17.48
1 NCN 83.82
Mean Delta
63.66
103.87
102.62
103.88
Range
134.13
31.42
49.86
34.88
Mean: Average of Growth Percent, 
Delta: Mean – Minimum value of Growth Percent, 
Range: Maximum – Minimum value of Growth Percent (from -150 to 150)
Comound
39
32a
32b
32c
 
In vitro growth inhibition was performed by the NCI (National Cancer Institute) according to 
a well-established procedure. First, newly prepared Vioxx® analogs were evaluated in a one 
dose primary anticancer screen at a 10 µM concentration against the full NCI 60 cell panel 
representing leukemia, melanoma, and cancers of the lung, colon, CNS, ovarian, renal, 
prostate, and breast. Table 14 shows the total growth inhibition values of a subset of the 60 
cell line panel, expressed by mean, delta and range values. Moreover, the mean was 
calculated for each anticancer activity parameter, giving an averaged activity parameter over 
all cell lines. To make the growth inhibitory effect more apparent, the delta values were also 
calculated by subtracting the minimum value of growth percent from the mean growth percent. 
Note that the range, which indicates the difference between maximum and minimum values of 
growth percent, is limited to between -150 to 150.  
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As shown in Table 14, sulfoximine-based Vioxx® compounds 32a-c only displayed minor 
effects. Among newly prepared Vioxx® derivatives, N-cyano sulfilimine 39 exhibited the best 
growth inhibitory effects against the full cell line panel, expressed by 63.66 % of mean 
growth value.  
 
Table 15. Growth inhibition against each cell line (at 10 µM) 
O
O
S
Me
N
CN
39
 
Growth percent at 10 µMPanel
(Number of Cell Lines)Entry
Leukemia
(6 cell lines)
Non-Small Cell Lung Cancer
(9 cell lines)
Colon Cancer
(7 cell lines)
CNS Cancer
(6 cell lines)
Melanoma
(9 cell lines)
Ovarian Cancer
(7 cell lines)
Renal Cancer
(8 cell lines)
Prostate Cancer
(2 cell lines)
Breast Cancer
(6 cell lines)
1
2
3
4
5
6
7
8
9
Mean Delta Range
66.04 36.31 61.00
62.12 38.98 65.00
56.96 37.06 63.76
44.77 11.82 27.37
52.74 72.90 107.41
70.85 38.62 79.45
81.51 31.05 63.51
83.43 1.00 2.00
67.87 18.27 62.26
 
The growth inhibition of N-cyano sulfilimine-based Vioxx® analog 39 against each cell line 
panel is highlighted in Table 15. In detailed analysis, N-cyano sulfilimine 39 exhibited very 
potent inhibitory effects on the growth of colon cancer (mean value 56.96, cell line HT29 and 
KM12), CNS cancer (mean value 44.77, cell line SF-295, SNB-75 and UZ51), and melanoma 
(mean value 52.74, cell line M14 and MDA-MB-435) cell line panels. Due to the positive 
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results of the screening at a single dose, this compound 39 was consequently selected by NCI 
for a full 5-dose assay. 
 
 
1.3.2.  A full 5-dose assay 
 
In the full cell line panel screening, the N-cyano sulfilimine-based Vioxx® 39 was evaluated 
using five concentrations at 10-fold dilutions, ranging from 10-4 to 10-8 M.  
 
Figure 18. Five dose response curve for melanoma cell lines 
 
For one particular example, the results for the various melanoma cell lines are shown in 
Figure 18. N-cyano sulfilimine-based Vioxx® 39 shows significant anti-proliferative activity 
against melanoma cell lines at concentrations above 10–6 molar. 
 
Anticancer activity was deduced from a dose response curve and expressed by three 
parameters (GI50, TGI, LC50), which are calculated for each cell line. The GI50 value reveals 
the concentration of the compound required for 50% inhibition of net cell growth. The TGI 
value indicates the concentration of the compound resulting in total growth inhibition. The 
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LC50 represents the concentration of the drug resulting in a 50% reduction in the measured 
protein at the end of the drug treatment. 
 
Table 16. Selected growth inhibitory properties of N-cyano sulfilimine-based Vioxx® 39 in the NCI’s 
full cancer cell line panel screening 
Panel
(Cell Lines)Entry
Leukemia
(K562)
Non-Small Cell Lung Cancer
(NCI-H460)
Colon Cancer
(KM12)
CNS Cancer
(SF-295)
Melanoma
(MDA-MB-435)
Ovarian Cancer
(NCI/ADR-RES)
Renal Cancer
(A498)
Prostate Cancer
(DU-145)
Breast Cancer
(HS 578T)
1
2
3
4
5
6
7
8
9
Log 10 GI50
-5.74
-5.75
-5.70
-5.76
-6.33
-5.65
-5.65
-5.02
-5.59
 
As reported in Table 16, N-cyano sulfilimine-based Vioxx® 39 displays potent efficacy on the 
selected cell lines, showed by Log10 GI50 values ranging from -5.02 (Table 16, entry 8) to -
6.33 (Table 16, entry 5). In particular, this compound 39 shows excellent activity against the 
melanoma MDA-MB-435 cell line, with a Log10GI50 value of -6.33. 
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Table 17. Mean in vitro activity of N-cyano sulfilimine-based Vioxx® over 60 cancer cell lines 
Log10 mean
GI50
Log10 mean
TGI
Log10 mean
LC50
-5.09 -4.13 -4.00
 
 
Mean GI50, TGI, and LC50 values are presented in Table 17. Importantly, this compound 39 
exhibited sufficient activity to indicate potential broad spectrum growth inhibition of a variety 
of tumors. 
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2. Arcoxia® analogs 
2.1. COX inhibitory activity 
 
All newly prepared Arcoxia® derivatives 47, 48a-c were evaluated for inhibitory activity on 
the constitutive (COX-1: human platelets) and the inducible form (COX-2: human 
recombinant insect Sf21 cells) of the enzymes. 
 
Table 18. COX inhibitory activity of Arcoxia® analogs 47, 48a-c 
S
Me
X Y
N N
Me
Cl
 
% inhibition (at 10 µM)
Entry
COX-1
X Y
3 O NH 5
5 O 9
2 NCN -7
1 NCN 2
NMe
4 NC(O)NH2 -1
O
O
COX-2
-7
-24
10
48
-23
Compound
47
48a
48b
48c
48e
 
 
The biological data of the compounds are summarized in Table 18. None of the sulfoximine-
based analogs 48a-c, 48e showed significant activity. Interestingly, N-cyano sulfilimine 47 
was a potent compound, exhibiting 48% inhibition against the COX-2 enzyme and displaying 
COX-2 selectivity. Combined with the COX-2 inhibitory effect of the N-cyano sulfilimine-
based Vioxx® analog 39, this result clearly suggests that the N-cyano sulfilimine group might 
be an important part of the pharmacophore. 
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2.2. Anticancer activity 
2.2.1.  A one-dose primary screening at 10 µM 
 
Table 19. Anticancer screening at a single dose (10 µM) 
Growth percent at 10 µM
X Y
O NH 18.96
O NMe 27.41
O NCN 23.07
NCN 18.23
Mean Delta
102.07
104.04
103.08
102.23
Range
38.80
38.84
37.41
61.06
Mean: Average of Growth Percent, 
Delta: Mean – Minimum value of Growth Percent, 
Range: Maximum – Minimum value of Growth Percent (from -150 to 150)
O NC(O)NH2 102.83 24.08 37.59
Entry
3
5
2
1
4
Compound
47
48a
48b
48c
48e
 
In a preliminary test, compounds 47, 48a-c, 48e were assayed against the full NCI 60 cell 
panel at a single high concentration (10 µM). This panel is organized into sub panels 
representing leukemia, melanoma, and cancers of the lung, colon, CNS, ovarian, renal, 
prostate, and breast. Unfortunately, none of those derivatives were considered active enough 
to enter the subsequent five-concentration test. 
 Results and discussion 
64 
 
3. L-784506 analogs 
3.1. COX inhibitory activity 
 
Table 20. COX inhibitory activity of L-784506 analogs 
S
Me
NO
X Y
 
% inhibition (at 10 µM)
Entry
COX-1
X Y
2 O NCN 19
1 -6NCN
15
40
COX-2
Compound
64
65
 
 
After the studies of the Vioxx® and Arcoxia® analogs, it was hypothesized that N-cyano 
sulfilimine and sulfoximine could lead to desirable biological activities against the COX-2 
enzyme. In order to understand the significance of the N-cyano group in binding to the COX 
enzymes, L-784506 derivatives were newly prepared and tested for COX inhibitory activities. 
Results for N-cyano sulfilimine- and sulfoximine-based L-784506 compounds 64, 65 are 
shown in Table 20. In fact, the N-cyano sulfilimine 64 was a good inhibitor of COX-2. It is 
reasonable to believe that the hypothesis was validated by the result of the N-cyano 
sulfilimine compound 64. 
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3.2. Anticancer activity 
3.2.1. A one-dose primary screening at 10 µM 
 
Table 21. Anticancer screening at a single dose (10 µM) 
Growth percent at 10 µM
X Y
O NCN 24.02
NCN 22.29
Mean Delta
99.29
99.21
Range
38.23
46.36
Mean: Average of Growth Percent, 
Delta: Mean – Minimum value of Growth Percent, 
Range: Maximum – Minimum value of Growth Percent (from -150 to 150)
Entry
2
1
Compound
64
65
 
 
The anticancer activities of these compounds 64, 65 were tested against the full NCI 60 cell 
panels by the NCI (National Cancer Institute) in a single-dose anticancer screen at 10 µM 
concentration. Neither, N-cyano sulfilimine 64 nor sulfoximine 65 displayed anticancer 
activity. 
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4. Fujisawa Pharm analogs 
4.1. COX inhibitory activity 
 
Table 22. In vitro inhibitory activities against COX enzymes 
S
Me
N N
X Y
FF3C
 
Entry
% inhibition (at 10 µM)
COX-1
X Y
4 O NCN -3
5 O -2
1 NCN 24
2 NCN -26
NNO2
3 NCN -2
76
-14
99
101
-2
COX-2
Compound
68a
69aa
69ca
68-Ιb
68-ΙΙb
 
                                     aRacemate; bThese enantiopure compounds (over 99% ee) 68-I and 68-II are believed  
                         to have S and R configurations, respectively. 
 
Newly prepared Fujisawa Pharm derivatives 68, 69a, 69c were evaluated against COX-1 and 
COX-2 enzymes in an initial screening for inhibitory activity. Generally, against COX-1, 
none of the compounds showed inhibitory activity. Fortunately, compound 68 displayed an 
excellent potency and selectivity on COX-2 (Table 22, entry 1, % inhibition at 10 µM, 
racemate: COX-1 = 24%, COX-2 = 99%). Interestingly, significant differences were found 
between the R- and S-enantiomers (Table 22, entry 2 and 3, S-enantiomer: COX-1 = –26%, 
COX-2 = 101%, R-enantiomer: COX-1 = -2%, COX-2 = -2%). Furthermore, the N-cyano 
sulfoximine 69a also showed a potent COX-2 inhibitory activity and selectivity. The 
possibility that this has strengthened the hypothesis about N-cyano sulfilimine and 
sulfoximine, similar to previous research on Vioxx®, Arcoxia® and L-784506, is noteworthy. 
To access a broader set of N-substituted sulfoximines and investigate further structural 
scaffolds, the N-nitro sulfoximine was tested.9a,48 Note that the nitro group was selected 
according to the studies of Sulfoxaflor by Dow Agrosciences, using N-nitro sulfoximine as a 
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starting point for the optimization of the aphicidal activity.9a The disappointing results, 
however, showed that the compound 69c was essentially inactive (Table 22, entry 5). 
Although this consequence was dissatisfying, it has notably established the cyano group as an 
important part of the most potent inhibitor of the COX-2 enzyme. 
 
4.2. Anticancer activity 
4.2.1.  A one-dose primary screening at 10 µM 
 
Table 23. Anticancer screening at a single dose (10 µM) 
Entry X Y
2 O NCN
1 NCN
Compound
68
69a
Growth percent at 10 µM
26.06
48.98
Mean Delta
93.70
94.39
Range
68.74
58.22
Mean: Average of Growth Percent, 
Delta: Mean – Minimum value of Growth Percent, 
Range: Maximum – Minimum value of Growth Percent (from -150 to 150)  
 
Among the compounds, the NCI only selected the racemates of N-cyano sulfilimine 68 and 
sulfoximine 69a for single-dose (10 µM) assays in the full NCI 60 cell panel. Unfortunately, 
both compounds 68, 69a showed no significant growth inhibitory effect.   
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5. SC-58125 analogs 
5.1. COX inhibitory activity 
 
Table 24. Initial screening at 10 µM for COX inhibitory activities 
S
Me
NN
N
F3C
F
CN
 
Compound
% inhibiton (at 10 µM)
73a
COX-1 COX-2
37 66
 
In the course of exploring the N-cyano sulfilimine structure for the new COX-2 inhibitors, N-
cyano sulfilimine-based SC-58125 73a was prepared and tested for a COX inhibitory effect. It 
was expected that the N-cyano sulfilimine moiety, which showed very good COX-2 inhibitory 
activity in other sulfilimine-based COX-2 inhibitors, could also lead to compounds with good 
potency. Confirming this hypothesis, compound 73a showed a potent COX-2 inhibitory 
activity.     
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5.2. Anticancer activity 
5.2.1.  A one-dose primary screening at 10 µM 
 
Table 25. Anticancer screening at a single dose (10 µM) 
Entry
1
Compound
73a
Growth percent at 10 µM
58.56
Mean Delta
88.08
Range
84.21
Mean: Average of Growth Percent, 
Delta: Mean – Minimum value of Growth Percent, 
Range: Maximum – Minimum value of Growth Percent (from -150 to 150)  
 
As an initial screen for anticancer activity, a single-dose assay (at 10 µM) of compound 73a 
was employed in the full NCI 60 cell panel.  Although it showed a moderated growth 
inhibition activity in various cell lines, it was not considered active enough to enter the 
subsequent five-concentration test. 
 
 
5.3. Initial attempts to perform para-fluoro substitution on N-cyano sulfilimine 
73a for Positron Emission Tomography (PET) studies 
 
Recently, it has been reported that selective COX-2 inhibitors are useful in the treatment of 
certain human cancer. Consequently, COX-2 is an attractive target molecule for the detection 
of cancer by imaging with radiolabeled COX-2 inhibitors. Indeed, syntheses of 18F-labeled 
COX-2 inhibitors as potential imaging agents have been reported. 28d,49 In 2002, Welch and 
co-workers described the radiosynthesis and evaluation of 18F-labeled COX inhibitors, 18F-
SC63217 (84a, COX-1) and 18F-SC58125 (84b, COX-2) (Scheme 30).49c 
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Ar
NNF3C
N CH3
H3C
Ar
NNF3C
N CH3
H3C CH3
Ar
NNF3C
18F
a b
Ar =
MeO2S SC58125 (COX-2 selective)
MeO SC63217 (COX-1 selective)
OTf
a:
b:
82a,b 83a,b 84a,b
 
Scheme 30. Welch’s work on radiosynthesis49c 
 
Based on their approach and the positive biological results of the molecule, N-cyano 
sulfilimine-based SC-58125 73a was considered as a target molecule for radiosynthesis.  To 
introduce a fluorine group on the para-position, initial efforts were focused on proving the 
tolerance of the N-cyano sulfilimine moiety under the previously established reaction 
conditions. In initial attempts, however, it was not possible to detect the cyano group by FT-
IR analysis after N-methylation of the compound 73b with MeOTf (Scheme 31). The FT-IR 
data seem to indicate that the cyano group was converted to a urea moiety (1711 cm-1). At the 
present stage, it seems that development of an efficient strategy to induce para-fluoro 
substitution of N-cyano sulfilimine 73b remains challenging. 
  
S
CH3
NNF3C
N
N
CN
CH3
H3C
MeOTf
CH2Cl2, RT
S
CH3
NNF3C
N
N
CN
CH3
H3C
OTf
overnight
CH3
73b 73b'  
Scheme 31. Attempt of N-methylation of N-cyano sulfilimine 73b 
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6. DuP 697 analogs 
6.1. COX inhibitory activity 
 
Table 26. COX inhibitory activity at 10 µM 
S
Me
S
X Y
Br
F
 
X Y
NCN 99
Entry Compound
1 80a
81a
2
3
4
5
6
NCN
NCN
O NCN 97
O 97
O NCN 28
NCN
% inhibition (at 10 µM)
COX-1 COX-2
57
-2 100
-20 97
69
-9
8
80-Ιb
80-ΙΙb
81-Ιc
81-ΙΙc
 
                         aRacemate; bAbsolute configurations:  80-I = S, 80-II = R;  
                         cAbsolute configurations: 81-I = R, 81-II = S. 
 
All N-cyano sulfilimine- and sulfoximine-based DuP 697 analogs 80, 81 were initially 
evaluated for inhibitory activity against both COX isozymes (COX-1: human platelets, COX-
2: human recombinant insect Sf21 cells) with arachidonic acid as the substrate. As reported in 
Table 26, the percentages of inhibition at 10 µM were determined and used in all of the 
following discussions of in vitro activity. Nearly all of the compounds showed an excellent 
inhibitory activity and selectivity against COX-2, whereas the S-enantiomer of N-cyano 
sulfoximine 81-II (Table 26, entry 6) exhibited poor potency in both COX-1 and COX-2 
inhibition. These results are consistent with earlier findings on the N-cyano sulfilimine- and 
sulfoximine-based COX-2 inhibitors. Comparing the COX-2 inhibitory activity of these 
derivatives with the previous compounds clearly shows that N-cyano sulfilimine and 
sulfoximine-based DuP 697 analogs have the greatest potency and selectivity. For example, 
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although racemates 80 and 81 displayed a weak selectivity for COX-2, they have an excellent 
potency against the COX-2 isozyme (Table 26, entry 1 and 4). Interestingly, as reported in the 
research on N-cyano sulfilimine-based Fujisawa Pharm, the S-enantiomer 80-I showed the 
same remarkable COX-2 inhibitory activity and high COX-2 selectivity (Table 26, entry 2). 
However, in this case, the R-enantiomer 80-II also exhibited the same outstanding potency 
and selectivity against the COX-2 isozyme (Table 26, entry 3). As for N-cyano sulfoximine 
derivatives, the S-enantiomer 81-II had weak potency against both COX isozymes (Table 26, 
entry 6), while the R-enantiomer 81-I showed excellent COX-2 inhibitory activity and 
selectivity (Table 26, entry 5). With respect to the activities of the single enantiomers, further 
studies are required to account for their binding modes and mechanistic principles.  
 
 
6.2. Anticancer activity 
6.2.1.  A one-dose primary screening at 10 µM 
 
Table 27. Anticancer screening at a single dose (10 µM) 
Entry X Y
2 O NCN
1 NCN
Compound
80
81
Growth percent at 10 µM
42.78
57.22
Mean Delta
74.21
48.44
Range
101.60
70.52
Mean: Average of Growth Percent, 
Delta: Mean – Minimum value of Growth Percent, 
Range: Maximum – Minimum value of Growth Percent (from -150 to 150)  
 
To further evaluate the anticancer activity of N-cyano sulfilimine and sulfoximine-based DuP 
697 analogs, the racemic compounds 80, 81 were submitted for screening within the 
Development Therapeutics Program of the NCI. It is noteworthy that not all of the 
enantiomers were selected by NCI. In preliminary testing, the compounds were assayed at a 
single dose (10 µM) in the full NCI 60 cell panel. Their anticancer abilities are summarized in 
Table 27. Importantly, the N-cyano sulfoximine 81 exhibited an excellent growth inhibition 
on a variety of cell panels, expressed by 48.44% of the mean value. Moreover, the uniform 
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range value (70.52) indicates that this compound 81 significantly affected various cell lines. 
Although it was not enough to select for 5-dose assay, the N-cyano sulfilimine 80 also 
displayed high potency for anticancer activity, at 74.21% of the mean value.   
 
 
Table 28. The growth inhibition on each cell line at 10 µM 
S
Me
S
O N
Br
F
CN
81
 
Growth percent at 10 µMPanel
(Number of Cell Lines)Entry
Non-Small Cell Lung Cancer
(8 cell lines)
Colon Cancer
(7 cell lines)
CNS Cancer
(5 cell lines)
Melanoma
(9 cell lines)
Ovarian Cancer
(6 cell lines)
Renal Cancer
(8 cell lines)
Prostate Cancer
(1 cell lines)
Breast Cancer
(6 cell lines)
1
2
3
4
5
6
7
8
Mean Delta Range
49.45 43.79 70.52
37.82 13.57 33.97
44.22 11.46 23.72
46.95 11.46 23.72
61.82 17.05 27.54
49.62 24.32 48.57
41.70 0.00 0.00
51.44 19.53 29.75
 
 
Table 28 emphasizes the growth inhibition of N-cyano sulfoximine-based DuP 697 (81) on 
each cell line panel. In particular, N-cyano sulfoximine 81 exhibited very potent growth 
inhibitory effects on non-small cell lung cancer (mean value 49.45, cell line NCI-H460) colon 
cancer (mean value 37.82, cell line HCT-116 and HT29), CNS cancer (mean value 44.22, cell 
line SF-295 and UZ51), melanoma (mean value 46.95, cell line LOX IMVI and SK-MEL-5), 
renal cancer (mean value 49.62, cell line RXF 393), prostate cancer (mean value 41.70, cell 
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line PC-3), and breast cancer (mean value 51.44, cell line MCF7) cell line panels. According 
to the outstanding results of the initial screening at a single dose (10 µM), the NCI selected 
this compound for the full 5-dose assay. 
 
6.2.2.  A full 5-dose assay 
 
N-Cyano sulfoximine-based DuP 697 (81) was evaluated using five concentrations at 10-fold 
dilutions, ranging from 10-4 to 10-8 M.  
 
Figure 19. Five-dose response curve for melanoma cell lines. Reused with permission from Ref. 52. 
WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim. 
 
The results of the various melanoma cell lines are selected for one particular example. As 
shown in Figure 19, the compound 81 shows a significant anti-proliferative activity at 
concentrations above 10–7 molar against melanoma cell lines. 
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Table 29. Selected growth inhibitory properties of N-cyano sulfoximine-based DuP 697 (81) in the 
NCI’s full cancer cell line panel screening 
Panel
(Cell Lines)Entry
Leukemia
(K562)
Non-Small Cell Lung Cancer
(NCI-H460)
Colon Cancer
(HCT-116)
CNS Cancer
(U251)
Melanoma
(LOX IMVI)
Ovarian Cancer
(OVCAR-8)
Renal Cancer
(CAKI-1)
Prostate Cancer
(PC-3)
Breast Cancer
(MCF7)
1
2
3
4
5
6
7
8
9
Log 10 GI50
-6.17
-6.26
-6.21
-6.12
-6.13
-5.74
-5.90
-5.90
-5.66
 
In Table 29, the selected growth inhibitions of compound 81 are highlighted. Generally, the 
N-cyano sulfoximine 81 displayed very potent growth inhibitory effects against various cell 
lines, expressed by Log10GI50 values ranging from -5.66 to -6.26. In particular, this compound 
81 showed remarkable activity against leukemia (K562), non-small cell lung cancer (NCI-
H460), colon cancer (HCT-116), CNS Cancer (U251) and melanoma (LOX IMVI), with 
Log10GI50 value below -6. 
 
Table 30. Mean in vitro activity of N-cyano sulfoximine-based DuP 697 (81) over 60 cancer cell lines 
Log10 mean
GI50
Log10 mean
TGI
Log10 mean
LC50
-5.52 -4.25 -4.02
 
Mean GI50, TGI, and LC50 values are reported in Table 30. These results indicate that N-cyano 
sulfoximine-based DuP 697 (81) exhibited noteworthy and potent growth inhibition activity 
against a variety of human tumor cell lines. 
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7. Hydrolysis studies of the N-cyano sulfilimine moiety with aqueous HCl 
solutions 
 
Encouraged by the promissing results of the N-cyano sulfilimine-based COX-2 inhibitors, the 
studies were extended to investigate the stability and degradation properties of the N-cyano 
sulfilimine moiety. It is strongly believed that these tests should be established for drug-like 
molecules an early stage. In fact, there were no such previous evaluations which took into 
account the behavior of the N-cyano sulfilimine molecule. To this end, stability characteristics 
of the simple N-cyanomethylphenyl sulfilimine 8213 were examined in aqueous HCl solutions 
at various pH values and reaction times.  
 
Scheme 32. Hydrolysis studies in acidic conditionsa 
S
CH3
N NH2
O
S
CH3
N
CN
xM HCl in H2O
RT
S
CH3
O
82 83
+
84  
                                            aFor detail, see Table 33 in experimental section 
 
When the reaction was run at a pH of 1.31, independent of time (1 or 7 h), very little 
conversion to the sulfoxide 83 was observed and almost all of the substrate 82 could be 
recovered following the reaction. When the pH value of the reaction mixture was lowered (to 
pH 0.24 or 0.03), after stirring for 20 h, decomposition of the sulfilimine took place, with the 
sulfoxide 83 being the major product formed (in up to 24% yield). Only trace amounts of the 
sulfilimine 82 could be recovered (10% yield). If much shorter reaction times were used, 
greater levels of the sulfilimine 82 could be recovered (69% yield after 10 mins). Interestingly, 
the formation of N-carbamoyl sulfilimine 8457 was also observed at low pH and longer 
reaction times (9 h or 20.5 h) in around 10% yield. These results demonstrated that the N-
cyano sulfilimine structure has a very sufficient tolerance in acidic conditions of over pH 1.3.  
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Summary 
 
In this work, sulfilimine- and sulfoximine-based COX-2 inhibitors, in which the sulfoximine 
group replaced a sulfonyl moiety, have been prepared and tested for COX-1/2 inhibitory 
effect and anti-cancer activity.   
Furthermore, in order to develop straightforward methods for the synthesis of sulfoximines, 
the direct structural conversion of a sulfone to a sulfoximine using arene diazonium 
tetrafluoroborate salts was trialed. While it was difficult to increase the yield, new methods 
have been established for the preparation of N-cyano sulfoximines. Of note, also N-cyano 
sulfonimidamides can be accessed when starting from sulfonamides. Although it has also 
shown the limitation for achieving a high yield, almost all of the excess substrate was readily 
recovered and reused.  
Due to these difficulties, the procedure involving N-cyano sulfilimine and sulfoximine 
intermediates has generally been applied to the synthesis of the new COX-2 inhibitors. 
Moreover, it has been proven that this is the preferable approach to introduce a sulfoximine 
moiety. 
While NH- and N-methyl sulfoximine-based Vioxx® analogs 32b,c have not exhibited the 
desirable inhibitory activity against COX isozymes, a compound 32b with reduced hERG 
blocking potency was obtained. In the results, it was indicated that a formal O/NH exchange 
(from a sulfone to a sulfoximine) could lead to remarkable biological activity changes. 
Further investigations have been undertaken by using N-cyano sulfilimine 39 and sulfoximine 
32a. Surprisingly, both analogs showed potent COX-2 inhibitory effect and selectivity. 
In order to extend the scope, subsequent studies employing sulfoximine-based Arcoxia® 
derivatives 48a-e have been carried out. Unfortunately, all newly prepared compounds except 
N-cyano sulfilimine 47, despite having the N-cyano 48a, NH 48b, N-urea 48c, and N-methyl 
48e groups on sulfoximine, demonstrated no activity at all. Interestingly, N-cyano sulfilimine-
based Arcoxia® 47 has shown the most promising biological activity against the COX-2 
isozyme. 
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The results of biological tests on sulfoximine-based Vioxx® and Arcoxia® analogs have led to 
the hypothesis that N-cyano sulfilimine and sulfoximine could be attractive moieties for drug 
discovery. 
To confirm the hypothesis, other methylphenyl sulfonyl-substituted COX-2 inhibitors (L-
784506, Fujisawa Pharm analog, SC-58125, DuP 697) have been selected, and the analogs of 
N-cyano sulfilimines and sulfoximines were prepared. They showed very promising COX 
inhibitory activities, especially in the cases of Fujisawa Pharm 68, 69a and DuP 697 (80, 81) 
analogs. Furthermore, it should be highlighted that the enantiomers of those analogs were 
superior to their racemic mixtures in the COX-2 inhibition and selectivity studies.        
Encouraged by these results, all newly prepared racemates have been evaluated for their 
cancer cell growth inhibitory effect against the full NCI 60 cell panel at the US National 
Cancer Institute (NCI). Among them, N-cyano sulfilimine-based Vioxx® 39 and N-cyano 
sulfoximine-based DuP 697 (81) were selected for a full five-dose assay. It is notable that 
those compounds, especially N-cyano sulfoximine-based DuP 697 (81), also exhibited 
remarkable potency with respect to COX-2 inhibitory activity. Subsequent studies are needed 
to validate the linkage of COX-2 with cancer. 
This thesis has demonstrated that the structural change from a sulfone to a sulfoximine could 
lead to compounds with beneficial biological effects. In addition, it has been proven that the 
N-cyano sulfilimine- and sulfoximine-based molecules, the key synthetic intermediates of 
NH-sulfoximine, could also be attractive targets for drug discovery.  
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Experimental section 
Part I. Syntheses 
 
1. General information 
 
Flash chromatography was carried out with Acros silica gel 60 (0.060-0.200mm, 60Å). 
Analytical TLC was performed with Merck silica gel 60 F254 plates. Melting points: Büchi B-
540, measurements were performed in open glass capillaries. Optical rotations: Perkin-Elmer 
Model 241, measurements were carried out at RT, λ = 589 nm. NMR spectra: Mercury 
300BB (1H-NMR: 300 MHz, 13C-NMR: 75 MHz), Varian Inova 400 (1H-NMR: 400 MHz, 
13C-NMR: 100 MHz, 19F-NMR: 376 MHz) and 600 (1H-NMR: 600 MHz, 13C-NMR: 150 
MHz, 19F-NMR: 560 MHz), the spectra were recorded in CDCl3 using TMS as internal 
standard and are reported in ppm. 1H NMR data are reported as: (s = singlet, d = doublet, t = 
triplet, q = quartet, m = multiplet, br = broad, dd = doublet doublet, dt = doublet of triplets, td 
= triplet of doublets, tt = triplet of triplets; coupling constant(s) in Hz; integration, proton 
assignment). IR: Perkin-Elmer FT/IR 1760, spectra were recorded as KBr pellet or film. MS: 
Varian MAT 212. High resolution mass spectra (HRMS): FinniganMAT 95 spectrometer. 
HPLC analysis: Agilent 1100-series system (chiral stationary phases from Chiral 
Technologies Inc.). Preparative HPLC: TharSFC Method Station II. All reagents were 
purchased from commercial sources and used as received. 
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2. Direct structural conversion using arene diazonium tetrafluoroborate salts 
2.1. Synthesis of arene diazonium tetrafluoroborate salts 
 
N2 BF4
R
 
Arene diazonium tetrafluoroborate salts were all prepared by the same general method (the 
known approach,29 see below for benzene diazonium tetrafluoroborate) and characterized by 
IR spectroscopy for detection of N2 bond and melting point for comparing with literature.29 
 
Benzene diazonium tetrafluoroborate (21a): To a solution of NaNO2 (3.2 g, 0.047 mol) and 
tetrafluoroboric acid (48% in H2O; 12.7 mL, 0.098 mol) in water (10 mL) was added aniline 
(3.6 g, 0.039 mol) at 0 oC. Then, the mixture was stirred at the same temperature for 30 min. 
The precipitate was filtered under reduced pressure and washed with diethyl ether. The 
product was purified by dissolution in acetone followed by precipitation with diethyl ether. 
This was carried out several times to remove colouration (4.9 g, 66% yield; m. p. 105 oC – 
110 oC, lit.;29 IR (KBr): ν 2294 (N2), 1570, 1025, 756 cm–1). 
p-Chlorobenzene diazonium tetrafluoroborate (21b): 71% yield; m. p. 131 oC – 133 oC, 
lit.;29 IR (KBr): ν 2289 (N2), 1562, 1033, 834, 774 cm–1. 
m-Chlorobenzene diazonium tetrafluoroborate (21c): 89% yield; m. p. 144 oC – 146 oC, 
lit.;29 IR (KBr): ν 2306 (N2), 1025, 792 cm–1. 
p-Methoxybenzene diazonium tetrafluoroborate (21d): 49% yield; m. p. 140 oC – 141 oC, 
lit.;29 IR (KBr): ν 2252 (N2), 1579, 1291, 1037, 842 cm–1. 
m-Methoxybenzene diazonium tetrafluoroborate (21e): 48% yield; m. p. 85 oC – 87 oC, 
lit.;29 IR (KBr): ν 2303 (N2), 1596, 1023, 861 cm–1. 
p-Methylbenzene diazonium tetrafluoroborate (21f): 55% yield; m. p. 109 oC – 111 oC, 
lit.;29 IR (KBr): ν 2289 (N2), 1583, 1016, 820 cm–1. 
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m-Methylbenzene diazonium tetrafluoroborate (21g): 95% yield; m. p. 101 oC – 102 oC, 
lit.;29 IR (KBr): ν 2297 (N2), 1028, 791 cm–1. 
m,m-Dimethoxybenzene diazonium tetrafluoroborate (21h): 25% yield; m. p. 100 oC – 
102 oC; IR (KBr): ν 2303 (N2), 1596, 1032, 838 cm–1. 
 
 
2.2. Preparative protocols of the N-cyano sulfoximines and sulfonimidamides 
2.2.1. General procedure of the oil-bath heating 
 
The reaction mixture of sulfone or sulfonamide and arene diazonium tetrafluoroborate salt 
was stirred at the chosen temperature (approximately 10 oC above the melting point of the 
corresponding arene diazonium tetrafluoroborate salt) for 0.5 h. Then, the mixture was cooled 
to room temperature. The resulting solid was dissolved in THF or CH3CN (below 0.5 mL). To 
a suspension of the mixture was added the nucleophile (NaHNCN or KHNCN) at room 
temperature and stirred at the same temperature over night. Water was added, and the 
resulting mixture was extracted with CH2Cl2 (3 x). The organic layer was dried over 
anhydrous Na2SO4, filtered and evaporated. The product was purified by flash column 
chromatography. 
 
2.2.2.  General procedure of the microwave heating 
 
The sulfone or sulfonamide and p-chlorobenzene diazonium tetrafluoroborate salt (21b) were 
charged in a microwave reaction vessel (sealed tube). The reaction mixture was heated to the 
chosen conditions (Table 31 and 32) for 5-8 minutes under instant cooling. The resulting solid 
was dissolved in CH3CN (below 0.5 mL). To a suspension of the mixture was added the 
nucleophile (NaHNCN or KHNCN) at room temperature and stirred at the same temperature 
over night. Water was added and the resulting mixture was extracted with CH2Cl2 (3 x). The 
organic layer was dried over anhydrous Na2SO4, filtered and evaporated. The product was 
purified by flash column chromatography. 
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Table 31. The screening of microwave heating conditions for the conversion of sulfone 20 to N-cyano 
sulfoximine 23b  
Entry
Step 1 (Microwave heating)a
1 40 oC, 15 min
Step 2b
(Yield)e
no reaction
2 60 oC, 20 min RT, overnight 38%
3 80 oC, 20 min RT, overnight 34%
4 100 oC, 20 min RT, overnight sulfide
5 145 oC, 15 min RT, overnight sulfide
6 60 oC, 20 min Microwave-heatingc 28%
7 60 oC, 20 min Oil-bath heatingd 21%
Sulfone (20) → 
Sulfoxonium salt (22b) Imination
N-Cyano sulfoximine (23b)
 
 aMethylphethyl sulfone (20, 5 eq), p-chlorobenzene diazonium tetrafluoroborate salt (21b, 1 eq, 0.442 mmol); 
bKHNCN (3 eq), CH3CN (15 eq); c80 oC , 20 min; d100 oC, overnight; e After column chromatography, over two 
steps 
 
 
Table 32. Optimization of the microwave heating conditions for the conversion of sulfonamide 24a to 
sulfonimidamide 26a 
1 60 oC, 20 min no reaction
2 80 oC, 20 min no reaction
3 100 oC, 20 min RT, overnight 37% (91%)d
4 120 oC, 20 min RT, overnight no reaction
5 100 oC, 40 min RT, overnight 37% (67%)d
6 100 oC, 40 mine RT, overnight 26% (86%)d
Entry
Step 1 (Microwave heating)a Step 2b
YieldcSulfonamide (24a) → Sulfonimidoxonium salt (25a) Imination
N-Cyano sulfonimidamide (26a)
-
-
 aSulfonamide (24a, 5 eq), p-chlorobenzene diazonium tetrafluoroborate salt (21b, 1 eq, 0.221 mmol); bNaHNCN  
(3 eq), CH3CN (15 eq); cAfter column chromatography, over two steps; dRecovered starting material; eCH3CN 
(15 eq) was added. 
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2.3. The sulfoximines 23a,b 
 
N-Benzylmethylphenyl sulfoximine (23a): 
Oil-bath heating: following the general procedure of the oil-bath heating, the 
reaction of sulfone 20 (144 mg, 0.922mmol) with p-chlorobenzene 
diazonium tetrafluoroborate salt (21b) (70 mg, 0.307 mmol, 145 oC) and N-
benzyl amine (0.1 mL, 0.922 mmol) in CH3CN (0.1 mL, 1.92 mmol) gave 23 mg (31% yield) 
of the desired product 23a; 
Analytical data: lit.56    
 
N-Cyanomethylphenyl sulfoximine (23b): 
Oil-bath heating: following the general procedure of the oil-bath heating, 
the reaction of sulfone 20 (133 mg, 0.852 mmol) with p-chlorobenzene 
diazonium tetrafluoroborate salt (21b) (64 mg, 0.284 mmol, 145 oC) and 
KHNCN (70 mg, 0.852 mmol) in CH3CN (0.2 mL, 4.26 mmol) gave 18 mg (35% yield) of 
the desired product 23b; 
Microwave heating (for microwave heating condition, see Table 31, entry 2): following the 
general procedure of the microwave heating, the reaction of sulfone 20 (345 mg, 2.209 mmol) 
with p-chlorobenzene diazonium tetrafluoroborate salt (21b) (100 mg, 0.442 mmol) and 
KHNCN (109 mg, 1.326 mmol) in CH3CN (0.3 mL, 6.630 mmol) gave 30 mg (38% yield) of 
the desired product 23b; 
Analytical data: lit.13 
 
 
S
CH3
O N
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2.4. The N-cyano sulfonimidamides 26a-d 
 
N-(4-Iodo-N-cyanosulfonimidoylphenyl)-N-methylmethanamine (26a): 
 Oil-bath heating: following the general procedure of the oil-bath heating, 
the reaction of sulfone 24a (687 mg, 2.209 mmol) with p-chlorobenzene 
diazonium tetrafluoroborate salt (21b) (100 mg, 0.442 mmol, 145 oC) 
and KHNCN (109 mg, 1.326 mmol) in CH3CN (0.3 mL, 6.630 mmol) afforded 54 mg (36% 
yield) of the desired product 26a; chromatography: gradient of ethyl acetate/n-pentane 1:1 to 
ethyl acetate. 
Microwave heating (for microwave heating condition, see Table 32, entry 3): following the 
general procedure of the microwave heating, the reaction of sulfone 24a (345 mg, 1.104 
mmol) with p-chlorobenzene diazonium tetrafluoroborate salt (21b) (50 mg, 0.221 mmol) and 
NaHNCN (43 mg, 0.663 mmol) in CH3CN (0.2 mL, 3.315 mmol) afforded 27 mg (37% yield) 
of the desired product 26a; chromatography: gradient of ethyl acetate/n-pentane 1:1 to ethyl 
acetate. 
1H NMR (400 MHz, CDCl3): δ 7.95 (dt, 2H, J = 2.2 Hz, J = 8.6 Hz, phenyl), 7.55 (dt, 2H, J = 
2.1 Hz, J = 8.6 Hz, phenyl), 2.83 (s, 6H, 2 x CH3) ppm; 
13C NMR (100 MHz, CDCl3): δ 139.0 (2 x CH), 132.2 (C), 129.0 (2 x CH), 110.5 (CN), 102.7 
(C), 38.1 (2 x CH3) ppm; 
IR (KBr): ν 2197 (CN), 1561, 1262, 1189, 1046, 936, 857, 815, 748 cm–1. 
 
N-Ethyl-N-(N-cyanosulfonimidoylphenyl)ethanamine (26b): 
 Oil-bath heating: following the general procedure of the oil-bath heating, 
the reaction of sulfone 24b (336 mg, 1.577 mmol) with p-chlorobenzene 
diazonium tetrafluoroborate salt (21b) (119 mg, 0.526 mmol, 145 oC) and 
KHNCN (130 mg, 1.578 mmol) in CH3CN (0.4 mL, 7.890 mmol) 
afforded 35 mg (28% yield) of the desired product 26b; chromatography: gradient of ethyl 
acetate/n-pentane 1:1 to ethyl acetate. 
S
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1H NMR (400 MHz, CDCl3): δ 7.88 (dt, 2H, J = 2.0 Hz, J = 7.9 Hz, phenyl), 7.65 (tt, 1H, J = 
1.4 Hz, J = 7.5 Hz, phenyl), 7.55 (tt, 2H, J = 1.7 Hz, J = 7.6 Hz, phenyl), 3.39 (sextet, 2H, J = 
7.3 Hz, -N-CH2-CH3), 3.31 (sextet, 2H, J = 7.3 Hz, -N-CH2-CH3), 1.17 (t, 6H, J = 7.1 Hz, -N-
CH2-CH3) ppm; 
13C NMR (100 MHz, CDCl3): δ 136.9 (C), 134.1 (CH), 129.6 (2 x CH), 127.3 (2 x CH), 111.5 
(CN), 42.3 (CH2), 13.7 (CH3) ppm. 
 
N-Benzyl(phenyl)-N-(N-cyanosulfonimidoylphenyl)methanamine (26c): 
Oil-bath heating: following the general procedure of the oil-bath 
heating, the reaction of sulfone 24c (389 mg, 1.153 mmol) with p-
chlorobenzene diazonium tetrafluoroborate salt (21b) (87 mg, 0.384 
mmol, 100 oC) and KHNCN (95 mg, 1.152 mmol) in CH3CN (0.3 mL, 
5.760 mmol) afforded 17 mg (12% yield) of the desired product 26c; 
chromatography: gradient of ethyl acetate/n-pentane 1:1 to ethyl acetate. 
1H NMR (400 MHz, CDCl3): δ 7.86 (dt, 2H, J = 1.7 Hz, J = 8.0 Hz, phenyl), 7.67 (tt, 1H, J = 
1.4 Hz, J = 7.5 Hz, phenyl), 7.54 (tt, 2H, J = 1.8 Hz, J = 8.0 Hz, phenyl), 7.26-7.23 (m, 6H, 
phenyl), 7.09-7.06 (m, 4H, phenyl), 4.40 (s, 4H, 2 x –N-CH2-Ph) ppm; 
13C NMR (100 MHz, CDCl3): δ 137.0 (C), 134.2 (CH), 133.8 (2 x C), 129.7 (2 x CH), 128.8 
(4 x CH), 128.7 (4 x CH), 128.3 (2 x CH), 127.5 (2 x CH), 50.8 (2 x CH2) ppm; 
IR (KBr): ν 2204 (CN), 1269, 1157, 1092, 892, 747, 687 cm–1. 
 
N-Methyl-N-(N-cyanosulfonimidoylphenyl)methanamine (26d): 
 Oil-bath heating: following the general procedure of the oil-bath heating, 
the reaction of sulfone 24d (539 mg, 2.907 mmol) with p-chlorobenzene 
diazonium tetrafluoroborate salt (21b) (219 mg, 0.969 mmol, 145 oC) and 
KHNCN (239 mg, 1.356 mmol) in CH3CN (0.7 mL, 14.535 mmol) afforded 51 mg (25% 
yield) of the desired product 26e; chromatography: gradient of ethyl acetate/n-pentane 1:1 to 
ethyl acetate. 
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1H NMR (400 MHz, CDCl3): δ 7.85 (dt, 2H, J = 1.9 Hz, J = 8.0 Hz, phenyl), 7.70 (tt, 1H, J = 
1.4 Hz, J = 7.5 Hz, phenyl), 7.60 (tt, 2H, J = 1.7 Hz, J = 7.8 Hz, phenyl), 2.82 (s, 6H, 2 x 
CH3) ppm; 
13C NMR (100 MHz, CDCl3): δ 134.5 (CH), 132.3 (C), 129.7 (2 x CH), 127.8 (2 x CH), 111.0 
(CN), 38.1 (2 x CH3) ppm; 
IR (KBr): ν 2200 (CN), 1268, 1195, 1097, 933, 847, 740 cm–1. 
 
 
 
3. Synthesis of sulfilimine- and sulfoximine-based COX-2 inhibitors 
3.1. Vioxx® analogs 
 
1-(4-phenyl)ethanone (28): 87% yield, lit.31  
S CH3
H3C
O  
 
1-[4-(N-Cyanomethylsulfilimidoyl)phenyl]ethanone (29): 
To a solution of 1-(4-phenyl)ethanone (28) (1 g, 6.015 mmol) in 
CH3CN (20 mL) was added cyanoamide (0.38 g, 9.023 mmol) and 
PhI(OAc)2 (2.13 g, 6.617 mmol) at 0 ºC. Then, the mixture was 
allowed to react at room temperature for 1 h. The solvent was removed 
under reduced pressure, water was added and the resulting mixture was extracted with CH2Cl2 
(3 x). The organic layer was dried over anhydrous Na2SO4, filtered and evaporated. Flash 
column chromatography (EtOAc/n-pentane = 5:1) gave 1 g (81% yield) of the desired product 
29;  
 
m. p. 140.0-140.9 oC; 
S CH3
H3C
O
N CN
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1H NMR (300 MHz, CDCl3): δ 8.15 (dt, 2H, J = 2.0 Hz, J = 8.9 Hz, phenyl), 7.89 (dt, 2H, J = 
2.0 Hz, J = 8.7 Hz, phenyl), 3.05 (s, 3H, -Ph-S(NCN)-CH3), 2.65 (s, 3H, CH3-CO-Ph-); 
13C NMR (75 MHz, CDCl3): δ 196.4 (CO), 140.7 (C), 140.4 (C), 129.9 (2 x CH), 126.1 (2 x 
CH), 119.9 (CN), 36.7 (CH3), 26,8 (CH3); 
IR (KBr): ν 2148, 1678, 1178, 978 cm–1; 
MS (EI), m/z (relative intensity): 206 (M+, 15), 166 (sulfide, 100), 151 (100), 137 (4); 
HRMS (ESI): [M+Na] calcd. for C10H10ON2NaS: 229.0406; found 229.0398. 
 
1-[4-(N-Cyanomethylsulfonimidoyl)phenyl]ethanone (30): 
To a solution of 1-[4-(N-cyanomethylsulfilimidoyl)phenyl]ethanone 
(29) (1 g, 4.848 mmol) in MeOH (15 mL) was added K2CO3 (2 g, 
14.545 mmol) and m-CPBA (70%; 1.3 g, 7.272 mmol) at 0 ºC. Then, 
the mixture was allowed to react at room temperature for 30 min. 
The solvent was removed under reduced pressure, water was added and the resulting mixture 
was extracted with CH2Cl2 (3 x). The organic layer was dried over anhydrous MgSO4, filtered 
and evaporated. Flash column chromatography (EtOAc/n-pentane = 1:1) gave 0.92 g (86% 
yield) of desired product 30; 
1H NMR (300 MHz, CDCl3): δ 8.15 (dt, 2H, J = 2.0 Hz, J = 8.9 Hz, phenyl), 8.05 (dt, 2H, J = 
2.0 Hz, J = 8.9 Hz, phenyl), 3.32 (s, 3H, -Ph-S(O)(NCN)-CH3), 2.63 (s, 3H, CH3-CO-Ph-); 
13C NMR (75 MHz, CDCl3): δ 196.1 (CO), 142.2 (C), 139.8 (C), 129.8 (2 x CH), 128.4 (2 x 
CH), 44.5 (CH3), 27.0 (CH3); 
IR (KBr): ν 2192, 1687, 1398, 1192, 973 cm–1. 
 
S
CH3H3C
O
O N
CN
 Experimental section 
88 
 
2-Bromo-1-[4-(N-cyanomethylsulfonimidoyl)phenyl]ethanone (31): 
To a solution of 1-[4-(N-cyanomethylsulfonimidoyl)-
phenyl]ethanone (30) (280 mg, 1.260 mmol) in CH2Cl2 (5 mL) was 
added AlCl3 (10 mg) and Br2 (201 mg, 1.260 mmol) at 0 ºC. Then, 
the mixture was allowed to react at room temperature overnight, 
and water was added and the resulting mixture was extracted with CH2Cl2 (3 x). The organic 
layer was dried over anhydrous MgSO4, filtered and evaporated. Flash column 
chromatography (EtOAc/n-pentane = 1:1) gave 185 mg (49% yield) of desired product 31; 
 
m. p. 99.2-99.9 oC; 
1H NMR (300 MHz, CDCl3): δ 8.20 (dt, 2H, J = 2.0 Hz, J = 8.7 Hz, phenyl), 8.07 (dt, 2H, J = 
2.0 Hz, J =, 8.9 Hz, phenyl), 4.40 (s, 2H, Br-CH2-CO-Ph-), 3.33 (s, 3H, -Ph-S(O)(NCN)-
CH3); 
13C NMR (75 MHz, CDCl3): δ 189.8 (CO), 140.5 (C), 139.2 (C), 130.6 (2 x CH), 128.6 (2 x 
CH), 44.5 (CH3), 30.0 (CH2); 
IR (KBr): ν 2188, 1690, 1396, 1192, 980 cm–1; 
MS (EI), m/z (relative intensity): 300 (M+, 23), 260 (sulfoxide, 14), 245, (sulfide, 21), 207 
(100), 168 (19); 
HRMS (ESI): [M+H] calcd. for C10H10O2N2BrS: 300.9641; found 300.9636. 
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4-[4-(N-Cyanomethylsulfonimidoyl)phenyl]-3-phenylfuran-2(5H)-one (32a): 
To a solution of 2-bromo-1-[4-(N-cyanomethylsulfonimidoyl)-
phenyl]ethanone (31) (208 mg, 0.691 mmol) in CH3CN (5 mL) was 
added phenylacetic acid (94 mg, 0.691 mmol), Et3N (70 mg, 0.691 
mmol), and DBU (210 mg, 1.382 mmol) at room temperature. Then, 
the mixture was refluxed overnight. After adding aqueous 1M HCl 
solution, the resulting mixture was extracted with CH2Cl2 (3 x). The organic layer was dried 
over anhydrous Na2SO4, filtered and evaporated. Flash column chromatography (EtOAc/n-
pentane = 3:1) gave 126 mg (54% yield) of desired product 32a; 
1H NMR (400 MHz, CDCl3): δ 7.90 (d, 2H, J = 8.6 Hz, phenyl), 7.54 (d, 2H, J = 8.6 Hz, 
phenyl), 7.37-7.31 (m, 5H, phenyl), 5.14 (s, 2H, -CO-O-CH2-C-Ph-), 3.28 (s, 3H, CH3-
S(O)(NH)-Ph-); 
13C NMR (100 MHz, CDCl3): δ 172.2 (CO), 152.4 (C), 138.0 (C), 137.4 (C), 130.0 (C), 129.8 
(CH), 129.7 (CH), 129.2 (2 x CH), 129.1 (4 x CH), 128.9 (C), 128.6 (2 x CH), 70.2 (CH2), 
44.6 (CH3); 
IR (KBr): ν 2197, 1748, 1196, 964 cm–1; 
MS (EI), m/z (relative intensity): 338 ([M]+, 100), 298 (sulfoxide, 17), 282 (sulfide, 68), 265 
(11), 242 (10), 226 (26), 178 (18); 
HRMS (ESI): [M+H] calcd. for C18H15O3N2S: 339.0798; found 339.0806. 
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4-[4-(NH-methylsulfonimidoyl)phenyl]-3-phenylfuran-2(5H)-one (32b): 
The solution of 4-[4-(N-cyanomethylsulfonimidoyl)phenyl]-3-
phenylfuran-2(5H)-one (32a) (121 mg, 0.358 mmol) in 50% of H2SO4 
in H2O (25 mL) was refluxed at 110 oC for 4 h. Then, the mixture was 
adjusted pH 11-12 by aqueous NaHCO3 and 1M NaOH. The resulting 
mixture was extracted with CH2Cl2 (3 x). The organic layer was dried 
over anhydrous Na2SO4, filtered and evaporated. Flash column chromatography 
(EtOAc/acetone = 1:1) gave 69 mg (62% yield) of desired product 32b; 
 
1H NMR (400 MHz, CDCl3): δ 7.93 (d, 2H, J = 8.5 Hz, phenyl), 7.44 (d, 2H, J = 8.5 Hz, 
phenyl), 7.33 (s, 5H, phenyl), 5.13 (s, 2H, -CO-O-CH2-C-Ph-), 3.10 (s, 3H, CH3-S(O)(NH)-
Ph-), 2.88 (br, 1H, CH3-S(O)(NH)-Ph-); 
13C NMR (100 MHz, CDCl3): δ 172.5 (CO), 153.5 (C), 144.3 (C), 135.8 (C), 129.4 (CH), 
129.2 (C), 129.1 (2 x CH), 128.9 (2 x CH), 128.8 (C), 128.4 (4 x CH), 70.4 (CH2), 45.9 
(CH3); 
IR (KBr): ν 3344, 1747, 1116, 958 cm–1; 
MS (EI), m/z (relative intensity): 313 [M+, 21], 250 [M+-S(O)(NH)CH3, 100], 192 [66], 178 
[61], 165 [43], 152 [23]; 
HRMS (EI), m/z: calcd. for C17H16O3NS: 314.0845; found 314.0845. 
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4-[4-(N-Methylmethylsulfonimidoyl)phenyl]-3-phenylfuran-2(5H)-one (32c): 
To a solution of 4-[4-(NH-sulfonimidoyl)phenyl]-3-
phenylfuran-2(5H)-one (32b) (18 mg, 0.057 mmol) in formic 
acid (5 mL) was added para-formaldehyde (17 mg, 0.574 
mmol) at room temperature. Then, the mixture was refluxed at 
150 oC for 3 days. After adding aqueous NaHCO3 solution, the 
resulting mixture was extracted with CH2Cl2 (3 x). The organic layer was dried over 
anhydrous MgSO4, filtered and evaporated. Flash column chromatography (EtOAc/acetone = 
1:1) gave 14 mg (75% yield) of desired product 32c; 
 
1H NMR (400 MHz, CDCl3): δ 7.82 (d, 2H, J = 8.5 Hz, phenyl), 7.45 (d, 2H, J = 8.8 Hz, 
phenyl), 7.35 (s, 5H, phenyl), 5.14 (s, 2H, -CO-O-CH2-C-Ph-), 3.05 (s, 3H, CH3-S(O)(NH)-
Ph-), 2.59 (s, 3H, CH3-S(O)(NCH3)-Ph-); 
13C NMR (100 MHz, CDCl3): δ 172.5 (CO), 153.5 (C), 140.5 (C), 135.4 (C), 129.4 (CH), 
129.4 (2 x CH), 129.3 (C), 129.1 (2 x CH), 128.9 (2 x CH), 128.8 (C), 128.5 (2 x CH), 70.4 
(CH2), 44.7 (CH3), 29.5 (CH3); 
HRMS (EI), m/z: calcd. for C18H18O3NS: 328.1002; found 328.1002. 
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2-Ethoxy-2-oxoethyl ester (34): 87% yield, lit.33 
O
O
O
EtO
 
 
4-Hydroxy-3-phenylfuran-2(5H)-one (35): 43% yield, lit.33 
O
OH
O  
2,5-Dihydro-5-oxo-4-phenylfuran-3-yl trifluoromethanesulfonate (36): 66% yield, lit.33 
O
OTf
O  
 
4-Bromo-3-phenylfuran-2(5H)-one (37): 88% yield, lit.33 
O
Br
O  
 
4-[4-(Methylthio)phenyl]-3-phenylfuran-2(5H)-one (38): 52% yield, lit.33 
O
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4-[4-(N-Cyanomethylsulfilimidoyl)phenyl]-3-phenylfuran-2(5H)-one (39): 
 
To a solution of 4-[4-(methylthio)phenyl]-3-phenylfuran-2(5H)-one 
(38) (100 mg, 0.354 mmol) in CH3CN (10 mL) was added 
cyanoamide (22 mg, 0.531 mmol) and PhI(OAc)2 (125 mg, 0.389 
mmol) at 0 ºC. Then, the mixture was allowed to react at room 
temperature for 1 h. The solvent was removed under reduced 
pressure, water was added and the resulting mixture was extracted 
with CH2Cl2 (3 x). The organic layer was dried over anhydrous Na2SO4, filtered and 
evaporated. Flash column chromatography (EtOAc/n-pentane = 5:1 to ethyl acetate) gave 105 
mg (92% yield) of the desired product 39;  
1H-NMR (400 MHz, CDCl3): δ 7.75 (dt, 2H, J = 1.97 Hz, J = 8.55 Hz, phenyl), 7.52 (dt, 2H, 
J = 1.97 Hz, J = 8.55 Hz, phenyl), 7.35–7.41 (m, 5H, phenyl), 5.17 (s, 2H, furanone), 3.01 (s, 
3H, methyl) ppm;  
13C-NMR (150 MHz, CDCl3): δ 172.4 (CO), 153.0 (C), 138.1 (C), 135.7 (C), 129.6 (CH), 
129.3 (2 x CH), 129.2 (C), 129.1 (2 x CH), 129.0 (2 x CH), 128.8 (C), 126.6 (2 x CH), 70.3 
(CH2), 36.3 (CH3) ppm; 
IR (KBr): ν 2144 (CN), 1742 (CO), 1156, 1036, 958, 831, 761 cm-1; 
HRMS (ESI): [M+Na] calcd. for C18H14O2N2NaS:  345.0668; found 345.0668. 
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3.2. Arcoxia® analogs 
 
3-Bromo-5-chloropyridin-2-ol (41): 66% yield, lit.17b 
N
Br
OH
Cl
 
 
2-(Benzyloxy)-3-bromo-5-chloropyridine (42): 86% yield, lit.17b 
N
Br
O
Cl
 
 
2-(Benzyloxy)-5-chloro-3-[4-(methylthio)phenyl]pyridine (43): 99% yield, lit.17b 
N O
S
CH3
Cl
 
 
5-Chloro-3-[4-(methylthio)phenyl]pyridin-2-ol (44): 63% yield, lit.17b 
N OH
S
CH3
Cl
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2,5-Dichloro-3-[4-(methylthio)phenyl]pyridine (45): 90% yield, lit.17b 
N Cl
S
CH3
Cl
 
5-{5-Chloro-3-[4-(methylthio)phenyl]pyridin-2-yl}-2-methylpyridine (46): 62% yield, 
lit.17b 
N
S
CH3
Cl
N
CH3  
 
5-Chloro-2-(6-methylpyridin-3-yl)-3-[4-(N-cyanomethylsulfilimidoyl)phenyl]pyridine 
(47): 
 
To a solution of 5-{5-Chloro-3-[4-(methylthio)phenyl]pyridin-2-
yl}-2-methylpyridine (46) (42 mg, 0.129 mmol) in CH3CN (5 
mL) was added cyanoamide (8 mg, 0.193 mmol) and PhI(OAc)2 
(46 mg, 0.129 mmol) at 0 ºC. Then, the mixture was allowed to 
react at room temperature for 2 h. The solvent was removed 
under reduced pressure, water was added and the resulting 
mixture was extracted with CH2Cl2 (3 x). The organic layer was dried over anhydrous Na2SO4, 
filtered and evaporated. Flash column chromatography (EtOAc/n-pentane = 5:1) gave 31 mg 
(66% yield) of the desired product 47; 
 
1H-NMR (300 MHz, CDCl3): δ 8.70 (s, 1H, 2-methylpyridyl), 8.34 (s, 1H, 3-chloropyridyl), 
7.77 (s, 1H, 2-methylpyridyl), 7.72-7.74 (m, 2H, phenyl), 7.59 (dd, 1H, J = 2.98 Hz, J = 8.16 
Hz, 3-chloropyridyl), 7.42 (d, 2H, J = 8.16 Hz, phenyl), 7.11 (d, 1H, J = 7.92 Hz, 2-
methylpyridyl), 3.04 (s, 3H, methyl), 2.53 (s, 3H, 2-methylpyridyl) ppm; 
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13C-NMR (75 MHz, CDCl3): δ 158.6 (C), 152.3 (C), 149.8 (CH), 148.5 (CH), 143.3 (C), 
137.9 (CH), 137.4 (CH), 136.1 (C), 135.0 (C), 131.3 (C), 131.2 (2 x CH), 131.0(C), 126.5 (2 
x CH), 122.9 (CH), 36.4 (CH3), 24.2 (CH3) ppm; 
MS (EI), m/z (relative intensity): 366 (M+, 6), 326 (sulfide, 100), 310 (21), 279 (24); 
IR (KBr): ν 2147 (CN), 1429, 1151, 1011, 968, 836, 768 cm-1; 
HRMS (ESI): [M+H] calcd. for C19H16N4ClS:  367.0779; found 367.0779. 
 
5-Chloro-2-(6-methylpyridin-3-yl)-3-[4-(N-cyanomethylsulfonimidoyl)phenyl]pyridine 
(48a): 
 
To a solution of 5-chloro-2-(6-methylpyridin-3-yl)-3-[4-(N-
cyanomethylsulfilimidoyl)phenyl]pyridine (47) (28 mg, 0.086 
mmol) in MeOH (5 mL) was added K2CO3 (36 mg, 0.258 
mmol) and m-CPBA (70%; 22 mg, 0.130 mmol) at 0 ºC. Then, 
the mixture was allowed to react at room temperature for 30 
min. The solvent was removed under reduced pressure, water was added and the resulting 
mixture was extracted with CH2Cl2 (3 x). The organic layer was dried over anhydrous MgSO4, 
filtered and evaporated. Flash column chromatography (EtOAc/n-pentane = 1:10 to 1:1) gave 
21 mg (64% yield) of desired product 48a; 
1H-NMR (300 MHz, CDCl3): δ 8.67 (dd, 1H, J = 2.35 Hz, J = 4.33 Hz, 2-methylpyridyl), 
8.28 (d, 1H, J = 2.22 Hz, 3-chloropyridyl), 7.89 (dt, 2H, J = 1.98 Hz, J = 8.40 Hz, phenyl), 
7.68 (dd, 1H, J = 2.35 Hz, J = 4.33 Hz, 2-methylpyridyl), 7.56 (dd, 1H, J = 2.23 Hz, J = 7.92 
Hz, 3-chloropyridyl), 7.44 (dt, 2H, J = 1.98 Hz, J = 8.41 Hz, phenyl), 7.07 (d, 1H, J = 7.91 Hz, 
2-methylpyridyl), 3.32 (s, 3H, methyl), 2.48 (s, 3H, 2-methylpyridyl) ppm; 
13C-NMR (75 MHz, CDCl3): δ 158.8 (C), 152.3 (C), 149.8 (CH), 148.8 (CH), 145.7 (C), 
138.0 (CH), 137.4 (CH), 135.7 (C), 134.5 (C), 131.3 (C), 131.2 (2 x CH), 131.0 (C), 128.5 (2 
x CH), 123.0 (CH), 111.5 (CN), 44.8 (CH3), 24.3 (CH3) ppm; 
MS (EI), m/z (relative intensity): 384 ([M+2]+, 23), 382 ([M]+, 100), 326 (sulfide, 50), 278 
(44); 
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IR (KBr): ν 2196 (CN), 1247, 1191, 1094, 972, 826, 778, 727 cm–1; 
HRMS (ESI): [M+H] calcd. for C19H16ON4ClS:  383.0728; found 383.0728. 
 
5-Chloro-2-(6-methylpyridin-3-yl)-3-[4-(NH-methylsulfonimidoyl)phenyl]pyridine (48b): 
 
The solution of 5-chloro-2-(6-methylpyridin-3-yl)-3-[4-(N-
cyanomethylsulfonimidoyl)phenyl]pyridine (48a) (12 mg, 0.031 
mmol) in 50% of H2SO4 in H2O (2 mL) was refluxed at 110 ºC for 
1 h. Then, the mixture was adjusted pH 11-12 by aqueous 
NaHCO3 and 1M NaOH. The resulting mixture was extracted with 
CH2Cl2 (3 x). The organic layer was dried over anhydrous Na2SO4, filtered and evaporated. 
Flash column chromatography (CH2Cl2/MeOH = 10:1) gave 8 mg (71% yield) of desired 
product 48b; 
 
1H-NMR (300 MHz, CDCl3): δ 8.72 (d, 1H, J = 2.32 Hz, 2-methylpyridyl), 8.36 (d, 1H, J = 
1.99 Hz, 3-chloropyridyl), 7.97 (dt, 2H, J = 1.99 Hz, J = 8.29 Hz, phenyl), 7.74 (d, 1H, J = 
2.32 Hz, 2-methylpyridyl), 7.61 (dd, 1H, J = 2.32 Hz, J = 7.97 Hz, 3-chloropyridyl), 7.38 (dt, 
2H, J = 1.83 Hz, J = 8.30 Hz, phenyl), 7.10 (d, 1H, J = 8.30 Hz, 2-methylpyridyl), 3.09 (s, 3H, 
methyl), 2.66 (br, 1H, NH-sulfoximine), 2.49 (s, 3H, 2-methylpyridyl) ppm; 
13C-NMR (75 MHz, CDCl3): δ 158.5 (C), 152.4 (C), 149.9 (CH), 148.3 (CH), 143.3 (C), 
143.1 (C), 137.9 (CH), 137.3 (CH), 135.4 (C), 131.3 (C), 131.1 (C), 130.2 (2 x CH), 128.2 (2 
x CH), 122.8 (CH), 46.2 (CH3), 24.3 (CH3) ppm; 
MS (EI), m/z (relative intensity): 357 ([M]+, 18), 342 (sulfoxide, 100), 326 (sulfide, 5), 278 
(21); 
IR (KBr): ν 1597, 1428, 1220, 1097, 1002, 801 cm–1; 
HRMS (ESI): [M+Na] calcd. for C18H16ON3ClNaS:  380.0595; found 380.0594. 
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5-Chloro-2-(6-methylpyridin-3-yl)-3-[4-(N-ureamethylsulfonimidoyl)phenyl]pyridine 
(48c): 
 
To a solution of 5-chloro-2-(6-methylpyridin-3-yl)-3-[4-(N-
cyanomethylsulfonimidoyl)phenyl]pyridine (48a) (20 mg, 
0.052 mmol) in CH3CN (5 mL) was added 
trifluoromethanesulfonic acid (16 mg, 0.105 mmol) at  0 ºC. 
Then, the mixture was stirred at 40 oC for 18 h, and adjusted 
pH 10-12 by aqueous NaHCO3 and 1M NaOH. The 
resulting mixture was extracted with CH2Cl2 (3 x). The organic layer was dried over 
anhydrous Na2SO4, filtered and evaporated. Flash column chromatography (CH2Cl2/MeOH = 
15:1) gave 8 mg (38% yield) of desired product 48c; 
 
1H-NMR (400 MHz, CDCl3): δ 8.73 (d, 1H, J = 2.32 Hz, 2-methylpyridyl), 8.39 (d, 1H, J = 
1.99 Hz, 3-chloropyridyl), 7.96 (dt, 2H, J = 1.83 Hz, J = 8.29 Hz, phenyl), 7.74 (d, 1H, J = 
2.32 Hz, 2-methylpyridyl), 7.60 (dd, 1H, J = 2.32 Hz, J = 7.97 Hz, 3-chloropyridyl), 7.41 (dt, 
2H, J = 1.83 Hz, J = 8.63 Hz, phenyl), 7.10 (d, 1H, J = 7.96 Hz, 2-methylpyridyl), 4.81 (2H, 
br, -CO-NH2), 3.35 (s, 3H, methyl), 2.50 (s, 3H, 2-methylpyridyl) ppm; 
13C-NMR (100 MHz, CDCl3): δ 161.1 (CO), 158.5 (C), 152.3 (C), 149.8 (CH), 148.4 (CH), 
143.7 (C), 143.1 (C), 139.0 (C), 138.0 (CH), 137.3 (CH), 135.2 (C), 131.1 (C), 130.5 (2 x 
CH), 127.9 (2 x CH), 122.8 (CH), 44.4 (CH3), 24.3 (CH3) ppm; 
IR (KBr): ν 1648, 1595, 1358, 1219, 1117, 961, 838, 728 cm–1; 
MS (EI), m/z (relative intensity): 400 ([M]+, 1), 357 (NH-sulfoximine, 18), 342 (sulfoxide, 
100), 326 (sulfide, 5), 278 (15). 
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5-Chloro-2-(6-methylpyridin-3-yl)-3-[4-(N-tert-butoxycarbonylmethylsulfonimidoyl)-
phenyl]pyridine (48d): 
 
To a solution of 5-chloro-2-(6-methylpyridin-3-yl)-3-[4-
(NH-methylsulfonimidoyl)phenyl]pyridine (48b) (33 mg, 
0.092 mmol) in THF (5 mL) was added NaH (60% in 
mineral oil; 3 mg, 0.138 mmol) and (Boc)2O (40 mg, 
0.184 mmol) at room temperature. Then, the mixture was 
refluxed overnight. The solvent was removed under 
reduced pressure, water was added and the resulting mixture was extracted with CH2Cl2 (3 x). 
The organic layer was dried over anhydrous MgSO4, filtered and evaporated. Flash column 
chromatography (CH2Cl2/MeOH = 15:1) gave 18 mg (43% yield) of desired product 48d; 
 
1H-NMR (400 MHz, CDCl3): δ 8.73 (d, 1H, J = 2.33 Hz, 2-methylpyridyl), 8.42 (d, 1H, J = 
1.99 Hz, 3-chloropyridyl), 7.95 (dt, 2H, J = 1.83 Hz, J = 7.96 Hz, phenyl), 7.75 (d, 1H, J = 
2.32 Hz, 2-methylpyridyl), 7.53 (dd, 1H, J = 2.32 Hz, J = 8.29 Hz, 3-chloropyridyl), 7.42 (dt, 
2H, J = 1.74 Hz, J = 7.96 Hz, phenyl), 7.07 (d, 1H, J = 8.29 Hz, 2-methylpyridyl), 3.25 (s, 3H, 
methyl), 2.49 (s, 3H, 2-methylpyridyl), 1.35 (s, 9H, tert-butoxy) ppm. 
 
5-Chloro-2-(6-methylpyridin-3-yl)-3-[4-(N-methylmethylsulfonimidoyl)phenyl]pyridine 
(48e): 
 
To a solution of 5-chloro-2-(6-methylpyridin-3-yl)-3-[4-(NH-
methylsulfonimidoyl)phenyl]pyridine (48b) (18 mg, 0.050 
mmol) THF (2 mL) was added NaH (60% in mineral oil; 2 mg, 
0.076 mmol) and MeI (14 mg, 0.100 mmol) at 0 ºC . Then, the 
mixture was allowed to react at room temperature overnight. 
The solvent was removed under reduced pressure, water was added and the resulting mixture 
was extracted with CH2Cl2 (3 x). The organic layer was dried over anhydrous MgSO4, filtered 
and evaporated. Flash column chromatography (CH2Cl2/MeOH = 15:1) gave 13 mg (70% 
yield) of desired product 48e; 
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1H-NMR (400 MHz, CDCl3): δ 8.73 (d, 1H, J = 2.32 Hz, 2-methylpyridyl), 8.38 (d, 1H, J = 
1.99 Hz, 3-chloropyridyl), 7.86 (dt, 2H, J = 1.66 Hz, J = 8.30 Hz, phenyl), 7.76 (d, 1H, J = 
2.32 Hz, 2-methylpyridyl), 7.62 (dd, 1H, J = 2.32 Hz, J = 7.96 Hz, 3-chloropyridyl), 7.39 (dt, 
2H, J = 1.66 Hz, J = 8.29 Hz, phenyl), 7.09 (d, 1H, J = 7.96 Hz, 2-methylpyridyl), 3.07 (s, 3H, 
methyl), 2.62 (s, 3H, N-methylsulfoximine), 2.50 (s, 3H, 2-methylpyridyl) ppm; 
13C-NMR (100 MHz, CDCl3): δ 158.5 (C), 152.4 (C), 149.9 (CH), 148.3 (CH), 142.9 (C), 
138.6 (C), 138.0 (CH), 137.3 (CH), 135.5 (C), 131.4 (C), 131.1 (C), 130.5 (2 x CH), 129.2 (2 
x CH), 122.7 (CH), 44.9 (CH3), 29.6 (CH3), 24.3 (CH3) ppm; 
IR (KBr): ν 1598, 1427, 1238, 1149, 1086, 974, 838, 772 cm–1. 
 
 
 
3-Bromo-5-chloropyridin-2-amine (50): 89% yield, lit.17b 
N
Cl
NH2
Br
 
 
5-Chloro-3-[4-(methylthio)phenyl]pyridin-2-amine (51): 91% yield, lit.17b 
N
Cl
NH2
S
CH3
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2-(Benzyloxy)-5-chloro-3-[4-(N-cyanomethylsulfonimidoyl)phenyl]pyridine (55): 
 
To a solution of 2-(benzyloxy)-5-chloro-3-[4-(N-
cyanomethylsulfilimidoyl)phenyl]pyridine (54) (53 mg, 0.139 
mmol) in MeOH (2 mL) was added K2CO3 (58 mg, 0.417 
mmol) and m-CPBA (70%; 36 mg, 0.208 mmol) at 0 ºC. Then, 
the mixture was allowed to react at room temperature for 30 
min. The solvent was removed under reduced pressure, water was added and the resulting 
mixture was extracted with CH2Cl2 (3 x). The organic layer was dried over anhydrous MgSO4, 
filtered and evaporated. Flash column chromatography (EtOAc/n-pentane = 1:1) gave 28 mg 
(51% yield) of desired product 55; 
 
1H NMR (300 MHz, CDCl3): δ 8.21 (dd, 1H, J = 1.4 Hz, J = 2.4 Hz, pyridyl), 8.03 (dd, 2H, J 
= 1.1 Hz, J = 8.5 Hz, phenyl), 7.87 (dd, 2H, J = 1.1 Hz, J = 8.5 Hz, phenyl), 7.66 (dd, 1H, J = 
1.4 Hz, J = 2.3 Hz, pyridyl), 7.30-7.38 (m, 5H, phenyl), 5.44 (s, 2H, -CH2-Ph), 3.33 (s, 3H, 
methyl); 
13C NMR (75 MHz, CDCl3): δ 158.4 (C), 145.7 (CH), 142.9 (C), 138.6 (CH), 136.5 (C), 
135.2 (C), 130.8 (2 x CH), 128.6 (CH), 128.1 (CH), 128.0 (2 x CH), 127.9 (CH), 124.8 (C), 
122.9 (C), 68.5 (CH2), 44.9 (CH3); 
IR (KBr): ν 2191 (CN), 1257, 1203, 1097, 976, 826, 730, 691 cm–1; 
MS (EI), m/z (relative intensity): 397 ([M]+, 100), 357 (sulfoxide, 42), 341 (sulfide, 12), 251 
(18); 
HRMS (ESI): [M+Na] calcd. for C20H16O2N3ClNaS:  420.0544; found 420.0527. 
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5-Chloro-3-[4-(N-cyanomethylsulfonimidoyl)phenyl]pyridin-2(1H)-one (57): 
 
 To a solution of 2-(benzyloxy)-5-chloro-3-[4-(N-
cyanomethylsulfonimidoyl)phenyl]pyridine (55) (500 mg, 1.257 
mmol) in MeOH (10 mL) was added Pd/C (10%; 70 mg) at 
room temperature. Then, the mixture was stirred at the same 
temperature for 30 min. After filtration with Celite 545, filtrate 
was evaporated. Flash column chromatography (CH2Cl2/MeOH = 15:1) gave 274 mg (71% 
yield) of desired product 57; 
1H NMR (300 MHz, DMSO): δ 12.31 (br, 1H, -NH-CO-), 8.13 (d, 2H, J = 8.7 Hz, phenyl), 
8.04 (d, 2H, J = 8.4 Hz, phenyl), 7.91 (d, 1H, J = 2.7 Hz, pyridyl), 7.74 (d, 1H, J = 3.0 Hz, 
pyridyl), 3.72 (s, 3H, methyl); 
13C NMR (75 MHz, DMSO): δ 160.1 (C), 142.6 (C), 140.9 (CH), 135.4 (CH), 130.2 (2 x CH), 
128.7 (C), 127.8 (2 x CH), 112.7 (C), 111.8 (CN), 43.2 (CH3); 
IR (KBr): ν 2193 (CN), 1641 (CO), 1252, 1200, 1090, 971, 821, 686 cm–1. 
 
5-Chloro-3-[4-(N-cyanomethylsulfonimidoyl)phenyl]pyridin-2-yl trifluoromethane-
sulfonate (58c): 
 
To a solution of 5-chloro-3-[4-(N-cyanomethyl-
sulfonimidoyl)phenyl]pyridin-2(1H)-one (57) (100 mg, 0.325 
mmol) in CH3CN (5 mL) was added pyridine (31 mg, 0.390 
mmol) and trifluoromethanesulfonyl anhydride (108 mg, 0.358 
mmol) at 0 ºC. Then, the mixture was allowed to react at room 
temperature overnight. The solvent was removed under reduced 
pressure, aqueous CuSO4 was added and the resulting mixture was extracted with CH2Cl2 (3 
x). The organic layer was dried over anhydrous MgSO4, filtered and evaporated. Flash 
column chromatography (EtOAc/n-pentane = 1:1) gave 101 mg (53% yield) of desired 
product 58c; 
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1H NMR (400 MHz, CDCl3): δ 8.41 (d, 1H, J = 2.7 Hz, pyridyl), 8.15 (dt, 2H, J = 2.0 Hz, J = 
8.6 Hz, phenyl), 7.87 (d, 1H, J = 2.7 Hz, pyridyl), 7.80 (dt, 2H, J = 2.0 Hz, J = 8.6 Hz, 
phenyl), 3.39 (s, 3H, methyl); 
13C NMR (100 MHz, CDCl3): δ 150.7 (C), 147.1 (CH), 140.8 (CH), 139.6 (C), 137.1 (C), 
132.7 (C), 130.9 (2 x CH), 128.6 (2 x CH), 127.7 (C), 118.3 (q, CF3, J = 321.13 Hz), 111.4 
(CN), 44.9 (CH3); 
MS (EI), m/z (relative intensity): 439 ([M]+, 100), 399 (sulfoxide, 81), 383 (sulfide, 94), 249 
(33), 219 (21), 203 (53); 
HRMS (ESI): [M+H] calcd. for C14H10O4N3ClF3S2:  439.9748; found 439.9755. 
 
5-Chloro-3-[4-(NH-methylsulfonimidoyl)phenyl]pyridin-2-yl trifluoromethanesulfonate 
(58c’): 
 To a solution of 5-chloro-3-[4-(N-cyanomethyl-
sulfonimidoyl)phenyl]pyridin-2-yl trifluoromethanesulfonate 
(58c) (86 mg, 0.146 mmol) in CH3CN (5 mL) was added 
trifluoromethanesulfonic acid (46 mg, 0.307 mmol) at 0 ºC. Then, 
the mixture was allowed to react at 40 ºC for 3 days. The solvent 
was removed under reduced pressure, water was added and the 
resulting mixture was extracted with CH2Cl2 (3 x) in basic condition with aqueous NaOH (5 
wt %). The organic layer was dried over anhydrous MgSO4, filtered and evaporated. Flash 
column chromatography (EtOAc/n-pentane = 1:1) gave 101 mg (67% yield) of desired 
product 58c’; 
1H NMR (300 MHz, CDCl3): δ 8.38 (d, 1H, J = 2.5 Hz, pyridyl), 8.17 (d, 2H, J = 8.7 Hz, 
phenyl), 7.90 (d, 1H, J = 2.5 Hz, pyridyl), 7.68 (d, 2H, J = 8.4 Hz, phenyl), 3.12 (s, 3H, 
methyl), 2.50 (br, 1H, NH-sulfoximine); 
13C NMR (75 MHz, CDCl3): δ 150.9 (C), 146.6 (CH), 144.7 (C), 140.8 (CH), 137.2 (C), 
132.4 (C), 130.0 (2 x CH), 128.6 (C), 128.4 (2 x CH), 118.3 (q, CF3, J = 320.78 Hz), 46.1 
(CH3). 
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3-Chloro-5-[4-(N-cyanomethylsulfonimidoyl)phenyl]pyridine (59): 
 To a solution of 5-chloro-3-[4-(N-cyanomethyl-
sulfonimidoyl)phenyl]pyridin-2-yl trifluoromethanesulfonate 
(58c) (58 mg, 0.139 mmol) in dried dioxane (5 mL) was added 
(Me3Sn)2 (46 mg, 0.139 mmol), LiCl (18 mg, 0.417 mmol), 
Pd(PPh3)4 (8 mg, 0.007 mmol), and 5-bromo-2-methylpyridine 
(24 mg, 0.139 mmol) in unhydrous conditions. Then, the mixture was allowed to react at 120 
ºC for 3 days. Aqueous KF was added and the resulting mixture was extracted with EtOAc (3 
x). The organic layer was dried over anhydrous MgSO4, filtered and evaporated. Flash 
column chromatography (EtOAc/n-pentane = 1:1 to 4:1) gave 30 mg (56% yield) of the 
product 59 as a mixture with the compound 48a (59:48a = 2.6:1); 
1H NMR (300 MHz, CDCl3): δ 8.77 (s, 1H, pyridyl), 8.69 (s, 1H, pyridyl), 8.13 (dt, 2H, J = 
1.9 Hz, J = 8.4 Hz, phenyl), 7.92 (t, 1H, J = 2.2 Hz, pyridyl), 7.87 (dt, 2H, J = 1.9 Hz, J = 8.4 
Hz, phenyl), 3.36 (s, 3H, methyl); 
13C NMR (75 MHz, CDCl3): δ 149.1 (CH), 146.1 (CH), 143.7 (C), 136.1 (C), 134.4 (CH), 
130.8 (C), 129.0 (2 x CH), 128.9 (2 x CH), 128.4 (C), 111.5 (CN), 44.8 (CH3); 
IR (KBr): ν 2191 (CN), 1244, 1181, 1092, 979, 823, 777, 701 cm–1. 
 
 
3.3. L-784506 analogs 
 
2-Bromo-3-ethoxycyclopent-2-enone (61): 98% yield, lit.17c 
O
OEt
Br  
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2-Bromo-3-[4-(methylthio)phenyl]cyclopent-2-enone (62): 
To a solution of 2-bromo-3-ethoxycyclopent-2-enone (61) (160 mg, 
0.780 mmol) in dried THF (5 ml) was added bromo[4-
(methylsulfanyl)phenyl]magnesium (0.5M in THF, 2.8 ml, 1.560 
mmol) at 0 oC. Then, the mixture was allowed to react at room 
temperature overnight. Water was added and the resulting mixture was extracted with Et2O (3 
x). The organic layer was dried over anhydrous MgSO4, filtered and evaporated. Flash 
column chromatography (EtOAc/n-pentane = 1:10 to 1:1) gave 56 mg (27% yield) of the 
desired product 62;  
Analytical data: lit.17c 
 
3-(4-(Methylthio)phenyl)-2-(pyridin-3-yl)cyclopent-2-enone (63): 82% yield, lit.17c 
S
CH3
O N
 
 
3-[4-(N-Cyanomethylsulfilimidoyl)phenyl]-2-(pyridin-3-yl)cyclopent-2-enone (64): 
 
To a solution of 3-[4-(methylthio)phenyl]-2-(pyridin-3-yl)cyclopent-
2-enone (63) (44 mg, 0.156 mmol) in CH3CN (5 mL) was added 
cyanoamide (10 mg, 0.235 mmol) and PhI(OAc)2 (55 mg, 0.172 
mmol) at 0 ºC. Then, the mixture was allowed to react at room 
temperature for 30 min. The solvent was removed under reduced 
pressure, water was added and the resulting mixture was extracted 
with CH2Cl2 (3 x). The organic layer was dried over anhydrous Na2SO4, filtered and 
evaporated. Flash column chromatography (EtOAc/n-pentane = 5:1) gave 40 mg (80% yield) 
of the desired product 64; 
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1H-NMR (400 MHz, CDCl3): δ 8.50 (s, 1H, 3-pyridyl), 8.27 (s, 1H, 3-pyridyl) 7.70 (dt, 2H, J 
= 1.99 Hz, J = 8.63 Hz, phenyl), 7.64 (dt, 1H, J = 1.99 Hz, J = 7.63 Hz, 3-pyridyl), 7.46 (dt, 
2H, J = 1.99 Hz, J = 8.63 Hz, phenyl), 7.31 (dd, 1H, J = 4.98 Hz, J = 7.96 Hz, 3-pyridyl), 
3.05 (dt, 2H, J = 2.49 Hz, J = 5.14 Hz, cyclopent-2-enone), 2.98 (s, 3H, methyl), 2.73 (dt, 2H, 
J = 2.49 Hz, J = 4.97 Hz, cyclopent-2-enone) ppm; 
13C-NMR (100 MHz, CDCl3): δ 206.0 (CO), 166.9 (C), 149.4 (CH), 148.7 (CH), 140.2 (C), 
138.4 (C), 137.6 (CH), 137.5 (CH), 129.6 (2 x CH), 127.5 (C), 126.5 (2 x CH), 123.8 (C), 
119.8 (CN), 36.3 (CH3), 34.8 (CH2), 30.0 (CH2) ppm; 
IR (KBr): ν 2144 (CN), 1694 (CO), 1159, 971, 818, 712 cm–1. 
 
3-[4-(N-Cyanomethylsulfonimidoyl)phenyl]-2-(pyridin-3-yl)cyclopent-2-enone (65): 
 
To a solution of 3-[4-(N-cyanomethylsulfilimidoyl)phenyl]-2-
(pyridin-3-yl)cyclopent-2-enone (64) (25 mg, 0.078 mmol) in 
MeOH (5 mL) was added K2CO3 (22 mg, 0.156 mmol) and m-
CPBA (70%; 20 mg, 0.117 mmol) at 0 ºC. Then, the mixture was 
allowed to react at room temperature for 30 min. The solvent was 
removed under reduced pressure, water was added and the resulting 
mixture was extracted with CH2Cl2 (3 x). The organic layer was dried over anhydrous MgSO4, 
filtered and evaporated. Flash column chromatography (EtOAc/n-pentane = 1:10 to 1:1) gave 
17 mg (65% yield) of desired product 65; 
1H-NMR (400 MHz, CDCl3): δ 8.51 (s, 1H, 3-pyridyl), 8.25 (s, 1H, 3-pyridyl) 7.89 (dt, 2H, J 
= 1.99 Hz, J = 8.63 Hz, phenyl), 7.65 (dt, 1H, J = 1.99 Hz, J = 7.63 Hz, 3-pyridyl), 7.52 (dt, 
2H, J = 1.99 Hz, J = 8.63 Hz, phenyl), 7.32 (dd, 1H, J = 4.97 Hz, J = 7.63 Hz, 3-pyridyl), 
3.30 (s, 3H, methyl), 3.06 (dt, 2H, J = 2.49 Hz, J = 5.14 Hz, cyclopent-2-enone), 2.75 (dt, 2H, 
J = 2.49 Hz, J = 4.98 Hz, cyclopent-2-enone) ppm; 
13C-NMR (100 MHz, CDCl3): δ 205.9 (CO), 166.0 (C), 149.6 (CH), 149.2 (CH), 142.6 (C), 
139.2 (C), 137.3 (CH), 137.0 (C), 129.5 (2 x CH), 128.5 (2 x CH), 127.1 (C), 123.8 (CH), 
111.4 (CN), 44.7 (CH3), 34.8 (CH2), 30.1 (CH2) ppm. 
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3.4. Fujisawa Pharm analogs 
 
4,4,4-Trifluoro-1-[4-(methylthio)phenyl]butane-1,3-dione (66): 68% yield, lit.17d,46 
S
CH3
F3C
O O  
 
 
1-(3-Fluorobenzyl)hydrazine hydrochloride: lit.17d,46 
 
F
N
H
NH2 HCl
.
 
 
 
1-(3-Fluorobenzyl)-3-(trifluoromethyl)-5-[4-(methylthio)phenyl]-1H-pyrazole (67): 
 
To a solution of 4,4,4-trifluoro-1-[4-(methylthio)phenyl]butane-
1,3-dione (66) (39 mg, 0.152 mmol) in EtOH (5 ml) was added 
1-(3-fluorobenzyl)hydrazine hydrochloride (30 mg, 0.170 mmol) 
at room temperature. Then, the reaction mixture was stirred at 90 
oC overnight. The solvent was removed under reduced pressure, water was added and the 
resulting mixture was extracted with CH2Cl2 (3 x). The organic layer was dried over 
anhydrous MgSO4, filtered and evaporated. Flash column chromatography (EtOAc/n-pentane 
= 1:40) gave 21 mg (38% yield) of the desired product 67; 
1H-NMR (400 MHz, CDCl3): δ 7.22-7.17 (m, 3H, phenyl and 3-fluorophenyl), 7.10 (dt, 2H, J 
= 1.99 Hz, J = 8.29 Hz, phenyl), 6.89 (td, 1H, J = 2.32 Hz, J = 8.37 Hz, 3-fluorophenyl), 6.75 
(d, 1H, J = 7.63 Hz, 3-fluorophenyl), 6.68 (dt, 1H, J = 1.66 Hz, J = 9.62 Hz, 3-fluorophenyl), 
6.51 (s, 1H, pyrazolyl), 5.26 (s, 2H, CH2), 2.43 (s, 3H, methyl) ppm; 
13C-NMR (100 MHz, CDCl3): δ 162.9 (d, C, J = 246.81 Hz, 3-fluorophenyl), 145.2 (C), 142.4 
(q, CCF3, J = 38.22 Hz), 141.0 (C), 138.8 (d, C, J = 7.04 Hz, 3-fluorophenyl), 130.4 (d, CH, J 
= 8.55 Hz, 3-fluorophenyl), 129.2 (2 x CH), 126.1 (2 x CH), 125.2 (C), 122.3 (d, CH, J = 3.12 
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Hz, 3-fluorophenyl), 121.2 (q, CF3, J = 268.63 Hz), 114.9 (d, CH, J = 21.02 Hz, 3-
fluorophenyl), 113.9 (d, CH, J = 22.63 Hz, 3-fluorophenyl), 104.8 (CH, pyrazolyl), 53.2 
(CH2), 15.2 (CH3) ppm; 
19F-NMR (376 MHz, CDCl3): δ –62.11 (s, CF3), –112.09 (td, 1F, J = 6.15, J = 9.03 Hz) ppm. 
 
1-(3-Fluorobenzyl)-3-(trifluoromethyl)-5-[4-(N-cyanomethylsulfilimidoyl)phenyl]-1H-
pyrazole (68): 
 
To a solution of 1-(3-fluorobenzyl)-3-(trifluoromethyl)-5-[4-
(methylthio)phenyl]-1H-pyrazole (67) (111 mg, 0.303 mmol) in 
CH3CN (10 mL) was added cyanoamide (19 mg, 0.455 mmol) 
and PhI(OAc)2 (107 mg, 0.333 mmol) at 0 ºC. Then, the mixture 
was allowed to react at room temperature for 2 h. The solvent 
was removed under reduced pressure, water was added and the resulting mixture was 
extracted with CH2Cl2 (3 x). The organic layer was dried over anhydrous Na2SO4, filtered and 
evaporated. Flash column chromatography (EtOAc/n-pentane = 5:1) gave 105 mg (98% yield) 
of the desired product 68; 
1H-NMR (400 MHz, CDCl3): δ 7.83 (dt, 2H, J = 1.83 Hz, J = 8.62 Hz, phenyl), 7.50 (dt, 2H, 
J = 1.83 Hz, J = 8.29 Hz, phenyl), 7.27 (td, 1H, J = 5.97 Hz, J = 8.13 Hz, 3-fluorophenyl), 
6.96 (td, 1H, J = 2.10 Hz, J = 8.21 Hz, 3-fluorophenyl), 6.78 (d, 1H, J = 8.29 Hz, 3-
fluorophenyl), 6.71 (dt, 1H, J = 1.99 Hz, J = 9.28 Hz, 3-fluorophenyl), 6.66 (s, 1H, pyrazolyl), 
5.35 (s, 2H, CH2), 3.04 (s, 3H, methyl) ppm; 
13C-NMR (100 MHz, CDCl3): δ 163.0 (d, C, J = 248.01 Hz, 3-fluorophenyl), 143.2 (C), 142.7 
(q, CCF3, J = 38.42 Hz), 138.1 (d, C, J = 7.44 Hz, 3-fluorophenyl), 137.6 (C), 133.8 (C), 
130.7 (d, CH, J = 8.25 Hz, 3-fluorophenyl), 130.6 (2 x CH), 126.5 (2 x CH), 122.2 (d, CH, J 
= 2.41 Hz, 3-fluorophenyl), 120.9 (q, CF3, J = 268.73 Hz), 120.0 (CN), 115.3 (d, CH, J = 
20.72 Hz, 3-fluorophenyl), 113.7 (d, CH, J = 22.43 Hz, 3-fluorophenyl), 105.8 (CH, 
pyrazolyl), 53.7 (CH2), 36.5 (CH3) ppm; 
19F-NMR (376 MHz, CDCl3): δ –62.16 (s, CF3), –111.53 (td, 1F, J = 5.65, J = 8.94 Hz) ppm; 
IR (KBr): ν 2152 (CN), 1129, 973, 773 cm–1; 
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HRMS (ESI): [M+Na] calcd. for C19H14N4F4NaS:  429.0768; found 429.0768; 
The enantiomers were separated by preparative HPLC using a Regispack AD-H column (flow 
rate 4 mL/min, methanol, λ = 225 nm, 34.1 °C); tr = 3.0 min [50 %], tr = 3.5 min [50%]; 
Optical activity of 68-I: [α]D20 = -46.6 (c = 1, CHCl3), 68-II: [α]D20 = +46.2 (c = 1, CHCl3). 
 
1-(3-Fluorobenzyl)-3-(trifluoromethyl)-5-[4-(N-cyanomethylsulfonimidoyl)phenyl]-1H-
pyrazole (69a): 
 
To a solution of 1-(3-fluorobenzyl)-3-(trifluoromethyl)-5-[4-
(N-cyanomethylsulfilimidoyl)phenyl]-1H-pyrazole (68) (38 
mg, 0.094 mmol) in MeOH (5 mL) was added K2CO3 (26 mg, 
0.188 mmol) and m-CPBA (70%; 24 mg, 0.140 mmol) at 0 ºC. 
Then, the mixture was allowed to react at room temperature 
for 30 min. The solvent was removed under reduced pressure, water was added and the 
resulting mixture was extracted with CH2Cl2 (3 x). The organic layer was dried over 
anhydrous MgSO4, filtered and evaporated. Flash column chromatography (EtOAc/n-pentane 
= 1:10 to 1:1) gave 34 mg (86% yield) of desired product 69a; 
 
m. p. 130 -132 ºC; 
1H-NMR (600 MHz, CDCl3): δ 7.98 (d, 2H, J = 8.43 Hz, phenyl), 7.52 (d, 2H, J = 8.43 Hz, 
phenyl), 7.24 (dd, 1H, J = 7.93 Hz, J = 13.87 Hz, 3-fluorophenyl), 6.94 (td, 1H, J = 2.47 Hz, J 
= 8.42 Hz, 3-fluorophenyl), 6.74 (d, 1H, J = 7.92 Hz, 3-fluorophenyl), 6.68 (d, 1H, J = 9.41 
Hz, 3-fluorophenyl), 6.66 (s, 1H, pyrazolyl), 5.33 (s, 2H, CH2), 3.31 (s, 3H, methyl) ppm;  
13C-NMR (150 MHz, CDCl3): δ 163.0 (d, C, J = 247.37 Hz, 3-fluorophenyl), 142.9 (q, CCF3, 
J = 38.46 Hz), 142.8 (C), 138.0 (d, C, J = 6.94 Hz, 3-fluorophenyl), 137.1 (C), 136.1 (C), 
130.8 (d, CH, J = 8.14 Hz, 3-fluorophenyl), 130.5 (2 x CH), 128.6 (2 x CH), 122.2 (d, CH, J 
= 2.41 Hz, 3-fluorophenyl), 120.9 (q, CF3, J = 269.24 Hz), 115.4 (d, CH, J = 20.81 Hz, 3-
fluorophenyl), 113.7 (d, CH, J = 23.08 Hz, 3-fluorophenyl), 111.3 (CN), 106.2 (CH, 
pyrazolyl), 53.9 (CH2), 44.7 (CH3) ppm; 
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19F-NMR (564 MHz, CDCl3): δ –62.17 (s, CF3), –111.39 (td, 1F, J = 5.83, J = 9.17 Hz) ppm; 
MS (EI), m/z (relative intensity): 422 ([M]+, 35), 381 (22), 327 (30), 109 (100); 
IR (KBr): ν 2195 (CN), 1245, 1191, 1137, 1092, 971, 818, 787 cm–1; 
HRMS (ESI): [M+H] calcd. for C19H15ON4F4S:  423.0897; found 423.0897. 
In this manner, both enantiomers of the sulfoximine could be accessed from the 
corresponding enantiopure sulfilimines. This process is stereospecific as confirmed in 
previous work.13a  
Determination of the enantiomer ratio by analytical HPLC: Chiralpak AD, n-heptane:i-PrOH 
= 8:2, 0.6 mL/min, 20 °C; tr (69a-I) = 29.7 min (over 99% ee) and tr (69a-II) = 40.4 min (over 
99% ee); 
Optical activity of 69a-I: [α]D20 = -53.9 (c = 0.6, CHCl3), 69a-II: [α]D20 = +53.9 (c = 0.6, 
CHCl3). 
 
1-(3-Fluorobenzyl)-3-(trifluoromethyl)-5-[4-(NH-methylsulfonimidoyl)phenyl]-1H-
pyrazole (69b): 
 
The solution of 1-(3-fluorobenzyl)-3-(trifluoromethyl)-5-[4-(N-
cyanomethylsulfonimidoyl)phenyl]-1H-pyrazole (69a) (237 mg, 
0.561 mmol) in 50% of H2SO4 in H2O (5 mL) was refluxed at 
110 oC for 30 min. Then, the mixture was adjusted pH 11-12 by 
aqueous NaHCO3 and 1M NaOH. The resulting mixture was 
extracted with CH2Cl2 (3 x). The organic layer was dried over anhydrous Na2SO4, filtered and 
evaporated. Flash column chromatography (EtOAc/acetone = 1:1) gave 158 mg (71% yield) 
of desired product 69b; 
 
1H-NMR (300 MHz, CDCl3): δ 8.01 (dt, 2H, J = 1.90 Hz, J = 8.16 Hz, phenyl), 7.41 (dt, 2H, 
J = 1.81 Hz, J = 8.16 Hz, phenyl), 7.22 (td, 1H, J = 5.85 Hz, J = 8.04 Hz, 3-fluorophenyl), 
6.92 (td, 1H, J = 1.98 Hz, J = 8.41 Hz, 3-fluorophenyl), 6.75 (d, 1H, J = 8.41 Hz, 3-
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fluorophenyl), 6.66 (dt, 1H, J = 1.98 Hz, J = 9.40 Hz, 3-fluorophenyl), 6.62 (s, 1H, pyrazolyl), 
5.31 (s, 2H, CH2), 3.10 (s, 3H, methyl) 2.65 (br, 1H, NH-sulfoximine) ppm; 
19F-NMR (564 MHz, CDCl3): δ –62.15 (s, CF3), –111.63 (dd, 1F, J = 9.32, J = 15.25 Hz) 
ppm; 
IR (KBr): ν 1247, 1215, 1123, 974, 753 cm–1; 
MS (EI), m/z (relative intensity): 397 ([M]+, 14), 382 (sulfoxide, 2), 366 (sulfide, 2), 336 (10), 
334 (100); 
HRMS (ESI): [M+H] calcd. for C18H16ON3F4S:  398.0945; found 398.0946. 
 
1-(3-Fluorobenzyl)-3-(trifluoromethyl)-5-[4-(N-nitromethylsulfonimidoyl)phenyl]-1H-
pyrazole (69c): 
 
To a solution of 1-(3-fluorobenzyl)-3-(trifluoromethyl)-5-[4-
(NH-methylsulfonimidoyl)phenyl]-1H-pyrazole (69b) (106 
mg, 0.267 mmol) in CH2Cl2 (1 mL) was added HNO3 (16 mg, 
0.254 mmol), H2SO4 (1 drop), and acetic anhydride (0.7 mL) 
at 0 ºC. Then, the mixture was allowed to react at 50 ºC for 15 
min. Aqueous NaHCO3 was added and the resulting mixture was extracted with CH2Cl2 (3 x). 
The organic layer was dried over anhydrous MgSO4, filtered and evaporated. Flash column 
chromatography (EtOAc/n-pentane = 1:10 to 1:1) gave 11 mg (11% yield) of desired product 
69c; 
 
1H-NMR (400 MHz, CDCl3): δ 8.02 (dt, 2H, J = 1.99 Hz, J = 8.63 Hz, phenyl), 7.55 (dt, 2H, 
J = 1.99 Hz, J = 8.62 Hz, phenyl), 7.28 (td, 1H, J = 5.86 Hz, J = 8.05 Hz, 3-fluorophenyl), 
6.98 (td, 1H, J = 2.21 Hz, J = 8.21 Hz, 3-fluorophenyl), 6.76 (d, 1H, J = 7.63 Hz, 3-
fluorophenyl), 6.73 (d, 1H, J = 1.99 Hz, 3-fluorophenyl), 6.70 (s, 1H, pyrazolyl), 5.38 (s, 2H, 
CH2), 3.33 (s, 3H, methyl) ppm; 
IR (KBr): ν 1497, 1283, 1219, 1128, 1092, 976, 785 cm–1; 
S
CH3
N N
F3C
NO
F
NO2
 Experimental section 
112 
 
MS (EI), m/z (relative intensity): 443 ([M+1]+, 0.4), 335 (26), 109 (100). 
 
3.5. SC-58125 analogs 
 
4,4,4-Trifluoro-1-(4-fluorophenyl)butane-1,3-dione (71a): 79% yield, lit.17e, 46 
F
O
CF3
O
 
 
3-(Trifluoromethyl)-5-(4-fluorophenyl)-1-(4-(methylthio)phenyl)-1H-pyrazole (72a): 
70% yield, lit.17e, 46 
S
CH3
NNF3C
F  
 
3-(Trifluoromethyl)-5-(4-fluorophenyl)-1-[4-(N-cyanomethylsulfilimidoyl)phenyl]-1H-
pyrazole (73a): 
 To a solution of 3-(trifluoromethyl)-5-(4-fluorophenyl)-1-[4-
(methylthio)phenyl]-1H-pyrazole (72a) (88 mg, 0.250 mmol) in 
CH3CN (10 mL) was added cyanoamide (15 mg, 0.357 mmol) 
and PhI(OAc)2 (89 mg, 0.275 mmol) at 0 ºC. Then, the mixture 
was allowed to react at room temperature for 2 h. The solvent 
was removed under reduced pressure, water was added and the 
resulting mixture was extracted with CH2Cl2 (3 x). The organic layer was dried over 
anhydrous Na2SO4, filtered and evaporated. Flash column chromatography (EtOAc/n-pentane 
= 5:1) gave 77 mg (79% yield) of the desired product 73a; 
1H-NMR (400 MHz, CDCl3): δ 7.78 (d, 2H, J = 8.96 Hz, phenyl), 7.53 (d, 2H, J = 8.63 Hz, 
phenyl), 7.21 (dd, 2H, J = 5.14, J = 8.79, 4-fluorophenyl), 7.08 (t, 2H, J = 8.62, 4-
fluorophenyl), 6,74 (s, 1H, pyrazolyl), 3.00 (s, 3H, methyl) ppm; 
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13C-NMR (100 MHz, CDCl3): δ 163.3 (d, C, J = 252.14 Hz, 4-fluorophenyl), 144.3 (q, CCF3, 
J = 39.02 Hz), 144.1 (C), 142.7 (C), 136.1 (C), 130.8 (d, 2 x CH, J = 9.15 Hz, 4-flurorphenyl), 
127.0 (2 x CH, phenyl), 126.5 (2 x CH, phenyl), 124.6 (d, C, J = 3.32 Hz, 4-fluorophenyl), 
120.8 (q, CF3, J = 269.43 Hz), 120.0 (CN), 116.5 (d, 2 x CH, J = 22.43 Hz, 4-fluorophenyl), 
106.9 (CH, pyrazolyl), 36.9 (CH3) ppm; 
19F-NMR (376 MHz, CDCl3): δ –62.56 (s, CF3), –109.91 (tt, 1F, J = 4.89, J = 8.47 Hz) ppm; 
IR (KBr): ν 2148 (CN), 1232, 1129, 969, 837, 762 cm-1; 
HRMS (ESI): [M+H] calcd. for C18H13N4F4S:  393.0791; found 393.0792. 
 
3-(Trifluoromethyl)-5-(4-fluorophenyl)-1-[4-(N-cyanomethylsulfonimidoyl)phenyl]-1H-
pyrazole (74a): 
To a solution of 3-(trifluoromethyl)-5-(4-fluorophenyl)-1-[4-
(N-cyanomethylsulfilimidoyl)phenyl]-1H-pyrazole (73a) (77 
mg, 0.196 mmol) in MeOH (5 mL) was added K2CO3 (61 mg, 
0.441 mmol) and m-CPBA (70%; 51 mg, 0.294 mmol) at 0 ºC. 
Then, the mixture was allowed to react at room temperature for 
0.5 h. The solvent was removed under reduced pressure, water 
was added and the resulting mixture was extracted with CH2Cl2 (3 x). The organic layer was 
dried over anhydrous MgSO4, filtered and evaporated. Flash column chromatography 
(EtOAc/n-pentane = 1:10 to 1:1) gave 45 mg (56% yield) of desired product 74a; 
1H-NMR (300 MHz, CDCl3): δ 7.93 (d, 2H, J = 8.40 Hz, phenyl), 7.57 (d, 2H, J = 8.40 Hz, 
phenyl), 7.20 (dd, 2H, J = 5.40, J = 8.40, 4-fluorophenyl), 7.06 (t, 2H, J = 8.55, 4-
fluorophenyl), 6,72 (s, 1H, pyrazolyl), 3.29 (s, 3H, methyl) ppm; 
13C-NMR (75 MHz, CDCl3): δ 163.4 (d, C, J = 251.97 Hz, 4-fluorophenyl), 145.3 (q, CCF3, J 
= 39.15 Hz), 144.5 (C), 144.4 (C), 135.3 (C), 130.9 (d, 2 x CH, J = 8.53 Hz, 4-flurorphenyl), 
129.2 (2 x CH, phenyl), 126.0 (2 x CH, phenyl), 124.5 (d, C, J = 3.47 Hz, 4-fluorophenyl), 
120.8 (q, CF3, J = 269.48 Hz), 116.7 (d, 2 x CH, J = 22.03 Hz, 4-fluorophenyl), 107.4 (CH, 
pyrazolyl), 104.7 (CN), 44.8 (CH3) ppm; 
19F-NMR (282 MHz, CDCl3): δ –62.64 (s, CF3), –109.51 (s, 1F) ppm; 
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MS (EI), m/z (relative intensity): 408 ([M]+, 43), 368 (sulfoxide, 3), 352 (sulfide, 100), 322 
( 14), 285 (8); 
HRMS (ESI): [M+H] calcd. for C18H13ON4F4S:  409.0741; found 409.0745. 
 
3-(Trifluoromethyl)-5-(4-fluorophenyl)-1-[4-(NH-sulfonimidoyl)phenyl]-1H-pyrazole 
(74a’): 
The solution of 3-(trifluoromethyl)-5-(4-fluorophenyl)-1-[4-(N-
cyanomethylsulfonimidoyl)phenyl]-1H-pyrazole (74a) (39 mg, 
0.096 mmol) in 50% of H2SO4 in H2O (3 mL) was refluxed at 
110 ºC for 1 h. Then, the mixture was adjusted pH 11-12 by 
aqueous NaHCO3 and 1M NaOH. The resulting mixture was 
extracted with CH2Cl2 (3 x). The organic layer was dried over 
anhydrous Na2SO4, filtered and evaporated. Flash column chromatography (EA/n-pentane = 
1:1 to 5:1) gave 25 mg (68% yield) of desired product 74a’; 
1H-NMR (600 MHz, CDCl3): δ 8.02 (d, 2H, J = 8.92 Hz, phenyl), 7.50 (d, 2H, J = 8.42 Hz, 
phenyl), 7.23 (dd, 2H, J = 4.96, J = 8.92, 4-fluorophenyl), 7.09 (t, 2H, J = 8.67, 4-
fluorophenyl), 6,77 (s, 1H, pyrazolyl), 3.15 (s, 3H, methyl) 2.93 (br, 1H, NH-sulfoximine) 
ppm; 
13C-NMR (150 MHz, CDCl3): δ 163.3 (d, C, J = 251.14 Hz, 4-fluorophenyl), 144.3 (q, CCF3, 
J = 38.81 Hz), 144.1 (C), 142.8 (C), 142.6 (C), 130.8 (d, 2 x CH, J = 8.45 Hz, 4-flurorphenyl), 
129.0 (2 x CH, phenyl), 125.6 (2 x CH, phenyl), 124.7 (d, C, J = 3.47 Hz, 4-fluorophenyl), 
120.9 (q, CF3, J = 269.29 Hz), 116.4 (d, 2 x CH, J = 22.03 Hz, 4-fluorophenyl), 106.7 (CH, 
pyrazolyl), 46.1 (CH3) ppm; 
19F-NMR (564 MHz, CDCl3): δ –62.52 (s, CF3), –110.10 (td, 1F, J = 5.08 Hz, J = 8.47 Hz) 
ppm; 
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MS (EI), m/z (relative intensity): 383 ([M]+, 31), 368 (sulfoxide, 11), 352 (sulfide, 5), 320 
(100), 303 (11); 
HRMS (ESI): [M+H] calcd. for C17H14ON3F4S:  384.0788; found 384.0792. 
 
1-[4-(Dimethylamino)phenyl]-4,4,4-trifluorobutane-1,3-dione (71b): 99% yield, lit.49c 
CF3
O O
N
H3C
CH3  
4-{3-(Trifluoromethyl)-1-[4-(methylthio)phenyl]-1H-pyrazol-5-yl}-N,N-dimethyl-
benzenamine (72b): 
 To a solution of 1-[4-(dimethylamino)phenyl]-4,4,4-
trifluorobutane-1,3-dione (71b) (113 mg, 0.436 mmol) in EtOH 
(10 mL) was added 1-[4-(methylthio)phenyl]hydrazine 
hydrochloride (93 mg, 0.488 mmol) at room temperature. Then, 
the mixture was allowed to react at 90 ºC overnight. The solvent 
was removed under reduced pressure, water was added and the 
resulting mixture was extracted with CH2Cl2 (3 x). The organic layer was dried over 
anhydrous MgSO4, filtered and evaporated. Flash column chromatography (EtOAc/n-pentane 
= 1:40) gave 149 mg (91% yield) of the desired product 72b; 
1H-NMR (400 MHz, CDCl3): δ 7.26-7.18 (m, 6H, phenyl & N,N-dimethylphenyl), 7.06 (dt, 
2H, J = 1.99 Hz, J = 8.95 Hz, N,N-dimethylphenyl), 6,62 (s, 1H, pyrazolyl), 2.96 (6H, s, N,N-
dimethyl), 2.47 (s, 3H, methyl) ppm; 
19F-NMR (376 MHz, CDCl3): δ –62.24 (s, CF3) ppm. 
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4-{3-(Trifluoromethyl)-1-[4-(N-cyanomethylsulfilimidoyl)phenyl]-1H-pyrazol-5-yl}-N,N-
dimethylbenzenamine (73b): 
 To a solution of 4-{3-(trifluoromethyl)-1-[4-(methylthio)-
phenyl]-1H-pyrazol-5-yl}-N,N-dimethyl-benzenamine (72b) (49 
mg, 0.130 mmol) in MeOH (5 mL) was added cyanoamide (7 
mg, 0.619 mmol), t-BuOK (18 mg, 0.156 mmol), and NBS (35 
mg, 0.195 mmol) at 0 ºC. Then, the mixture was allowed to react 
at room temperature for 30 min. The solvent was removed under 
reduced pressure, water was added and the resulting mixture was 
extracted with CH2Cl2 (3 x). The organic layer was dried over anhydrous Na2SO4, filtered and 
evaporated. Flash column chromatography (EtOAc/n-pentane = 9:1 to EtOAc only) gave 26 
mg (48% yield) of the desired product 73b; 
1H-NMR (400 MHz, CDCl3): δ 7.80 (d, 2H, J = 8.62 Hz, phenyl), 7.58 (d, 2H, J = 8.62 Hz, 
phenyl), 7.50 (s, 2H, N,N-dimethylphenyl), 6.98 (s, 2H, N,N-dimethylphenyl), 6.67 (s, 1H, 
pyrazolyl), 3.00 (s, 3H, methyl), 2.85 (s, 6H, N,N-dimethyl) ppm; 
13C-NMR (100 MHz, CDCl3): δ 152.9 (C), 144.4 (q, CCF3, J = 39.02 Hz), 143.7 (C), 142.9 
(C), 136.1 (C), 128.5 (2 x CH, N,N-dimethylphenyl), 126.9 (2 x CH, phenyl), 126.6 (2 x CH, 
phenyl), 123.0 (C), 120.8 (q, CF3, J = 269.33 Hz), 120.4 (2 x CH), 118.2 (CN), 106.6 (CH, 
pyrazolyl), 43.7 (2 x CH3), 37.1 (CH3) ppm; 
19F-NMR (376 MHz, CDCl3): δ –62.59 (s, CF3)  ppm; 
HRMS (ESI): [M+H] calcd. for C20H19N5F3S:  418.1308; found 418.1294. 
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3.6. DuP 697 analogs 
 
3-[4-(Methylthio)phenyl]thiophene (76):17g 
 
To a solution of 3-bromothiophene (500 mg, 3.067 mmol) in 
toluene/EtOH (1:1, 15 mL) was added Pd(PPh3)4 (107 mg, 0.092 
mmol), 4-(methylthio)benzeneboronic acid (619 mg, 3.681 mmol) and 
aqueous sodium carbonate (2.32 mL of a 2M solution, 4.601 mmol) at 
room temperature. Then, the reaction mixture was stirred at 90 ºC overnight. The solvent was 
removed under reduced pressure, water was added and the resulting mixture was extracted 
with CH2Cl2 (3 x). The organic layer was dried over anhydrous MgSO4, filtered and 
evaporated. Flash column chromatography (EtOAc/n-Pentane = 1:99) gave the desired 
product 76 in quantitative yield; 
 
1H-NMR (400 MHz, CDCl3): δ 7.53 (dt, 2H, J = 2.21 Hz, J = 8.82 Hz, phenyl), 7.42 (dd, 1H, 
J = 1.40 Hz, J = 3.01 Hz, thienyl), 7.39 (dd, 1H, J = 3.01 Hz, J = 5.01 Hz, thienyl), 7.37 (dd, 
1H, J = 1.40 Hz, J = 5.01 Hz, thienyl), 7.29 (dt, 2H, J = 2.21 Hz, J = 8.42 Hz, phenyl), 2.50 (s, 
3H, methyl) ppm;  
13C-NMR (100 MHz, CDCl3): δ 141.7 (C, thienyl), 137.2 (C, phenyl), 132.8 (C, phenyl), 
127.0 (2 × CH, phenyl), 126.8 (2 × CH, phenyl), 126.2 (CH, thienyl), 126.1 (CH, thienyl), 
119.9 (CH, thienyl), 15.9 (CH3) ppm. 
 
 
2-(4-Fluorophenyl)-3-[4-(methylthio)phenyl]thiophene (78):17g 
 
The bromination reaction: To a solution of 3-[4-
(methylthio)phenyl]thiophene (76) (1 eq) in CH2Cl2 was added NBS 
(1.1 eq) at 0 ºC. Then, the reaction mixture was allowed to react at 50 
ºC for 1h and extracted with CH2Cl2 (3 x). The organic layer was 
dried over anhydrous MgSO4, filtered and evaporated. Flash column 
chromatography (EtOAc/n-Pentane = 1:99) gave the desired product 77; 
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The coupling reaction: To a solution of 2-bromo-3-[4-(methylthio)phenyl]thiophene (77) (96 
mg, 0.337 mmol) in toluene/EtOH (1:1, 4 mL) was added Pd(PPh3)4 (12 mg, 0.010 mmol), 4-
Fluorophenylboronic acid (57 mg, 0.404 mmol) and aqueous sodium carbonate (0.26 mL of a 
2M solution, 0.506 mmol) at room temperature. Then, the reaction mixture was stirred at 90 
ºC overnight. The solvent was removed under reduced pressure, water was added and the 
resulting mixture was extracted with CH2Cl2 (3 x). The organic layer was dried over 
anhydrous MgSO4, filtered and evaporated. Flash column chromatography (EtOAc/n-Pentane 
= 1:99) gave 83 mg (82% yield) of desired product 78; 
 
1H-NMR (400 MHz, CDCl3): δ 7.32 (d, 2H, J = 5.21 Hz, phenyl), 7.28 (dd, 2H, J = 5.21 Hz, J 
= 8.82 Hz, 4-fluorophenyl), 7.18 (s, 2H, thienyl), 7.13 (d, 2H, J = 5.21 Hz, phenyl), 6.98 (t, 
2H, J = 8.82 Hz, 4-fluorophenyl), 2.48 (s, 3H, methyl) ppm;  
13C-NMR (100 MHz, CDCl3): δ 162.2 (d, C, J = 247.9 Hz, 4-fluorophenyl), 137.6 (C), 137.3 
(C), 137.2 (C), 133.0 (C), 131.0 (d, 2 × CH, J = 8.25 Hz, 4-fluorophenyl), 130.4 (d, C, J = 
3.32 Hz, 4-fluorophenyl), 130.2 (CH), 129,4 (2 × CH), 126.3 (2 × CH), 124.2 (CH), 115.5 (d, 
CH, J = 21.5 Hz, 4-fluorophenyl), 15.6 (CH3) ppm; 
19F-NMR (376 MHz, CDCl3): δ –114.39 (tt, 1F, J = 5.27 Hz, J= 8.47 Hz) ppm. 
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5-Bromo-2-(4-fluorophenyl)-3-[4-(methylthio)phenyl]thiophene (79):58 
 
To a solution of 2-(4-fluorophenyl)-3-[4-
(methylthio)phenyl]thiophene (78) (82.7 mg, 0.275 mmol) in 
CH2Cl2 (10 mL) was added NBS (53.9 mg, 0.303 mmol) at 0 ºC. 
Then, the reaction mixture was allowed to react at 50 ºC for 1h 
and extracted with CH2Cl2 (3 x). The organic layer was dried 
over anhydrous MgSO4, filtered and evaporated. Flash column chromatography (EtOAc/n-
Pentane = 1:99) gave 47 mg (45% yield) of desired product 79; 
 
1H-NMR (400 MHz, CDCl3): δ 7.26 (s, 2H, phenyl), 7.20 (dd, 2H, J = 5.21 Hz, J = 8.82 Hz, 
4-fluorophenyl), 7.13 (d, 2H, J = 5.61 Hz, phenyl), 7.07 (s, 1H, thienyl), 6.97 (t, 2H, J = 8.82 
Hz, 4-fluorophenyl), 2.47 (s, 3H, methyl) ppm;  
13C-NMR (100 MHz, CDCl3): δ 162.4 (d, C, J = 248.82 Hz, 4-fluorophenyl), 138.5 (C), 138.0 
(C), 137.8 (C), 132.7 (CH), 131,8 (C), 130.4 (d, 2 × CH, J = 3.32 Hz, 4-fluorophenyl), 129.4 
(C, 4-fluorophenyl), 129.2 (2 × CH), 126.2 (2 × CH), 115.7 (d, CH, J = 21.5 Hz, 4-
fluorophenyl), 111.0 (C), 15.5 (CH3) ppm; 
19F-NMR (376 MHz, CDCl3): δ –113.49 (tt, 1F, J = 5.27 Hz, J= 8.47 Hz) ppm. 
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5-Bromo-2-(4-fluorophenyl)-3-[4-(N-cyanomethylsulfilimidoyl)phenyl]thiophene (80): 
 
To a solution of 5-bromo-2-(4-fluorophenyl)-3-[4-
(methylthio)phenyl]thiophene (79) (48 mg, 0.127 mmol) in 
CH3CN (5 mL) was added cyanoamide (8 mg, 0.190 mmol) and 
PhI(OAc)2 (45 mg, 0.140 mmol) at 0 ºC. Then, the mixture was 
allowed to react at room temperature for 10 min. The solvent was 
removed under reduced pressure, water was added and the 
resulting mixture was extracted with CH2Cl2 (3 x). The organic layer was dried over 
anhydrous Na2SO4, filtered and evaporated. Flash column chromatography (EtOAc/n-pentane 
= 5:1) gave 34 mg (64% yield) of the desired product 80; 
 
1H-NMR (400 MHz, CDCl3): δ 7.67 (dt, 2H, J = 2.01 Hz, J = 8.82 Hz, phenyl), 7.39 (dt, 2H, 
J = 2.01 Hz, J = 8.42 Hz, phenyl), 7.15 (dd, 2H, J = 5.21 Hz, J = 8.82 Hz, 4-fluorophenyl), 
7.08 (s, 1H, thienyl), 6.95 (t, 2H, J = 8.82 Hz, 4-fluorophenyl), 2.99 (s, 3H, methyl); 
13C-NMR (100 MHz, CDCl3): δ 162.7 (d, C, J = 249.62 Hz, 4-fluorophenyl), 140.7 (C), 140.2 
(C), 136.2 (C), 134.8 (C), 132.1 (CH), 131.1 (d, 2 x CH, J = 8.25 Hz, 4-fluorophenyl), 130.6 
(2 x CH), 128.4 (d, C, J = 3.52 Hz, 4-fluorophenyl), 126.3 (2 x CH), 120.4 (CN), 116.1 (d, 2 x 
CH, J = 21.82 Hz, 4-fluorophenyl), 112.0 (C), 36.4 (CH3); 
19F-NMR (376 MHz, CDCl3): δ –112.16 (tt, 1F, J = 5.27 Hz, J= 8.47 Hz); 
MS (EI), m/z (relative intensity): 420 ([M+2]+, 2), 418 ([M]+, 2), 380 (100), 252 (43), 207 
(13), 150 (5); 
IR (KBr): ν 2144 (CN), 1502, 1228, 1154, 974, 822, 763 cm–1; 
HRMS (ESI): [M+Na] calcd. for C18H12N2BrFNaS2 : 440.9502; found 440.9493. 
The enantiomers were separated by preparative HPLC using a Regispack AD-H column (flow 
rate 4 mL/min, methanol, λ = 265 nm, 35.1 °C); tr = 15.9 min [47 %], tr = 17.9 min [48%]. 
Optical activity of 80-I: [α]D20 = -13.6 (c = 0.5, CHCl3), 80-II: [α]D20 = +13.1 (c = 0.5, CHCl3). 
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5-Bromo-2-(4-fluorophenyl)-3-[4-(N-cyanomethylsulfonimidoyl)phenyl]thiophene (81): 
 
To a solution of 5-bromo-2-(4-fluorophenyl)-3-[4-(N-
cyanomethylsulfilimidoyl)phenyl]thiophene (80) (18 mg, 0.043 
mmol) in MeOH (2 mL) was added K2CO3 (12 mg, 0.086 
mmol) and m-CPBA (70%; 11 mg, 0.064 mmol) at 0 ºC. Then, 
the mixture was allowed to react at room temperature for 30 
min. The solvent was removed under reduced pressure, water 
was added and the resulting mixture was extracted with CH2Cl2 (3 x). The organic layer was 
dried over anhydrous MgSO4, filtered and evaporated. Flash column chromatography 
(EtOAc/n-pentane = 1:10 to 1:1) gave 10 mg (53% yield) of desired product 81; 
1H-NMR (600 MHz, CDCl3): δ 7.82 (d, 2H, J = 8.42 Hz, phenyl), 7.42 (d, 2H, J = 8.42 Hz, 
phenyl), 7.14 (dd, 2H, J = 4.96 Hz, J = 8.42 Hz, 4-fluorophenyl), 7.08 (s, 1H, thienyl), 6.96 (t, 
2H, J = 8.42 Hz, 4-fluorophenyl), 3.27 (s, 3H, methyl) ppm;  
13C-NMR (150 MHz, CDCl3): δ 162.9 (d, C, J = 249.78 Hz, 4-fluorophenyl), 142.6 (C), 141.6 
(C), 135.7 (C), 134.4 (C), 132.0 (CH), 131.1 (d, 2 × CH, J = 8.15 Hz, 4-fluorophenyl), 130.4 
(2 x CH), 128.3 (C, 4-fluorophenyl), 128.2 (2 x CH), 116.3 (d, 2 x CH, J = 21.87 Hz, 4-
fluorophenyl), 112.4 (C), 111.7 (CN), 44.9 (CH3); 
19F-NMR (560 MHz, CDCl3): δ –111.79 (tt, 1F, J = 5.08 Hz, J= 8.47 Hz); 
MS (EI), m/z (relative intensity): 436 ([M+2]+, 100), 434 ([M]+, 82), 379 (84), 252 (17), 207 
(12), 126 (4); 
IR (KBr): ν 2196 (CN), 1503, 1242, 1195, 1093, 977, 817, 779 cm–1; 
HRMS (ESI), [M+Na] calcd. for C18H12ON2BrFNaS2: 456.9551;  found 456.9450. 
In this manner, both enantiomers of the sulfoximine could be accessed from the 
corresponding enantiopure sulfilimines. This process is stereospecific as confirmed in 
previous work.13a  
Determination of the enantiomer ratio by analytical HPLC: Chiralpak AD, n-heptane:i-PrOH 
= 8:2, 0.7 mL/min, 20 °C; tr (81-I) = 23.0 min (over 99% ee) and tr (81-II) = 31.0 min (over 
99% ee); 
Optical activity of 81-I: [α]D20 = -83.1 (c = 1, CHCl3), 81-II: [α]D20 = +82.7 (c = 1, CHCl3). 
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1. Hydrolysis studies of N-cyanomethylphenyl sulfilimine 82 with aqueous 
HCl solutions 
 
 
Table 33. The investigation of stablility of N-cyanosulfilimine 82 under various acidic conditions 
 
S
CH3
N NH2
O
S
CH3
N
CN
xM HCl in H2O
RT
S
CH3
O
S
CH3
N
CN
+
82 8382
+
84  
Reaction conditions
HCl [M] pH Time
0.058 1.31 1 h
Yield (%)b
> 95 -a -a
> 95 trace -a0.058 1.31 7 h
0.58 0.24 10 min 69 6 -a
2 h
9 h
20.5 h
62 9
28 16
10 24
-a
10
13
0.58 0.24
0.58 0.24
0.58 0.24
2 h 62 10 -a1.0 0.03
Entry
1
2
3
4
5
6
7
sulfilimine (82) sulfoxide (83) N-carbamoyl-sulfilimine (84)
 
                  aNot observed; bAfter column chromatography. 
 
 
General procedure 
 
N-Cyanomethylphenyl sulfilimine (82, 500 mg, 3.045 mmol) was dissolved in an aqueous 
HCl solution (20 mL). The solution was stirred at room temperature, quenched with NaHCO3, 
extracted with CH2Cl2 (2 x), dried over anhydrous Na2SO4, filtered and evaporated. The 
residue was separated by flash column chromatography (EtOAc/n-pentane = 5:1 to EtOAc 
only) to give the sulfimine 82, sulfoxide 83 and N-carbamoylsulfilimine 84. 
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N-Cyanomethylphenyl sulfilimine (82): lit.13   
 
Methylphenyl sulfoxide (83): Commercially available (CAS 1193-82-4);  
1H-NMR (400 MHz, CDCl3): δ 7.55–7.57 (m, 2H, phenyl), 7.40–7.46 (m, 3H, phenyl), 2.62 
(s, 3H, methyl) ppm;  
13C-NMR (100 MHz, CDCl3): δ 145.7 (C), 131.0 (2 x CH), 129.3 (2 x CH), 123.4 (3 x CH), 
43.9 (CH3) ppm;  
IR (KBr): ν 1088, 1044, 956, 751 cm-1. 
 
[Methyl(phenyl)-sulfanylidene]urea (84): lit.57  
1H-NMR (300 MHz, CDCl3): δ 7.72–7.75 (m, 2H, phenyl), 7.53–7.62 (m, 3H, phenyl), 5.36 
(br, 2H, NH2) 2.86 (s, 3H, methyl) ppm;  
13C-NMR (75 MHz, CDCl3): δ 168.2 (CO), 137.5 (C), 132.4 (CH), 130.2 (2 x CH), 126.7 (2 x 
CH), 35.2 (CH3) ppm;  
IR (KBr): ν 3331, 3168, 1650 (CO), 1563, 1388, 966, 837, 688 cm-1. 
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Part II. Biological activities 
1. hERG Screening study 
 
NH-Sulfoximine-based Vioxx® (32b): Compound A 
Vioxx®: Compound B 
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2. COX inhibitory activities 
 
N-Cyano sulfilimine-based Vioxx® (39): 
Ricerca PT #: 1146758; Compound code: IF-9; Alt. Code 1: Compound A  
 
N-Cyano sulfoximine-based Vioxx® (32a): 
Ricerca PT #: 1146759; Compound code: IF-10; Alt. Code 1: Compound B 
  
N-Urea sulfoximine-based Arcoxia® (48c):  
Ricerca PT #: 1146760; Compound code: IF-11; Alt. Code 1: Compound C 
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NH-Sulfoximine-based Vioxx® (32b): 
Ricerca PT #: 1132170; Compound code: IF-5; Alt. Code 1: Compound A  
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N-Methyl sulfoximine-based Vioxx® (32c): 
Ricerca PT #: 1139644; Compound code: IF-6; Alt. Code 1: Compound B  
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N-Cyano sulfilimine-based Arcoxia® (47):  
Ricerca PT #: 1148651; Compound code: IF-13; Alt. Code 1: PSE-1  
 
N-Cyano sulfoximine-based Arcoxia® (48a):  
Ricerca PT #: 1148652; Compound code: IF-14; Alt. Code 1: PSE-2 
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NH-Sulfoximine-based Arcoxia® (48b): 
Ricerca PT #: 1150557; Compound code: IF-15; Alt. Code 1: PSE-3 
 
N-Methyl sulfoximine-based Arcoxia® (48e):  
Ricerca PT #: 1150558; Compound code: IF-16; Alt. Code 1: PSE-4 
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N-Cyano sulfilimine-based L-784506 (64):  
Ricerca PT #: 1154780; Compound code: IF-19; Alt. Code 1: Park ESI-1a 
 
N-Cyano sulfoximine-based L-784506 (65):  
Ricerca PT #: 1154781; Compound code: IF-20; Alt. Code 1: Park ESI-1b 
 
N-Cyano sulfilimine-based Fujisawa Pharm analog (68):  
Ricerca PT #: 1154782; Compound code: IF-21; Alt. Code 1: Park ESI-2a 
 
N-Cyano sulfoximine-based Fujisawa Pharm analog (69a):  
Ricerca PT #: 1154783; Compound code: IF-22; Alt. Code 1: Park ESI-2b 
 
N-Cyano sulfilimine-based DuP 697 (80):  
Ricerca PT #: 1154784; Compound code: IF-23; Alt. Code 1: Park ESI-3a 
 
N-Cyano sulfoximine-based DuP 697 (81):  
Ricerca PT #: 1154785; Compound code: IF-24; Alt. Code 1: Park ESI-3b 
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N-Nitro sulfoximine-based Fujisawa Pharm analog (69c):  
Ricerca PT #: 1158038; Compound code: IF-29; Alt. Code 1: Park 14N 
 
N-Cyano sulfilimine-based Fujisawa Pharm analog (68-I, S configuration):  
Ricerca PT #: 1158039; Compound code: IF-30; Alt. Code 1: Park 15E1 
 
N-Cyano sulfilimine-based Fujisawa Pharm analog (68-II, R configuration):  
Ricerca PT #: 1158040; Compound code: IF-31; Alt. Code 1: Park 15E2 
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N-Cyano sulfoximine-based DuP 697 (81-I, R configuration): 
Ricerca PT #: 1160473; Compound code: IF-34; Alt. Code 1: Park 18a.15.3 
 
N-Cyano sulfoximine-based DuP 697 (81-II, S configuration): 
Ricerca PT #: 1160474; Compound code: IF-35; Alt. Code 1: Park 18b.15.3 
 
N-Cyano sulfilimine-based SC-58125 (73a): 
Ricerca PT #: 1160475; Compound code: IF-36; Alt. Code 1: Park 41.15.3 
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N-Cyano sulfilimine-based DuP 697 (80-I, S configuration): 
Ricerca PT #: 1164111; Compound code: IF-37; Alt. Code 1: Park 19a.15.3 
 
N-Cyano sulfilimine-based DuP 697 (80-II, R configuration): 
Ricerca PT #: 1164112; Compound code: IF-38; Alt. Code 1: Park 19b.15.3 
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3. Anticancer activities 
3.1. Vioxx® analogs 
 
N-Cyano sulfilimine-based Vioxx® (39): a one dose primary screening 
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N-Cyano sulfilimine-based Vioxx® (39): a full 5-dose assay 
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N-Cyano sulfoximine-based Vioxx® (32a): a one dose primary screening 
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NH-Sulfoximine-based Vioxx® (32b): a one dose primary screening 
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N-Methyl sulfoximine-based Vioxx® (32c): a one dose primary screening 
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3.2. Arcoxia® analogs 
 
N-Cyano sulfilimine-based Arcoxia® (47): a one dose primary screening 
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N-Cyano sulfoximine-based Arcoxia® (48a): a one dose primary screening 
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NH-Sulfoximine-based Arcoxia® (48b): a one dose primary screening 
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N-Urea sulfoximine-based Arcoxia® (48c): a one dose primary screening 
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N-Methyl sulfoximine-based Arcoxia® (48e): a one dose primary screening 
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3.3. L-784506 analogs 
 
N-Cyano sulfilimine-based L-784506 (64): a one dose primary screening 
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N-Cyano sulfoximine-based L-784506 (65): a one dose primary screening 
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3.4. Fujisawa Pharm analogs 
 
N-Cyano sulfilimine-based Fujisawa Pharm analog (68): a one dose primary screening 
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N-Cyano sulfoximine-based Fujisawa Pharm analog (69a): a one dose primary screening 
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3.5. SC-58125 analog 
 
N-Cyano sulfilimine-based SC-58125 (73a): a one dose primary screening 
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3.6. DuP 697 analogs 
 
N-Cyano sulfilimine-based DuP 697 (80): a one dose primary screening 
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N-Cyano sulfoximine-based DuP 697 (81): a one dose primary screening 
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N-Cyano sulfoximine-based DuP 697 (81): a full 5-dose assay 
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Appendix 
1. Abbreviations 
 
L-Glu L-Glutamine 
ATP Adenosine-5’-triphosphate 
L-Cys L-Cysteine 
ADP Adenosine diphosphate 
Pi orthophosphate 
γ-GCS γ-glutamylcysteine synthetase 
CYP24 25-hydroxyvitamin D3-24-hydroxylase 
HIV Human Immunodeficiency Virus 
hERG the human Ether-à-go-go-Related Gene 
PYK2 Proten tyrosine kinase 2 
CDK Cyclin-dependent kinase 
NSAID Non Steroidal Anti-Inflammatory Drugs 
COX Cyclooxygenase 
PGs Prostaglandins 
HETEs Hydroxyeicosatetraenoic acids 
TXA2 Thromboxane A2 
HEK 293 Human embryonic kidney 293 
IC50 The half maximal inhibitory concetration 
CNS Central nervous system 
NCI National Cancer Institute 
PET Positron Emission Tomography  
m-CPBA meta-Chlroperoxybenzoic acid 
DBU 1,8-Diazabicyclo[5.4.0]undec-7-ene 
NCS, NBS N-Chlorosuccinimide, N-bromosuccinimide 
Bn Benzyl 
TfOH Trifluoromethanesulfonic acid 
MTBE Methyl-tert-butyl ether 
ECD Electronic circular dichroism 
FT-IR Fourier transform infrared spectroscopy 
HPLC High performance/pressure liquid chromatography 
 Appendix 
241 
 
 
2. Curriculum Vitae 
 
Biographical 
 
Birth of Date: September 18, 1978 
Birth Place: Seoul, Korea 
 
 
Education 
 
Doctoral Student in Chemistry (Nov. 2009 – July 2013)  
Institute of Organic Chemistry, RWTH Aachen University, Germany 
Advisor: Prof. Dr. Carsten Bolm 
Thesis Title: Sulfilimine- and Sulfoximine-Based Bioactives: Syntheses, COX inhibition, and 
Anticancer Activity 
 
Master of Science in Chemistry (Feb. 2006) 
Department of Chemistry, Korea University, Korea 
Advisor: Prof. Dr. Bong Young Chung 
Life Science Research Division, Korea Institute and Science & Technology (KIST), Korea 
Advisor: Prof. Dr. Jae Yeol Lee 
Thesis Title: “Synthesis and SAR studies of 3,4-dihydroquinazoline derivatives for T-type Ca2+ 
channel blockers”  
 
Bachelor of Science in Chemistry (Feb. 2004)  
Department of Chemistry, Hankuk University of Foreign Studies, Korea 
(Minor : English Linguistics) 
 
 Appendix 
242 
 
Work Experience 
 
LG Chem / Research Park, Korea                        
Information Technology & Electronics Materials R&D                                         Jan. 2006 – Sep. 2009 
 
Korea Institute and Science & Technology (KIST), Korea 
Life Science Research Division                                                                               Jan. 2004 – Dec. 2005 
 
 
 
Publications 
 
Journal Papers 
[1] Park, S. J.; Baars, H.; Buschmann, H.; Baron, J. M.; Amann, P. M.; Czaja, K.; Hollert, H.; 
Bluhm, K.; Redelstein, R.; Bolm, C. “N-Cyano Sulfoximines: COX Inhibition, Anticancer 
Activity, Mutagenicity, and Cellular Toxicity” ChemMedChem. 2013, 8, 217. 
 
[2] Chen, X. Y.; Park, S. J.; Buschmann, H.; Bolm, C. “Syntheses and biological activities of 
sulfoximine-based acyclic triaryl olefins” Bioorg. Med. Chem. Lett. 2012, 22, 4307. 
 
[3] Park, S. J.; Buschmann, H.; Bolm, C. “Bioactive sulfoximines: Syntheses and properties of 
Vioxx® analogs” Bioorg. Med. Chem. Lett. 2011, 21, 4888. 
   
[4] Choi, J. Y.; Seo, H. N.; Lee, M. J.; Park, S. J.; Park S. J.; Jeon, J. Y.; Kang, J. H.; Pae, A. N.; 
Rhim, H.; Lee, J. Y. “Synthesis and biological evaluation of novel T-type calcium channel 
blockers” Bioorg. Med. Chem. Lett. 2007, 17, 471. 
 
[5] Lee, J. Y.; Park, S. J.; Park, S. J.; Lee, M. J.; Rhim, H.; Seo, S. H.; Kim, K. “Growth 
inhibition of human cancer cells in vitro by T-type calcium channel blockers” Bioorg. Med. 
Chem. Lett. 2006, 16, 5014. 
 
[6] Park, S. J.; Park, S. J.; Lee, M. J.; Rhim, H.; Kim, Y.; Lee, J.-H.; Chung, B. Y.; Lee, J. Y. 
“Synthesis and SAR studies of a novel series of T-type calcium channel blockers” Bioorg. 
Med. Chem. 2006, 14, 3502. 
 
[7] Rhim, H.; Lee, Y. S.; Park, S. J.; Chung, B. Y.; Lee, J. Y. “Synthesis and biological activity 
of 3,4-dihydroquinazolines for selective T-type Ca2+ channel blockers” Bioorg. Med. Chem. 
Lett. 2005, 15, 283. 
 
[8] Lee, Y. S.; Lee, B. H.; Park, S. J.; Kang, S. B.; Rhim, H.; Park, J.-Y.; Lee, J.-H.; Jeong, S.-
W.; Lee, J. Y. “3,4-Dihydroquinazoline derivatives as novel selective T-type Ca2+ channel 
blockers” Bioorg. Med. Chem. Lett. 2004, 14, 3379. 
 Appendix 
243 
 
Patents 
[1] Park, S. J.; Na, G. I. “Cycloolefin polymer film surface modifier compositions containing 
peroxides or peroxo compounds for polarizing plates good adhesion and appearance” Patent 
No. KR 2011029276, Sep. 15, 2009. 
 
[2] Park, S. H.; Park, S. J.; Na, G. I. “Composition for modifying polarizer protection film, and 
modifying method” Patent No. KR 2011027298, JP 2011057985, Sep. 10, 2010. 
 
[3] Park, S. J.; Lee, J. S.; Na, G. I. “Adhesive compositions with good adhesion for polarizing 
plates with good durability” Patent No. KR 2011003085, July 03, 2009. 
 
[4] Lee, J. S.; Choi, Y. S.; Park, S. J.; Park, S. H. “Surface-modifying protection film of 
polarizer by using alcohol and akali agent” Patent No. KR 2010098110, Feb. 27, 2009. 
 
[5] Park, S. J.; Kwon, K. O.; Rah, K. I. “Modified polyvinyl alcohol adhesives with good 
adhesion and water and moisture resistance for polarizers and display devices” Patent No. 
WO 2010095905, Feb. 02, 2010. 
 
[6] Lee. J. S.; Park, S. J.; Na, G. I. “Surface treating method of protecting film for polarizing 
plate and method for manufacturing polarizing plate” Patent No. KR 2010092265, Feb. 12, 
2009.  
 
[7] Park, S. J.; Lee, J. S. “Production of sulfonate-modified polyvinyl alcohol resin-based 
adhesive for polarizing plate and display device” Patent No. KR 2010090602, Feb. 06, 2010. 
 
[8] Ahn, H. G.; Park, S. J.; Park, N. H.; Cho, Y. G.; Lim, C. H. “Anisotropic conductive 
adhesive compositions containing anthracene-based epoxy resins with good adhesion for 
circuit connection structure” Patent No. KR 2010000726, Jun. 25, 2008. 
 
[9] Park, S. J.; Park, N. H.; Cho, Y. G.; Kim, J. H.; Song, M. S.; Lim, C. H. “Surface modified 
amine curing agent, one-component type epoxy resin composition, and anisotropic 
conductive adhesives” Patent No. WO 2009014353, July. 18, 2008. 
 
[10] Cho, Y. G.; Park, N. H.; Song, M. S.; Park, S. J.; Kim, J. H. “Anisotropic conductive 
connection material and circuit connection method” Patent No. KR 2008098841, May. 07, 
2007.  
 
[11] Cho, Y. G.; Park, N. H.; Song, M. S.; Park, S. J.; Kim, J. H. “Insulated conductive ball 
contained in anisotropic electric connection material” Patent No. KR 2008098815, May. 07, 
2007.  
 
[12] Cho, Y. G.; Park, N. H.; Song, M. S.; Park, S. J.; Kim, J. H. “Insulated conductive ball 
contained in anisotropic electric connection material” Patent No. KR 2008098827, May. 07, 
2007. 
 
[13] Park, N. H.; Cho, Y. G.; Song, M. S.; Kim, J. H.; Park, S. J. “Imidazole-adduct type latent 
polymer curing agent, its preparing method, one-component epoxy resin composition the 
latent polymer curing agent, and anisotropic electroconductive adhesive” Patent No. KR 
2008092577, Apr. 12, 2007. 
 
[14] Park, S. J.; Cho, Y. G.; Park, N. H.; Kim, J. H.; Song, M. S. “One-component type resin 
composition containing non-encapsulative surface modified amine curing agent, and 
 Appendix 
244 
 
anisotropic electroconductive adhesive” Patent No. KR 2008090090, Apr. 04, 2007. 
 
[15] Song, M. S.; Cho, Y. G.; Park, N. H.; Kim, J. H.; Park, S. J. “Core-shell conductive particle 
for anisotropy conductive connecting material” Patent No. KR 2008088082, Mar. 28, 2007. 
 
[16] Park, S. J.; Cho, Y. G.; Park, N. H.; Lee, Y. B.; Kim, J. H.; Song, M. S. “Amine-based 
hardener for surface modification, and masking-type hardener and one-component type 
epoxy resin composition” Patent No. KR 2008039166, Nov. 02, 2006. 
 
 
